Trispecific binding molecules against tumor-associated antigens and uses thereof
Trispecific binding molecules targeting TAA, CD2, and TCR components stimulate T cell activation, addressing immune evasion in tumors and enhancing RTCC therapy efficacy.
Patent Information
- Application Number
- JP2024138929
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-11-21
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2038-11-20
AI Technical Summary
Current RTCC therapies for treating tumors, particularly acute lymphoma and solid tumors, face challenges due to immune evasion mechanisms and the suppressive tumor microenvironment, which reduce their effectiveness.
Development of trispecific binding molecules (TBMs) that target tumor-associated antigens (TAA), CD2, and components of the T cell receptor (TCR) complex to stimulate T cell activation and overcome anergy, enhancing antitumor activity by promoting tumor cell lysis and T cell proliferation.
The TBMs improve clinical outcomes by inducing T cell-mediated tumor cell lysis and proliferation, overcoming anergy and enhancing therapeutic efficacy against tumors.
Smart Images

Figure 2024161539000157 
Figure 2024161539000158 
Figure 2024161539000159
Abstract
Description
[Technical Field]
[0001] 1. CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Patent Application No. 62 / 589,333, filed November 21, 2017. This provisional patent application claims the benefit of priority to US Provisional Patent Application No. 2004 / 0109994, filed on May 1, 2004, the entire contents of which are incorporated herein by reference. No. 6,299,499, filed on Oct. 1, 2004, which is incorporated herein by reference.
[0002] 2. Sequence Listing This application contains a Sequence Listing which has been submitted electronically in ASCII format, the entirety of which is as follows: The ASCII copy was published on November 19, 2018. It was created and named NOV-001WO_SL.txt and was 592,187 bytes in size. It is. [Background technology]
[0003] Redirected targeted T-cytotoxicity (RTCC) for first-line and refractory settings This is an interesting mechanism. Antibodies and antibody fragments with excellent selectivity target T cells. Problems with different formats that allow for the bispecificity required to crosslink to a single receptor on a cell It is operated without any control.
[0004] First-line treatment for an indication or the indication itself may involve immunization to promote T cell anergy. This may promote an immunosuppressive environment, reducing the effectiveness of existing RTCC therapies. Lymphoma, for example, has been shown to be a particularly evasive disease with respect to evading immune surveillance. (Teague and Klein,2013,Journal for Immun The solid tumor microenvironment also contains various pathway, which may provide a mechanism for tumor cell escape and promote tumor cell survival (Vaney et al.,2015,Seminars in Cancer Biology 35:S151-S184). Summary of the Invention [Problem to be solved by the invention]
[0005] Therefore, there is a need for an improved RTCC approach. [Means for solving the problem]
[0006] The present disclosure provides a method for detecting tumor-associated antigens ("TAA") and other molecules of the CD3 or TCR complex on T cells. By providing a multispecific binding molecule that associates with CD2 in addition to the components, RTCC Extending the principle of
[0007] The present invention demonstrates that association with CD2 in addition to components of the TCR complex contributes to the development of TAAs and TCs. T that would not respond to stimulation with a bispecific engager that targets only the R complex The finding that activating a cell subpopulation improves clinical outcomes of RTCC therapy has led to a number of advances. As shown in the examples, the TAA, CD2 and CD3 The outcome of tumor treatment with the associated trispecific binding molecules is particularly pronounced in the presence of anergic T cells. showed improved antitumor activity compared to engagement with TAA and CD3 alone. Without being bound by theory, the inventors believe that By combining CD2 association and TCR complex association in Primary signaling that promotes T cell-mediated lysis of tumor cells (by star formation) pathway and a second costimulatory pathway that induces T cell proliferation and potentially overcomes anergy. I think it can be inspiring.
[0008] Thus, the present disclosure provides a method for identifying tumor-associated antigens ("TAA"), (2) CD2, and (3) ) Trispecific Binding Molecules ("TBM") that Bind CD3 or Other Components of the TCR Complex The TBM provides at least one molecule capable of binding to TAAs, CD2, and components of the TCR complex. Each of the three antigen binding modules ("ABMs") comprises three antigen binding modules ("ABMs"). The binding module binds to each of the other antigen binding modules to its respective target. Each ABM is capable of binding to its respective target simultaneously. The TBM of the present disclosure may be immunoglobulin-based or non-immunoglobulin-based. may include immunoglobulin-based ABMs, non-immunoglobulin-based ABMs, or combinations thereof. The immunoglobulin-based ABM that can be used in the TBM of the present disclosure is the following sixth aspect: Section 2.1 and specific embodiments 31-406, 575-583, 591-660, 66 2-667, 671, 673-762, and 830-898. Non-immunoglobulin-based ABMs that may be used in BM are described below in Section 6.2.2 and and specific embodiments 2-30, 403-406, and 584-589. Further characteristics of exemplary ABMs that bind to components of the CR complex are described in Section 6.5 below and and specific embodiments 38-106, 590-667, and 1045. Further features of exemplary ABMs that bind to 2 are described in Section 6.6 below, as well as in specific embodiments. 2-37, 403-406, 575-589 and 1044. Further features of the exemplary ABM that are compatible are described in Section 6.7 below, as well as in specific embodiments 107. ~276, 346~406, 668~762 and 1046.
[0009] The ABM of the TBM (or portion thereof) of the present disclosure may be, for example, a short peptide linker or an Fc The ABMs can be linked to each other by domains. Methods for Linking ABMs to Form TBMs and components are described in Section 6.3 below and in specific embodiments 401-453, 763-82. 9 and 899-957.
[0010] The TBM of the present disclosure has at least three ABMs (i.e., the TBM has at least ABMs are also trivalent, but can have more than four ABMs. For example, a TBM can have four ABMs. BM (i.e., tetravalent), five ABM (i.e., pentavalent), or six ABM ( i.e., hexavalent), provided that the TBM has at least one valence capable of binding to a TAA. the ABM, at least one ABM capable of binding to CD2, and a component of the TCR complex. Exemplary trivalent, tetravalent, pentavalent, and hexavalent TBM forms include: This embodiment is shown in FIG. 1 and described in Section 6.4 below and in specific embodiments 958-1042. are.
[0011] The present disclosure provides a method for the preparation of a TBM of the present disclosure (either in a single nucleic acid or multiple nucleic acids). Nucleic acids and recombinant host cells engineered to express the nucleic acids and TBMs of the disclosure. Exemplary nucleic acids, host cells, and cell lines are further provided in Sections 6.8, below, and and specific embodiments 570-573 and 1169-1176.
[0012] The present disclosure further provides drug conjugates comprising the TBMs of the present disclosure. The conjugates may be constructed using a non-immunoglobulin domain, although some or all of the ABM may be a non-immunoglobulin domain. Regardless, for convenience, they are referred to herein as "antibody drug conjugates" or "ADCs." Examples of ADCs are described in Section 6.9 below and in specific embodiments 469-507 and 1054. ~1093.
[0013] The present disclosure further provides formulations comprising the TBM or conjugates of the present disclosure. See Section 6.10 below and specific embodiments 508-565 and 1094-1151. It is written.
[0014] Pharmaceutical compositions comprising the TBM and ADC of the present disclosure are also provided. Exemplary pharmaceutical compositions include the following: Section 6.11 and specific embodiments 566 and 1152.
[0015] For example, to treat a proliferative disorder (e.g., cancer) in which a TAA is expressed, the TAA of the present disclosure can be used. Methods of using the BMs, ADCs, and pharmaceutical compositions are further provided herein. Typical methods are described in Section 6.12 below and in specific embodiments 567-568 and 1153-1154. It is described in 155.
[0016] The present disclosure also provides methods for combining the TBMs, ADCs, and pharmaceutical compositions of the present disclosure with other drugs and therapies. Exemplary agents, therapeutic methods, and combination treatment methods are described below. As described in Section 6.13 and specific embodiments 569 and 1156-1168. [Brief explanation of the drawings]
[0017] [Figure 1-1]Exemplary TBM Configurations. Figure 1A shows the components of the exemplary TBM configurations shown in Figures 1B-1Z. Not all regions connecting the different domains of each chain are shown (e.g., the linker connecting the VH and VL domains of an scFv, the linker connecting the CH2 and CH3 domains of an Fc, etc. are omitted). Figures 1B-1O and 1V-Z show trivalent TBMs; Figures 1P-1R show tetravalent TBMs; Figure 1S shows a pentavalent TBM, and Figures 1T-1U show a hexavalent TBM. [Figure 1-2] (As mentioned above.) [Figure 1-3] (As mentioned above.) [Figure 1-4] (As mentioned above.) [Figure 1-5] (As mentioned above.) [Figure 1-6] (As mentioned above.) [Figure 1-7] (As mentioned above.) [Figure 1-8] (As mentioned above.) [Figure 1-9] (As mentioned above.) [Figure 1-10] (As mentioned above.) [Figure 1-11] (As mentioned above.) [Figure 1-12] (As mentioned above.) [Figure 1-13] (As mentioned above.) [Figure 1-14] (As mentioned above.) [Figure 1-15] (As mentioned above.) [Figure 1-16] (As mentioned above.) [Figure 1-17] (As mentioned above.) [Figure 1-18] (As mentioned above.) [Figure 1-19] (As mentioned above.) [Figure 1-20] (As mentioned above.) [Figure 1-21] (As mentioned above.) [Figure 1-22] (As mentioned above.) [Figure 1-23] (As mentioned above.) [Figure 1-24] (As mentioned above.) [Figure 1-25] (As mentioned above.) [Figure 1-26] (As mentioned above.) [Figure 2] FIG. 1 is a schematic diagram of the bispecific and trispecific constructs of Example 1. [Figure 3-1] Figures 3A-3B show results of redirected T cell cytotoxicity assays using human CD19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. Figures 3A-3B show results obtained with pan-T effector cells from a first donor after 24 hours (Figure 3A) and 48 hours (Figure 3B) of incubation. Figures 3C-3D show results obtained with pan-T effector cells from a second donor after 24 hours (Figure 3C) and 48 hours (Figure 3D) of incubation. [Figure 3-2] (As mentioned above.) [Figure 3-3] (As mentioned above.) [Figure 3-4] (As mentioned above.) [Figure 4-1] Figure 4A shows the results of a redirected T cell cytotoxicity assay using human CD-19-expressing Daudi target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. Figure 4A shows the results obtained with pan-T effector cells from a first donor after 48 hours of incubation. Figure 4B shows the results obtained with pan-T effector cells from a second donor after 48 hours of incubation. [Figure 4-2] (As mentioned above.) [Figure 5]1 shows the results of a redirected T cell cytotoxicity assay using negative control human K562 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. [Figure 6-1] Figures 6A-6E show the results of redirected T cell cytotoxicity assays using human CD19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. Figures 6A-6E show the results obtained using pan-T effector cells from five different donors. [Figure 6-2] (As mentioned above.) [Figure 6-3] (As mentioned above.) [Figure 6-4] (As mentioned above.) [Figure 6-5] (As mentioned above.) [Figure 7] Figure 7 shows the results of a redirected T cell cytotoxicity assay using human CD-19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. Figure 7 shows results obtained using human cryopreserved PBMCs from a patient diagnosed with acute myeloid leukemia. [Figure 8-1] Figures 8A-8D show the results of redirected T cell cytotoxicity assays using human CD19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. Figures 8A-8D show the results obtained from target cell reinoculation at 48, 72, 96, and 120 hours, respectively. [Figure 8-2] (As mentioned above.) [Figure 8-3] (As mentioned above.) [Figure 8-4] (As mentioned above.) [Figure 9-1] Cell proliferation assay results: CD4+ sorted cells are shown in Figure 9A, and CD8+ sorted cells are shown in Figure 9B. [Figure 9-2] (As mentioned above.) [Figure 10-1] Cytokine release assay results using human CD-19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. (Figure 10A: IFNγ; Figure 10B: TNFα; Figure 10C: IL2; Figure 10D: IL10; Figure 10E: IL6; Figure 10F: Figure legend). [Figure 10-2] (As mentioned above.) [Figure 10-3] (As mentioned above.) [Figure 10-4] (As mentioned above.) [Figure 10-5] (As mentioned above.) [Figure 10-6] (As mentioned above.) [Figure 11] 1 shows the results of a granzyme B ELISpot assay using human CD-19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. [Figure 12-1] Schematic diagram of the trispecific constructs of Example 2. Figure 12A: AB2-1; Figure 12B: AB2-2; Figure 12C: AB2-3. [Figure 12-2] (As mentioned above.) [Figure 12-3] (As mentioned above.) [Figure 13] 1 shows the results of a redirected T cell cytotoxicity assay using human CD-19-expressing Nalm6 target cells and TBM targeting human CD3, human CD2, and human CD19 (Example 2). [Figure 14]Figure 14 shows the results of a redirected T cell cytotoxicity assay using human CD-19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human growth hormone, bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19 (Example 2). Figure 14 shows the results obtained using cynomolgus monkey pan-T effector cells. [Figure 15] 1 shows the results of an NFAT activation assay using TBM targeting human CD3, human CD2, and human CD19 (Example 2). [Figure 16-1] Schematic diagram of the trispecific constructs of Example 3. Figure 16A: AB3-1; Figure 16B: AB3-2; Figure 16C: AB3-3; Figure 16D: AB3-4; Figure 16E: AB3-5. [Figure 16-2] (As mentioned above.) [Figure 16-3] (As mentioned above.) [Figure 16-4] (As mentioned above.) [Figure 16-5] (As mentioned above.) [Figure 17] 1 shows the results of a redirected T cell cytotoxicity assay using human CD-19-expressing Nalm6 target cells and TBM targeting human CD3, human CD2, and human CD19 (Example 3). [Figure 18] 1 shows the results of an NFAT activation assay using TBM targeting human CD3, human CD2, and human CD19 (Example 3). [Figure 19-1] Schematic diagram of the trispecific constructs of Example 4. Figure 19A: AB4-1; Figure 19B: AB4-2; Figure 19C: AB4-3. [Figure 19-2] (As mentioned above.) [Figure 19-3] (As mentioned above.) [Figure 20] 1 shows the results of a redirected T cell cytotoxicity assay using human CD-19-expressing Nalm6 target cells and TBM targeting human CD3, human CD2, and human CD19 (Example 4). [Figure 21]1 shows the results of an NFAT activation assay using TBM targeting human CD3, human CD2, and human CD19 (Example 4). [Figure 22-1] Figure 22 shows the results of a cytokine release assay using TBM targeting human CD3, human CD2, and human CD19 (Example 4). Figure 22A: IL-2; Figure 22B: TNFα; Figure 22C: IFNγ; Figure 22D: Figure legend. [Figure 22-2] (As mentioned above.) [Figure 22-3] (As mentioned above.) [Figure 22-4] (As mentioned above.) [Figure 23-1] 23A-23B are schematic diagrams of the bispecific and trispecific constructs of Example 5. Figure 23A: Bispecific construct; Figure 23B: Trispecific construct. [Figure 23-2] (As mentioned above.) [Figure 24-1] 1 shows the results of a redirected T cell cytotoxicity assay using human CD-19-expressing Nalm6 target cells and either a bispecific construct targeting human CD3 and human CD19 or a TBM targeting human CD3, human CD2, and human CD19 (Example 5). [Figure 24-2] (As mentioned above.) [Figure 25-1] Figure 25 shows the results of a cytokine release assay (Example 5) using human CD-19-expressing Nalm6 target cells and bispecific constructs targeting human CD3 and human CD19, and TBM targeting human CD3, human CD2, and human CD19. Figure 25A shows the results for a construct with a CD3-binding arm corresponding to BMA031, and Figure 25B shows the results for a construct with a CD3-binding arm corresponding to OKT3. Results for trispecific constructs are shown in black; results for bispecific constructs are shown in gray. [Figure 25-2] (As mentioned above.) [Figure 26-1] 26A-26B are schematic diagrams of the bispecific and trispecific constructs of Example 6. Figure 26A: bispecific construct; Figure 26B: trispecific construct. [Figure 26-2] (As mentioned above.) [Figure 27] 1 shows the results of a redirected T cell cytotoxicity assay using human Her2-expressing HCC1954 target cells and a bispecific construct targeting human CD3 and human Her2 or a TBM targeting human CD3, human CD2, and human Her2 (Example 6). [Figure 28] 1 shows the results of a cytokine release assay using human Her2-expressing HCC1954 target cells and bispecific constructs targeting human CD3 and human Her2, and TBM expressing human CD3, human CD2, and either human Her2 or GH (Example 6). [Figure 29-1] 29A-29B are schematic diagrams of the bispecific and trispecific constructs of Example 7. Figure 29A: bispecific construct; Figure 29B: trispecific construct. [Figure 29-2] (As mentioned above.) [Figure 30] FIG. 10 shows the results of a redirected T cell cytotoxicity assay using human mesothelin-expressing OVCAR8 target cells and a bispecific construct targeting human CD3 and human mesothelin or a TBM targeting human CD3, human CD2, and human mesothelin (Example 7). [Figure 31] FIG. 1 shows the results of a cytokine release assay using human mesothelin-expressing Ovcar8 target cells and bispecific constructs targeting human CD3 and human mesothelin (MSLN) and TBM targeting human CD3, human CD2, and either human mesothelin or GH (Example 6). [Figure 32] FIG. 1 is a schematic diagram of the trispecific construct of Example 8. DETAILED DESCRIPTION OF THE INVENTION
[0018] 6.1.Definition As used herein, the following terms are intended to have the following meanings: .
[0019] Antigen binding module: As used herein, "antigen binding module" or " The term "ABM" refers to a molecule that has the ability to bind non-covalently, reversibly, and specifically to an antigen. ABM refers to the portion of the TBM of the present disclosure that is immunoglobulin-based or non-immunoglobulin-based. As used herein, "ABM1" and "CD2 AB The terms "ABM" (and the like) refer to ABMs that specifically bind to CD2, and "ABM2" and The term "TCR ABM" (and the like) refers to a molecule that specifically binds to a component of the TCR complex. The terms "ABM3" and "TAA ABM" (and others) refer to tumor-associated antigens. The terms ABM1, ABM2, and ABM3 refer to ABMs that specifically bind to the antigen. It is used for convenience only and is not intended to refer to any particular form of TBM. In some embodiments, the TCR ABM binds to CD3 (referred to herein as "CD3 Therefore, disclosures related to ABM2 and TCR ABM is also applicable to CD3 ABM.
[0020] Antibody: The term "antibody" as used herein refers to a non-covalently, reversibly A polypeptide of the immunoglobulin family capable of efficiently and specifically binding to an antigen. For example, naturally occurring "antibodies" of the IgG type are composed of disulfide bonds. It contains at least two heavy (H) chains and two light (L) chains interconnected by bond bonds. Each heavy chain is a tetramer. The heavy chain constant region is composed of three domains: CH1, CH2, and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light The light chain constant region is composed of one domain (referred to herein as CL). The VH and VL regions are called framework regions (FR). They contain hypervariable regions called complementarity-determining regions (CDRs), interspersed with more conserved regions. Each VH and VL can be further subdivided into regions in the following order: FR1, CDR1, FR2 , CDR2, FR3, CDR3, FR4 arranged from the amino terminus to the carboxy terminus It consists of three CDRs and four FRs. The variable regions of the heavy and light chains interact with antigens. The constant region of an antibody contains a binding domain that binds to various cells of the immune system (e.g., immune cells). to host tissues or factors, including the first component of the classical complement system (Clq) and the first component of the classical complement system (C1q). The term "antibody" includes, but is not limited to, monoclonal antibodies capable of mediating the binding of immunoglobulins. Clonal antibodies, human antibodies, humanized antibodies, camelized antibodies, chimeric antibodies, bispecific or polyclonal antibodies Polyspecific and anti-idiotypic (anti-Id) antibodies (e.g., anti-Id antibodies to the antibodies of the present disclosure) Antibodies include antibodies of any isotype / class (e.g., IgG, IgE , IgM, IgD, IgA and IgY) or subclass (e.g., IgG1, IgG2, The antibodies may be of the following types: IgG3, IgG4, IgA1 and IgA2.
[0021] Both the light and heavy chains are divided into regions of structural and functional homology. The term "variable" is used functionally. In this context, light (VL) and heavy (VH) It will be appreciated that the variable domains of both chains determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CL) and heavy chain (CH1, CH2, or CH3) are involved in secretion, They confer important biological properties such as transplacental mobility, Fc receptor binding, and complement fixation. Therefore, the numbering of the constant region domains is more distal from the antigen binding site or amino terminus of the antibody. The N-terminus is the variable region and the C-terminus is the constant region; The CH3 and CL domains actually comprise the carboxy termini of the heavy and light chains, respectively.
[0022] Antibody fragment: As used herein, an "antibody fragment" of an antibody The term "antibody" refers to one or more portions of an antibody. In certain embodiments, these portions are part of an antibody. In certain other embodiments, these portions are part of the contact domains of the In the context of the present invention, the term "antigen-binding fragment," "antigen-binding fragment thereof," "antigen-binding portion," etc. The ability to bind antigen non-covalently, reversibly, and specifically, sometimes referred to as Examples of binding fragments include, but are not limited to, However, single chain Fv (scFv), Fab fragments, VL, VH, CL and CH1 domains monovalent fragments consisting of F(ab)2 fragments, disulfides in the hinge region; A bivalent fragment containing two Fab fragments linked by a peptide bridge; an Fd fragment consisting of the CH1 domain and the VL and VH domains of a single arm of an antibody; Fv fragments consisting of the VH domain; dAb fragments (Ward et al. al., (1989) Nature 341:544-546); and isolated complement The term "antibody fragment" therefore includes the CDRs. Proteolytic fragments of antibodies (e.g., Fab and F(ab)2 fragments) and and modified proteins comprising one or more portions of an antibody (e.g., scFv).
[0023] Antibody fragments include single domain antibodies, maxibodies, minibodies, intrabodies, bibodies, Also in bispecific antibodies, trispecific antibodies, tetraspecific antibodies, v-NAR and bis-scFv (e.g., Hollinger and Hudson, 2005, Na (See Nature Biotechnology 23:1126-1136). Antibody fragments are based on polypeptides such as fibronectin type III (Fn3). and can be grafted into a scaffold (US Pat. No. 6,233,199 describes a fibronectin polypeptide monobody). See Patent No. 6,703,199).
[0024] An antibody fragment comprises a complementary light chain polypeptide (e.g., VL-VC-VL-VC). A pair of tandem Fv segments (e.g., VH) that together form a pair of antigen-binding regions -CH1-VH-CH1) (Zapata et al. al., 1995, Protein Eng. 8:1057-1062; and U.S. Pat. 5,641,870).
[0025] Antigen-binding domain: The term "antigen-binding domain" refers to a non-covalently, reversibly acting An antigen-binding domain refers to a portion of a molecule that has the ability to specifically bind to an antigen. Exemplary antigen-binding domains are antigen-binding fragments that retain the ability to non-covalently, reversibly, and specifically bind antigens; The present invention includes fragments and portions of both immunoglobulin and non-immunoglobulin based scaffolds. As used herein, the term "antigen-binding domain" refers to a domain that non-covalently binds to an antigen. Antibody fragments that retain the ability to reversibly and specifically bind antigen are included.
[0026] Half antibody: The term "half antibody" refers to an antibody that contains at least one ABM or ABM chain, e.g., For example, disulfide bridges or molecular interactions (e.g., knob-in-hole interactions between Fc heterodimers) ABM or another molecule containing an ABM chain can be bound to it by a knob-in-hole interaction. A half antibody refers to a molecule that can associate with one polypeptide chain or two or more polypeptides. In a preferred embodiment, the polypeptide chains are composed of two polypeptide chains (e.g., two polypeptide chains of a Fab). In this case, the half antibody comprises an Fc region.
[0027] An example of a half antibody is a molecule that contains the heavy and light chains of an antibody (e.g., an IgG antibody). Another example is a first polypeptide comprising a VL domain and a CL domain, and a VH domain a second polypeptide comprising a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; and a peptide, wherein the VL and VH domains form an ABM. Yet another example of a half antibody includes an scFv domain, a CH2 domain, and a CH3 domain. It is a polypeptide.
[0028] A half antibody can contain two or more ABMs, for example, a half antibody can contain (in order from N-terminus to C-terminus) 2) scFv domain, CH2 domain, CH3 domain and another scFv domain nothing.
[0029] A half antibody forms a complete ABM when associated with another ABM chain in another half antibody. It may also include a BM chain.
[0030] Thus, a TBM may contain one, more typically two or even three or more half antibodies. , a half antibody may comprise one or more ABMs or ABM chains.
[0031] In some TBMs, the first half antibody associates with a second half antibody, e.g., In other TBMs, the first half antibody is heterodimerized, e.g., by a disulfide bridge. or by chemical cross-linking. One half antibody has both covalent and non-covalent interactions, e.g., disulfide bridges and knob- It associates with the second half antibody through in-hole interactions.
[0032] The term "half antibody" is intended for descriptive purposes only and does not refer to a specific form or preparation. The "first" half antibody, the "second" half antibody, the "left" half antibody, The description of half antibodies as "right" half antibodies is for convenience and illustrative purposes only.
[0033] Complementarity Determining Region: "Complementarity Determining Region" or "CDR" as used herein The term refers to the sequence of amino acids within an antibody variable region that confers antigen specificity and binding affinity. For example, each heavy chain variable region generally has three CDRs (e.g., CDR-H1, CDR-H2, CDR-H3, CDR-H4, CDR-H5, CDR-H6, CDR-H7, CDR-H8, CDR-H9, CDR-H10, CDR-H11, CDR-H12, CDR-H13, CDR-H14, CDR-H15, CDR-H16, CDR-H and CDR-H2 and CDR-H3) and three CDRs in each light chain variable region (CDR-L1, The exact amino acid sequence boundaries of a given CDR are abat et al., 1991, “Sequences of Proteins of Immunological Interest”,5th Ed.Public Health Service,National Institutes of H health, Bethesda, MD ("Kabat" numbering scheme), Al-La zikani et al., 1997, JMB 273:927-948 (“Chot hia numbering scheme) and ImMunoGenTics (IMGT) numbering scheme (L efranc,1999,The Immunologist 7:132-136(1 999);Lefranc et al.,2003,Dev.Comp.Immuno l.27:55-77 ("IMGT" numbering scheme) , can be determined using any of several well-known schemes. For example, in the classical form The CDR amino acid residues in the heavy chain variable domain (VH) are 31 to 33 by the Kabat method. 5 (CDR-H1), 50-65 (CDR-H2), and 95-102 (CDR-H3) The CDR amino acid residues in the light chain variable domain (VL) are numbered 24 to 34 (CDR -L1), 50 to 56 (CDR-L2) and 89 to 97 (CDR-L3) According to the Chothia method, the CDR amino acids in VH are 26 to 32 (CDR-H1), Numbered 52–56 (CDR-H2) and 95–102 (CDR-H3); in VL The amino acid residues of CDR-L1 are 26-32, those of CDR-L2 are 50-52, and those of CDR-L3 are 91-92. 96 (CDR-L3). Both Kabat and Chothia CDRs Combining the definitions, the CDRs are amino acid residues 26 to 35 (CD R-H1), 50-65 (CDR-H2) and 95-102 (CDR-H3) and human Amino acid residues 24-34 (CDR-L1), 50-56 (CDR-L2), and 8 in VL The CDR amino acid residues in VH are 9 to 97 (CDR-L3). Approximately 26-35 (CDR-H1), 51-57 (CDR-H2) and 93-102 (CDR -H3), and the CDR amino acid residues in the VL are approximately 27 to 32 (CDR-L1). , numbered 50-52 (CDR-L2) and 89-97 (CDR-L3) ("K The IMGT method numbers the CDR regions of an antibody according to the program IM This can be determined using GT / Domain Gap Align.
[0034] Single-chain Fv or scFv: As used herein, "single-chain Fv" or "scFv" The term "Fv" refers to an antibody fragment comprising the VH and VL domains of an antibody, and these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide The peptides comprise the VH and VH domains, which enable the scFv to form the desired structure for antigen binding. The scFv further comprises a polypeptide linker between the VL domain and the VL domain. lueckthun in The Pharmacology of Monoclo nal Antibodies,vol.113,Rosenburg and Moo re eds., (1994) Springer-Verlag, New York, p. Please refer to p.269-315.
[0035] Bispecific antibody: The term "bispecific antibody" as used herein means Typically, it is a small antibody with two antigen-binding sites formed by the pairing of scFv chains. Each scFv is a light chain variable domain (VL) in the same polypeptide chain. ) (VH-VL, where VH is linked to VL) (VH and VL are either N-terminal or C-terminal to each other) a linker that enables VH and VL to pair to form an antigen-binding domain Unlike typical scFvs, which are separated, bispecific antibodies typically have VH and VH on the same chain. and VL domains, thereby The VL and VL domains pair with the complementary domains of another chain to form two antigen-binding sites. Bispecific antibodies are described, for example, in EP 404,097; WO 93 / 1 1161; and Hollinger et al., 1993, Proc. More fully described in Natl Acad Sci USA 90:6444-6448 It has been done.
[0036] Fv: The term "Fv" refers to an immunoglobulin that contains a complete target recognition and binding site. This refers to the smallest antibody fragment that can be derived from this region. This region consists of a single tightly non-covalently bound In this form, the antibody consists of a dimer of one light chain variable domain and one light chain variable domain (VH-VL dimer). The three CDRs of each variable domain interact to form a target binding site on the surface of the VH-VL dimer. In most cases, six CDRs confer target binding specificity to an antibody. However, in some cases, a single variable domain (or only three CDRs) specific for a target Even a single Fv half containing the target may have the ability to recognize and bind to the target. Reference to a VH-VL dimer in this specification is not intended to denote any particular form. For example, but not limited to, VH and VL can be combined in any manner described herein. The half antibodies can be formed by the addition of the nucleotides, or each can be present on a separate half antibody and can be separated into separate half antibodies. When antibodies assemble together they form an antigen binding domain, e.g., a TBM of the disclosure. When present on a single polypeptide chain (e.g., scFv), The VH can be N-terminal or C-terminal to the VL.
[0037] Multispecific binding molecule: The term "multispecific binding molecule" refers to a molecule that binds to at least two antigens. It refers to a molecule that specifically binds to and contains two or more antigen-binding domains. Independently, antibody fragments (e.g., scFv, Fab, nanobodies), ligases, and non-antibody-derived binding agents (e.g., fibronectin, Fynomer, DARPin) It could be.
[0038] Trispecific Binding Molecule: The term "trispecific binding molecule" or "TBM" refers to a molecule that binds three antibodies. A TBM of the present disclosure refers to a molecule that specifically binds to an antigen and contains three or more antigen-binding domains. , at least one antigen-binding domain specific for a component of the TCR complex, at least one antigen-binding domain specific for the TAA and at least one antigen-binding domain specific for the TAA The antigen-binding domains each independently comprise an antibody fragment (e.g., scFv, Fab, nanobody), ligand or non-antibody derived binder (e.g., fibro A representative TBM is shown in Figure 1. A TBM can comprise one, two, three, four or even more polypeptide chains. For example, the TBM shown in Figure 1M is a single polypeptide chain bound by an ABM linker. It contains a single polypeptide chain containing three linked scFvs. TBM shown in Figure 1K Specifically, it comprises two polypeptide chains containing three scFvs linked by an Fc domain. The TBM shown in Figure 1J contains, inter alia, scFv linked by an Fc domain. The TBM shown in Figure 1C contains three polypeptide chains that form the Fab, the ligand, and the Fab. Specifically, it consists of four polypeptides that form three Fabs, linked by an Fc domain. The TBM shown in Figure 1T contains, in particular, four Fc domains linked by Fc domains. It contains six polypeptide chains that form 1 Fab and two scFv.
[0039] VH: The term "VH" refers to an antibody containing the heavy chain of an Fv, scFv, dsFv, or Fab. It refers to the variable region of the immunoglobulin heavy chain of the body.
[0040] VL: The term "VL" refers to the light chain of an immunoglobulin, including the light chain of an Fv, scFv, dsFv, or Fab. Refers to the variable region of the immunoglobulin light chain.
[0041] Operably linked: The term "operably linked" refers to two or more peptides or refers to a functional relationship between polypeptide domains or nucleic acid (e.g., DNA) segments. The term "operably linked" in reference to a fusion protein or other polypeptide The term refers to two or more amino acid segments linked to form a functional polypeptide. For example, in the context of the TBMs of this disclosure, a separate ABM (or chain of ABMs) The polypeptide chains of the TBMs of the present disclosure may be linked via a peptide linker sequence. With respect to nucleic acids encoding proteins, "operably linked" means that two nucleic acids are linked together in a manner that allows the two nucleic acids to The amino acid sequences encoded by the nucleic acids are joined so that they remain in frame. In the context of transcriptional regulation, the term refers to the function of a transcriptional regulatory sequence on a transcribed sequence. For example, a promoter or enhancer sequence may be used in a manner that is compatible with the host cell or is operative for a coding sequence if it stimulates or regulates transcription of the coding sequence in another expression system. is linked to.
[0042] Associated: In relation to TBM, the term "associated" refers to two or more polypeptides. In particular, the term "associated" refers to the functional relationship between two or more polypeptide chains. The domains are functional T domains that allow ABM1, ABM2, and ABM3 to bind to their respective targets. non-covalently or by molecular interactions to form one or more disulfides covalently associated with each other by sulfide bridges or chemical bridges Examples of associations that may be present in the TBM of the present disclosure include (but are not limited to) Fc domains. Association between Fc regions in the Fc domains (homodimeric association or, more preferably, the Fc domains described in Section 6.3.1.5) heterodimeric associations, such as those described above, the association between the VH and VL regions in Fab or Fv, and the F The association between CH1 and CL in ab is shown.
[0043] ABM chain: An individual ABM is expressed as a single polypeptide chain (e.g., in the case of an scFv). may be present or by association of two or more polypeptide chains (e.g., in the case of Fab) As used herein, the term "ABM chain" refers to a single polynucleotide. The term "ABM chain" refers to all or part of the ABM present on a peptide chain. are intended for convenience and illustrative purposes only and do not imply any particular form or method of manufacture. Not yet.
[0044] Host cell or recombinant host cell: The term "host cell" or "recombinant host cell" refers to a refers to cells that have been genetically modified, for example, by the introduction of heterologous nucleic acid. It is understood that the term "cell" is intended to refer not only to the particular subject cell but also to the progeny of such a cell. It should be understood that certain modifications may occur in subsequent generations, either due to mutation or environmental influences. Such progeny may not, in fact, be identical to the parent cell, since they may exist in different However, these are still included within the scope of the term "host cell" as used herein. The host cell may be, for example, transiently expressing an extrachromosomal heterologous expression vector or, for example, The heterologous nucleic acid can be stably carried by integration into the genome. For purposes of illustration, the host cells are preferably monkey kidney cells (COS, e.g., COS- 1, COS-7), HEK293, baby hamster kidney (BHK, e.g., BHK21) , Chinese hamster ovary (CHO), NSO, PerC6, BSC-1, human hepatocyte Cellular carcinoma cells (e.g., Hep G2), SP2 / 0, HeLa, Madin-Darby-Williams Myeloma and lymphoma cells or their derivatives and / or modified forms and cell lines of mammalian origin or mammalian-like characteristics, such as variants. Examples include glycan profile modified and / or site-specific integrated site derivatives. .
[0045] Sequence Identity: The term percent "identity" refers to the percentage of two or more nucleic acid or polypeptide sequences. In the context of a sequence, this refers to two or more sequences that are the same. When measured using one of the rhythms or by manual alignment and visual inspection , compared and aligned for maximum matches over a comparison window or specified region. If so, a specified percentage of amino acid residues or nucleotides that are the same (e.g., a specified 60% identity over a specified region or, if not specified, over the entire sequence, optionally Selectively 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 7 9%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 8 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 9 Two sequences are "substantially identical" if they share at least 9% identity (9% identity or less). Identity is measured over at least about 50 nucleotides (or in the case of a peptide or polypeptide). over a region of length (in this case, at least about 10 amino acids) or more preferably 100 ~500 or 1000 or more nucleotides (or 20, 50, 20 The nucleotide sequence is present over a region of length (0 or more amino acids).
[0046] For sequence comparison, typically one sequence acts as a reference sequence, When using a sequence comparison algorithm, test and reference sequences are compared. The coordinates of the subarray are specified and the array algorithm program is executed as needed. Program parameters are specified. Default program parameters can be used, or Alternative parameters can be designated. The sequence comparison algorithm then runs Based on the data, the percent sequence identity of the test sequence relative to the reference sequence is calculated. Methods for aligning sequences for comparison are well known in the art. The optimal alignment of Nee by the local homology algorithm in Adv. Appl. Math. 2:482c dleman and Wunsch, 1970, J. Mol. Biol. 48:443 The homology alignment algorithm of Pearson and Lipman,1 988, Proc. Nat'l. Acad. Sci. USA 85:2444 The search methodology used by these algorithms (the Wisconsin Genetic GAP, BESTFIT, FASTA and T in the Software Package FASTA(Genetics Computer Group,575 Scienc. e Dr., Madison, WI)) by computer implementation or manual application Alignment and visual inspection (e.g., Brent et al., 2003, Curre See Protocols in Molecular Biology ) can be performed.
[0047] Two examples of suitable algorithms for determining percent sequence identity and sequence similarity are , BLAST, and BLAST 2.0 algorithms, which are Alts chul et al.,1977,Nuc.Acids Res.25:3389-3 402; and Altschul et al., 1990, J. Mol. Biol. 21 5:403-410. Software for performing BLAST analysis is available from Applied Mathematics, vol. National Center for Biotechnology Information This information is publicly available from the National Institute of Standards and Technology (NIS).
[0048] The percent identity between two amino acid sequences is calculated using the method of Meyers and Miller, Using the algorithm from 1988, Comput. Appl. Biosci. 4:11-17 The algorithm uses the PAM120 residue weight table, 12 gaps, and The ALIGN program (vers) was used with a group length penalty of 1 and a gap penalty of 4. Furthermore, the percent identity between two amino acid sequences is Needleman and Wunsch, 1970, J. Mol. Biol. 48:444-453) algorithm, which , Blossom 62 matrix or PAM250 matrix and 1 Gap weights of 6, 14, 12, 10, 8, 6, or 4 and lengths of 1, 2, 3, 4, 5, or 6 weights in the GCG software package (available at www.gcg.com) It is incorporated into the GAP program.
[0049] Conservative sequence modification: The term "conservative sequence modification" refers to a modification of a TBM or a component thereof (e.g., Amino acids that do not substantially affect or alter the binding properties of the ABM or Fc region Such conservative modifications include amino acid substitutions, additions, and deletions. Mutagenesis can be achieved by techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions can be introduced into the TBM of the present disclosure by conventional techniques. The amino acid residues are replaced with amino acid residues having similar side chains. Families of amino acid residues have been defined in the art. Examples include amino acids with basic side chains (e.g., lysine, arginine, histidine), Amino acids with polar side chains (e.g., aspartic acid, glutamic acid), amino acids (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with nonpolar side chains (e.g., arabinose, leucine, valine, leucine, isoleucine, proline, phenylalanine, methionine), Amino acids with β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic Amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine, Thus, one or more amino acid residues in the TBM of the present disclosure may be Other amino acid residues from the same side chain family can be substituted, and the modified TBM can be, for example, For binding to target molecules and / or effective heterodimerization and / or effector functions can be tested.
[0050] Mutation or modification: As used herein, in reference to a polypeptide, The terms "mutation" and "modification" may include substitution, addition, or deletion of one or more amino acids. .
[0051] Antibody numbering system: As used herein, numbered amino acid residues in an antibody domain References to the EU numbering system are based on the EU numbering system unless otherwise specified (e.g., Table 7B and 7C). This method is described by Edelman et al., 1969, Proc. Na Acad.Sci.USA 63:78-85, originally conceived by Kab at et al.,1991,in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA for details. It is written.
[0052] dsFv: The term "dsFv" refers to a disulfide-stabilized Fv fragment. In dsFv, VH and VL are linked by an interdomain disulfide bond. To generate a molecule such as are each mutated to cysteine, which then form stable interchain disulfide bonds Typically, position 44 in VH and position 100 in VL are mutated to cysteine. Brinkmann,2010,Antibody Engineering 181- 189,DOI:10.1007 / 978-3-642-01147-4_14 The term dsFv is known in the art. and VLs linked by interchain disulfide bonds rather than linker peptides) or scdsFv (VH and VL linked by a linker and an interchain disulfide bond) The term "molecules" encompasses both the nucleotide sequence and the nucleotide sequence.
[0053] Tandem of VH domains: As used herein, a "VH domain (or VH The term "tandem of VH domains" refers to a series of VH domains consisting of multiple identical VH domains of an antibody. Each VH domain, except for the last one at the end of the tandem, is connected to the linker - has its C-terminus linked to the N-terminus of another VH domain. has at least two VH domains, and in certain embodiments of the TBMs of the present disclosure, three , 4, 5, 6, 7, 8, 9 or 10 VH domains. Combinations with or without linkers that allow them to be produced as a single polypeptide chain 3. Use a recombination method (e.g., as described in Section 6.3.3) to recombine each V in the desired order. The first VH domain in tandem can be generated by combining nucleic acids encoding the VH domains. The main N-terminus is defined as the N-terminus of the tandem, while the final VH domain of the tandem The C-terminus of the in is defined as the C-terminus of the tandem.
[0054] Tandem of VL domains: As used herein, a "VL domain (or VL The term "tandem of VL domains" refers to a series of VL domains consisting of multiple identical VL domains of an antibody. Each VL domain, except for the last one at the end of the tandem, is connected to the linker The VL has its C-terminus linked to the N-terminus of another VL, with or without a VL. and in certain embodiments of the TBM of the present disclosure, 3, 4, 5 , 6, 7, 8, 9 or 10 VL domains. Recombinant methods with or without linkers that allow the polypeptide chains to be produced 3. Select each VL domain in the desired order using a method (e.g., as described in Section 6.3.3). The first VL domain of the tandem can be produced by combining the coding nucleic acid of the first VL domain. The N-terminus is defined as the N-terminus of the tandem, while the C of the last VL domain of the tandem The termini are defined as the C-termini of the tandem.
[0055] Monovalent: The term "monovalent" as used herein in reference to antigen-binding molecules , refers to an antigen-binding molecule that has a single antigen-binding domain.
[0056] Bivalent: The term "bivalent" as used herein in reference to an antigen-binding molecule refers to an antigen-binding molecule having two antigen-binding domains. The domains may be the same or Thus, a bivalent antigen-binding molecule can be monospecific or bispecific.
[0057] Trivalent: As used herein in reference to an antigen-binding molecule (e.g., TBM), The term "trivalent" refers to an antigen-binding molecule having three antigen-binding domains. The BM is trispecific, binding specifically to CD2, a component of the TCR complex, and a TAA Thus, the trivalent TBM of the present disclosure comprises at least three TBMs each binding to a different antigen. An example of a trivalent TBM of the present disclosure is shown schematically in Figures 1B-1U. will be done.
[0058] Tetravalent: "tetravalent" as used herein in reference to an antigen-binding molecule (e.g., TBM) The term "tetravalent" refers to an antigen-binding molecule having four antigen-binding domains. The BM is trispecific, binding specifically to CD2, a component of the TCR complex, and a TAA Thus, the tetravalent TBMs of the present disclosure generally bind to the same antigen (preferably a TAA). Two antigen-binding domains that combine with another antigen (preferably CD2 and TCR complexes) An example of a tetravalent TBM of the present disclosure is , which are shown schematically in Figures 1P-1R.
[0059] Pentavalent: "pentavalent" as used herein in reference to an antigen-binding molecule (e.g., TBM) The term "pentavalent" refers to an antigen-binding molecule having five antigen-binding domains. The BM is trispecific, binding specifically to CD2, a component of the TCR complex, and a TAA Thus, the pentavalent TBMs of the present disclosure generally comprise: (a) five TBMs each binding to the same antigen; two pairs of antigen-binding domains and a single antigen-binding domain that binds to a third antigen; or (b) Three antigen-binding domains that bind to the same antigen and two that each bind to a different antigen An example of a pentavalent TBM of the present disclosure is shown schematically in FIG. 1S. do.
[0060] Hexavalent: "hexavalent" as used herein in reference to an antigen-binding molecule (e.g., TBM). The term "hexavalent" refers to an antigen-binding molecule having six antigen-binding domains. The BM is trispecific, binding specifically to CD2, a component of the TCR complex, and a TAA The hexavalent TBM of the present disclosure generally comprises three pairs of antigen-binding domains, each of which binds to the same antigen. three antigen-binding domains that bind to TAAs, but in different forms (e.g., TC Two antigen-binding domains that bind to components of the R complex and one antigen-binding domain that binds to CD2 Three antigen-binding domains that bind to the binding domain or TAA, two antigen-binding domains that bind to CD2, The antigen-binding domain and one antigen-binding domain that binds to a component of the TCR complex are It is within the scope of the disclosure. Examples of hexavalent TBMs of the present disclosure are shown schematically in Figures 1T-1U.
[0061] Specific (or selective) binding: "specifically (or selectively)" binding to an antigen or epitope The term "bind" refers to the binding of a homologous antigen or enzyme to a heterogeneous population of proteins and other biological substances. The term "binding reaction" refers to a binding reaction that determines the presence of a target. It can be, but need not be, mediated by a sixth factor, e.g., a ligand, a DARPin, etc. The ABM of this disclosure may also be mediated by any type of ABM described in Section 3.2. , typically 5 × 10 -2 Under M, 10-2 Less than M, 5 x 10 -3 Under M, 10 -3 M not yet Full, 5 x 10 -4 Under M, 10 -4 Less than M, 5 x 10 -5 Under M, 10 -5 Less than M, 5x 10 -6 Under M, 10 -6 Less than M, 5 x 10 -7 Under M, 10 -7 Less than M, 5 x 10 -8 Under M, 10 -8 Less than M, 5 x 10 -9 Less than M or 10 -9 Dissociation rate constant (KD) less than M ) (koff / kon) and its ability to bind to non-specific antigens (e.g., HSA). Binds to a target antigen with an affinity at least two times higher than the affinity of the target antigen. The term "antigen" does not exclude cross-species reactivity. For example, an antibody that "specifically binds" to an antigen from one species may be An antigen-binding module (e.g., an antigen-binding fragment of an antibody) that is capable of binding to one or more other species Therefore, such cross-species cross-reactivity can be achieved by "specifically binding" to the corresponding antigen in the The sex itself does not change the classification of an antigen binding module as a "specific" binder. In embodiments, an antigen binding module of the disclosure that specifically binds to a human antigen (e.g., ABM1, ABM2 and / or ABM3) can be expressed in one or more non-human mammalian species, e.g., primates. Species (Macaca fascicularis, Rhesus macaques) aca mulatta) and pig-tailed macaques (Macaca nemestrina) or rodent species, such as, but not limited to, Mus musculus In another embodiment, the antigen of the present disclosure is The binding modules (e.g., ABM1, ABM2, and / or ABM3) have cross-species reactivity. No.
[0062] Monoclonal antibody: As used herein, the term "monoclonal antibody" refers to a The term refers to antibodies, antibody fragments, molecules (including TBMs) derived from the same genetic source. It refers to a polypeptide comprising:
[0063] Humanized: The term "humanized" forms of non-human (e.g., murine) antibodies refers to the use of non-human immunoglobulins. A humanized antibody is a chimeric antibody that contains minimal sequence derived from a human globulin. Residues from the recipient hypervariable region are selected to provide a polypeptide with the desired specificity, affinity, and potency. derived from the hypervariable regions of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate In some cases, the target antibody is a human immunoglobulin (recipient antibody) in which the target amino acid residues have been replaced by the target amino acid residues. , in which framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues Furthermore, humanized antibodies may contain residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. Generally, humanization An antibody comprises substantially all of at least one, and typically two, variable domains, wherein: All or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and the FR All or substantially all of the antibody is human immunoglobulin lo sequence. Optionally, at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin For further details, see Jones et al., 1986, Nature 321:522-525;Riechmann et al.,1988 , Nature 332:323-329; and Presta, 1992, Curr. O See p. Struct. Biol. 2:593-596. References cited in: Vaswani and Hamilton, 1998, An n.Allergy,Asthma&Immunol.1:105-115;Harri s,1995,Biochem.Soc.Transactions 23:1035- 1038;Hurle and Gross,1994,Curr.Op.Biotec See also h.5:428-433.
[0064] Human antibody: As used herein, the term "human antibody" refers to a human antibody in the framework Also included are antibodies having variable regions in which both the CDR and CDR regions are derived from sequences of human origin. Additionally, if the antibody contains a constant region, the constant region may be derived from such human sequences, e.g., human germline sequences. Human germline sequences or mutants of the human germline sequence or, for example, Knappik et al. As described in J Mol Biol 296, 57-86, 2000, The antibody-containing consensus framework sequence derived from framework sequence analysis also The structure and location of immunoglobulin variable domains, e.g., CDRs, are determined according to well-known numbering schemes. numbering scheme, e.g., Kabat numbering scheme, Chothia numbering scheme, or Kab It can be defined using a combination of at and Chothia (e.g., Lazikani e t al.,1997,J.Mol.Bio.273:927 948;Kabat e et al., 1991, Sequences of Proteins of Immu. nological interest,5th edit.,NIH Publica tion no.91-3242 USDepartment of Health and Human Services;Chothia et al.,1987, J.Mol.Biol.196:901-917;Chothia et al.,19 89, Nature 342:877-883).
[0065] Human antibodies may contain amino acid residues that are not encoded by human sequences (e.g., amino acids derived from in vitro Introduced by random or site-specific mutation or in vivo somatic mutation However, the present invention may contain mutations that enhance the stability or production of the polypeptides. However, the term "human antibody" as used herein refers to antibodies derived from other mammals, such as mice. CDR sequences derived from the germline of a mammalian species are grafted onto human framework sequences. The term "antibodies" is not intended to include antibodies.
[0066] Chimeric antibody: The term "chimeric antibody" (or antigen-binding fragment thereof) refers to: (a) The constant region or a part thereof is a class of antigen-binding site (variable region) that is different or modified. The chimeric antibody may also contain other antibody-specific constant regions, such as the nucleotide sequence, effector function, and / or species constant region, or a whole antibody that confers new properties to the chimeric antibody. They can be modified to be linked to different molecules, such as enzymes, toxins, hormones, growth factors, drugs, etc. (b) the variable region or a portion thereof is different or modified; Antibody molecules (or their antigen binding domains) that have been modified, substituted, or replaced with variable regions that have antigen specificity. For example, mouse antibodies derive their constant regions from human immunoglobulins. The substitution with a human constant region can modify the The murine antibody has reduced antigenicity in humans compared to the original murine antibody, while retaining its anti- It is possible to retain the specificity of the original when recognizing it.
[0067] Effector function: The term "effector function" usually refers to the binding of an effector molecule. by binding through a domain of the antibody other than the antigen-binding domain, which is mediated by binding Effector functions refer to the activities of antibody molecules mediated by the antibody. Complement activation involves the activation of complement-mediated effector functions mediated by the binding of complement factors. It is important in the opsonization and lysis of vacuolar pathogens. Complement activation also stimulates the inflammatory response. Effector functions are mediated by Fc receptors (FcRs) and may also be involved in autoimmune hypersensitivity. Effector functions also include binding of the constant domain of an antibody to an Fc receptor (FcR) Binding of antibodies to Fc receptors on the cell surface can sometimes result in the formation of antibodies that are coated on the cell surface. Phagocytosis and destruction of infected particles, clearance of immune complexes, and antibody-coated particles by killer cells Lysis of target cells (called antibody-dependent cell-mediated cytotoxicity or ADCC), inflammatory mediators, It plays many important and diverse roles in the regulation of receptor release, placental transit, and immunoglobulin production. The effector functions of antibodies are expressed through binding to antigens such as Fc receptors or complement components. By altering, e.g., increasing or decreasing, the affinity of the antibody for the effector molecule. Binding affinity can generally be altered by modifying the effector molecule binding site. In this case, the region of interest is located and at least a portion of this region is subjected to a suitable It is suitable to modify the antibody by the following method. The mutation need not substantially alter overall binding affinity, but may counteract effector mechanisms. It is also conceivable that the geometry of the interaction can be altered to nullify the binding. Effector functions can also be involved in the binding of effector molecules but not directly. It is further believed that the target function can be altered by modifying sites that are otherwise involved in the performance of target function. It is also possible that
[0068] Recognize: The term "recognize" as used herein refers to the ability of an individual to recognize an epitope. ABM refers to an ABM that finds a target and interacts with (e.g., binds to) it.
[0069] Epitope: An epitope or antigenic determinant is a molecule that binds to an antibody or other antigen described herein. An epitope is the portion of an antigen that is recognized by a binding moiety. An epitope can be linear or conformational. do.
[0070] Nucleic Acid: The term "nucleic acid" is used interchangeably herein with the term "polynucleotide." and deoxyribonucleotides or ribonucleotides in either single-stranded or double-stranded form. The term refers to nucleotides and their polymers, including synthetic, natural, and non-natural nucleotides. A known nucleotide that has similar binding properties to the reference nucleic acid and is metabolized similarly to the reference nucleotide. These include nucleic acids containing nucleotide analogs or modified backbone residues or linkages. Examples of thiol groups include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphatides, and the like. Sulfonates, chiral-methylphosphonates, 2-O-methylribonucleotides, peptides -nucleic acids (PNA).
[0071] Unless otherwise indicated, a particular nucleic acid sequence refers to the nucleic acid sequence, not just the sequence explicitly indicated. Conservatively modified variants of a sequence (e.g., degenerate codon substitutions) and complementary sequences are also implicitly encompassed. Specifically, as detailed below, degenerate codon substitutions are made by using one or more selected ( or all) codons with a substitution of mixed base and / or deoxyinosine residues at the third position. This can be achieved by generating sequences (Batzer et al., (1991) Nucleic Acid Res.19:5081;Ohtsuka et al., (1985) J. Biol. Chem. 260:2605-2608; and Rossol ini et al.,(1994)Mol.Cell.Probes 8:91-98 ).
[0072] Vector: The term "vector" refers to a vector that transports another polynucleotide to which it is linked. A vector is intended to refer to a polynucleotide molecule capable of carrying out the steps of: is a "plasmid," which is a vector into which additional DNA segments can be ligated. Another type of vector is a viral vector. wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial bacterial vectors with an origin of replication and episomal mammalian vectors). Other vectors (e.g. (e.g., non-episomal mammalian vectors) are vectors that, upon introduction into a host cell, are integrated into the genome of the host cell. In addition, certain vectors can be integrated into the host genome, thereby replicating along with the host genome. They are capable of inducing the expression of genes to which they are operably linked. These vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). Generally, expression vectors useful in recombinant DNA techniques are in the form of plasmids. Since plasmids are the most commonly used form of vector, In the specification, the terms "plasmid" and "vector" may be used interchangeably. However, the present disclosure also provides viral vectors (e.g., replication-deficient retroviruses) that perform equivalent functions. such other forms of expression vectors (e.g., HIV, adenoviruses and adeno-associated viruses) is intended to include.
[0073] Combination Sequence: Refer to Table 7, 8, 9, 11, 12 or 13 (including subportions thereof) The term "binding sequence" refers to a set of CDRs, a VH-VL pair or an scF means ABM with v.
[0074] VH-VL or VH-VL pair: refers to a VH-VL pair, either on the same polypeptide chain or on different polypeptide chains. Regardless of which polypeptide chains are involved, the terms "VH-VL" and "VH-VL pair" refer to are used for convenience and are not intended to indicate any particular orientation unless the context requires otherwise. Therefore, scFs containing "VH-VL" or "VH-VL pairs" are not intended to be synonymous with "VH-VL" or "VH-VL pairs." v can be VH and VL in any orientation, e.g., VH N-terminus to VL or VL N-terminus to VH. and a VL domain.
[0075] Polypeptides and proteins: The terms "polypeptide" and "protein" refer to The term is used interchangeably herein to refer to a polymer of amino acid residues. An amino acid in which one or more amino acid residues are artificial chemical mimics of the corresponding natural amino acid It also applies to polymers and to natural and non-natural amino acid polymers. Unless otherwise indicated, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof. do.
[0076] Subject: The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates. Animals, e.g., mammals such as non-human primates, sheep, dogs, cows, chickens, amphibians, and reptiles Unless otherwise specified, the term "patient" or "subject" refers to a mammal or non-mammal. Used interchangeably herein.
[0077] Cancer: The term "cancer" refers to the uncontrolled (often rapid) growth of abnormal cells. Cancer cells spread to the rest of the body either locally or through the bloodstream and lymphatic system. It may spread to other sites. Examples of various cancers are described herein, including but not limited to breast cancer, Prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colon cancer, kidney cancer, liver cancer, brain cancer, adrenal gland cancer Cancer, autonomic ganglionic cancer, biliary tract cancer, bone cancer , endometrial cancer, eye cancer, fallopian tube cancer, reproductive tract cancer, colon cancer, meningeal cancer Cancer of the esophagus, peritoneum, pituitary gland, penile cancer, placenta, pleural cancer, salivary gland cancer, small intestine cancer, stomach cancer, Testicular cancer, thymus cancer, thyroid cancer, upper respiratory tract cancer, urinary tract cancer, vaginal cancer, vulvar cancer, lymphoma, leukemia, lung Cancers, such as any TAA-positive cancer of any of the types described above.
[0078] Tumor: The term "tumor" is used interchangeably herein with the term "cancer." For example, both terms encompass solid and liquid, e.g., diffuse or circulating tumors. As used herein, the term "cancer" or "tumor" refers to pre-malignant as well as malignant cancers and This includes tumors.
[0079] Tumor-associated antigen: The term "tumor-associated antigen" or "TAA" refers to a molecule that is present on the surface of a cancer cell. It is expressed either as a whole or as a fragment (e.g., MHC / peptide) and acts on cancer cells. Molecules (typically proteins, carbohydrates, lipids) that are useful for preferential targeting of drugs In one embodiment, the TAA refers to a normal cell and Markers expressed by both cancer cells and cells, e.g., cell lineage markers, e.g., B cell markers In one embodiment, the TAA is CD19, which is expressed in cancer cells compared to normal cells. Overexpressed (e.g., 1-fold overexpression, 2-fold overexpression, 3-fold or more overexpression compared to normal cells) In one embodiment, the TAA is a cell surface molecule that is expressed on cancer cells, e.g., Inappropriate sequences within a molecule containing deletions, additions, or mutations compared to the molecule expressed in normal cells In one embodiment, the TAA is a cell surface molecule that is selectively synthesized on the cell surface of a cancer cell. expressed entirely or as fragments (e.g., MHC / peptide) on the surface only , are not synthesized or expressed on the surface of normal cells. Hence, the term "TAA" , sometimes known in the art as tumor-specific antigens ("TSAs"); It includes antigens specific to cancer cells.
[0080] Treat, Treatment, Treating: As used herein, "treat," "cure," The terms "therapy" and "treating" refer to a therapeutic agent resulting from the administration of one or more TBMs of the present disclosure. , a reduction or amelioration of the progression, severity and / or duration of a proliferative disorder or a reduction or amelioration of one of the proliferative disorders In certain embodiments, the term "improvement" refers to the improvement of one or more symptoms (preferably one or more identifiable symptoms). In this context, the terms "treat," "treatment," and "treating" are not necessarily used by patients. at least one measurable physical symptom of a proliferative disorder, such as tumor growth, that is not identified by In other embodiments, "treat," "treatment," and "treating" refer to an improvement in a patient's condition. The term "physical" refers to, for example, the stabilization of discernible symptoms, e.g., physical The stabilization of parameters may result in the inhibition of the progression of proliferative disorders, either physiologically or both. In other embodiments, the terms "treat," "treatment," and "treating" are used interchangeably. The term refers to a reduction or stabilization of tumor size or cancerous cell number.
[0081] 6.2. Antigen-binding Module Typically, one or more ABMs of the TBM of the present disclosure are immunoglobulin-based antigen-binding domains. These antibody fragments and derivatives include sequences of the antibody fragments and derivatives. The fragments and derivatives typically contain the CDRs of the antibody, as well as larger fragments and derivatives thereof. For example, it may include Fab, scFab, Fv and scFv.
[0082] 6.2.1. Immunoglobulin-based modules 6.2.1.1.Fab In certain embodiments, the ABM of the present disclosure is a Fab domain. Proteolytic cleavage of immunoglobulin molecules using enzymes such as papain or recombinant expression The Fab domain typically comprises a CL domain linked to a VL domain. It comprises a CH1 domain coupled to a VH domain that pairs with the CH2 domain.
[0083] In wild-type immunoglobulins, the VH domain is paired with the VL domain to form the Fv region. The CH1 domain is paired with the CL domain to further stabilize the binding module. The disulfide bond between the two constant domains may further stabilize the Fab domain. do.
[0084] In the TBM of the present disclosure, Fab heterodimerization techniques are used to separate Fabs belonging to the same ABM. Allows proper association of domains and prevents aberrant pairing of Fab domains belonging to different ABMs For example, the Fab heterodimerization shown in Table 1 below is advantageous. The technique can be used.
[0085] [Table 1]
[0086] Thus, in certain embodiments, the proper association between the two polypeptides of a Fab is , for example, Fab as described in WO 2009 / 080251 by swapping the VL and VH domains with each other, or by swapping the CH1 and CL domains with each other. This is facilitated by exchanging
[0087] A suitable Fab pairing may involve one or more amino acid modifications in the CH1 domain and one or more amino acid modifications in the CH2 domain. amino acid modifications into the CL domain of the Fab and / or one or more amino acid modifications into the V by introducing one or more amino acid modifications into the H domain and into the VL domain Fab components preferentially pair with each other over other Fab components. Thus, the amino acids that are modified are typically part of the VH:VL and CH1:CL boundaries. do.
[0088] In one embodiment, one or more amino acid modifications are indicated by the Kabat numbering of the residues. As shown, the conserved frames of the variable (VH, VL) and constant (CH1, CL) domains Almagro, 2008, Frontiers in Bioscience 13:1619-1633, Kabat, Chothia and and framework residue definitions based on the IMGT numbering scheme are provided.
[0089] In one embodiment, the VH and CH1 and / or VL and CL domains are introduced The modifications are complementary to each other. Complementarity at the heavy and light chain interface is due to steric and hydrophobic contacts. This can be achieved based on electrostatic / charge interactions or a combination of various interactions. Complementarity between surfaces allows for lock-and-key mating, knob-into-hole, protrusion and cavity , donors and acceptors, etc., which are all described in the literature as This suggests the nature of the structural and chemical match between the interacting surfaces.
[0090] In one embodiment, the one or more modifications introduced are novel modifications spanning the boundaries of the Fab components. In one embodiment, one or more of the modifications introduced are in the Fab structure. Introducing new salt bridges across the boundaries of the constituent elements. Exemplary substitutions are described in WO 2014 / 013494. 150973 brochure and WO 2014 / 082179 brochure and the contents of which are incorporated herein by reference.
[0091] In one embodiment, the Fab domain comprises a 192E substitution in the CH1 domain and a C It contains 114A and 137K substitutions in the L domain, which are located between the CH1 and CL domains. Introducing salt bridges (Golay et al., 2016, J Immunol 196 :3199-211).
[0092] In one embodiment, the Fab domain comprises 143Q and 188V in the CH1 domain. substitutions in the CH1 and CL domains, as well as 113T and 176V substitutions in the CL domain. It plays a role in alternating hydrophobic and polar contact regions between domains (Golay et al. l., 2016, J Immunol 196:3199-211).
[0093] In one embodiment, the Fab domains are directly linked to facilitate proper assembly of the Fab domains. In order to introduce cross-Fab boundaries, some or all of the VH, CH1, VL, and CL domains (Lewis et al., 2014 Nature Biol. (Echnology 32:191-198). In one embodiment, 39K, 62E The modification was introduced into the VH domain, and H172A and F174G modifications were introduced into the CH1 domain. The 1R, 38D, and (36F) modifications were introduced into the VL domain, and L135Y, S17 In another embodiment, a 6W modification is introduced into the CL domain. A 38R modification is introduced into the VL domain.
[0094] The Fab domain replaces the native CH1:CL disulfide bond with an engineered disulfide bond The Fab fragments may also be modified to increase the efficiency of Fab component pairing. The disulfide bonds are 126C in the CH1 domain and 121C in the CL domain. It can be introduced by introducing (Mazor et al., 2015, MAbs 7:377-89).
[0095] The Fab domain binds the CH1 and CL domains to another domain that facilitates proper assembly. It can also be modified by substitution at the base. For example, Wu et al., 2015 ,MAbs 7:364-76, which uses the CH1 domain of the α T cell receptor as a constant domain. and replacing the CL domain of the T cell receptor with the β domain, and The introduction of the D modification into the VL domain and the 39K modification into the VH domain resulted in a VL and combining these domain substitutions with additional charge-charge interactions between the VH domains. It is stated that:
[0096] The ABM of the present disclosure can comprise a single chain Fab fragment, which can be an antibody heavy chain. Variable domain (VH), antibody constant domain 1 (CH1), antibody light chain variable domain (VL), It is a polypeptide consisting of an antibody light chain constant domain (CL) and a linker. In the above, the antibody domains and linker are arranged in one of the following orders from N-terminus to C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1 c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-C The linker has at least 30 amino acids, preferably 32 to 50 amino acids. A single-chain Fab domain can be a polypeptide of 2 or 3 amino acids. It is stabilized by a natural disulfide bond between the amino acid and the hydroxyl group.
[0097] In one embodiment, the antibody domains and linker in the single chain Fab fragment are In one of the following orders from the terminal to the C-terminus: a) VH-CH1-linker-VL-CL or b) VL-CL-linker-VH-CH1, more preferably VL-CL-linker -VH-CH1.
[0098] In another embodiment, the antibody domains and linker in a single-chain Fab fragment are In one of the following orders from N-terminus to C-terminus: a) VH-CL-linker-VL-CH 1 or b) VL-CH1-linker-VH-CL.
[0099] Optionally, in the single chain Fab fragment, the CL-domain and the CH1 domain In addition to the natural disulfide bonds between the antibody heavy chain variable domain (VH) and the antibody light chain variable domain (LCH), The variable domains (VL) are located at the following positions: i) position 44 in the heavy chain variable domain and position 54 in the light chain variable domain ii) position 105 in the heavy chain variable domain and position 43 in the light chain variable domain, or iii) Heavy chain variable domain position 101 and light chain variable domain position 100 (Kabat EU index) Disulfide stabilization can also be achieved by the introduction of disulfide bonds between the amino acids (numbered by the amino acid sequence).
[0100] This additional disulfide stabilization of the single-chain Fab fragment provides This is achieved by introducing a disulfide bond between the variable domains VH and VL of the fragment. Techniques for introducing non-native disulfide bridges for the stabilization of single-chain Fvs are available, e.g. For example, see International Publication No. 94 / 029350, Rajagopal et al. ,1997,Prot.Engin.10:1453-59;Kobayashi et. al.,1998,Nuclear Medicine&Biology,25:38 7-393; and Schmidt, et al., 1999, Oncogene 18: 1711-1721. In one embodiment, a single chain Fab fragment The optional disulfide bond between the variable domains of the heavy chain and the light chain is at position 44 of the variable domain. In one embodiment, the variable region of the single chain Fab fragment is located between domains 100 and 100. An optional interdomain disulfide bond is located at position 105 of the heavy chain variable domain and at position 106 of the light chain variable domain. It is between 43rd and 44th place (numbering according to Kabat's EU index).
[0101] 6.2.1.2.scFv Single-chain Fv or "scFv" antibody fragments contain the V of an antibody in a single polypeptide chain. It contains H and VL domains and can be expressed as a single polypeptide chain, scFv polypeptides retain the specificity of the intact antibody from which they are derived. V between the VH and VL domains, which enables them to form the desired structure for target binding. The scFv further comprises a polypeptide linker. Examples of linkers are the ABM linkers identified in Section 6.3.3, e.g., L1-L54. The linker is either one of the linkers shown as
[0102] Unless otherwise specified, as used herein, scFv refers to, e.g., a polypeptide and may have the VL and VH variable regions in either order with respect to the N- and C-termini of the peptide, The scFv may comprise VL-linker-VH or VH-linker-VL.
[0103] To generate scFv-encoding nucleic acids, VH- and VL-encoding DNA fragments are 6.3.3, encoding an ABM linker, e.g., any of the ABM linkers described in Section 6.3.3 Another fragment encoding the amino acid sequence (Gly4-Ser) (SEQ ID NO: 1) and the VL and VH regions are joined by a flexible linker, The VH and VL sequences are designed to be expressed as a contiguous single-chain protein ( See, e.g., Bird et al., 1988, Science 242:423-426 ;Huston et al.,1988,Proc.Natl.Acad.Sci.U SA 85:5879-5883;McCafferty et al.,1990,N ature 348:552-554).
[0104] 6.2.1.3. Other Immunoglobulin-Based Modules The TBM of the present disclosure can be a Fab or scFv, e.g., Fv, dsFv, (Fab'), single Single domain antibodies (SDAB), VH or VL domains or camelids ) ABMs with immunoglobulin formats other than VHH domains (also called nanobodies) It may also include.
[0105] ABMs consist of a single VH or VL domain that exhibits sufficient affinity for the target. In certain embodiments, the single domain antibody may be a camelid-derived single domain antibody. family VHH domains (e.g., Riechmann, 1999, Journal of f Immunological Methods 231:25-38; International Publication No. 9 (See brochure no. 4 / 04678).
[0106] 6.2.2. Non-immunoglobulin-based modules In certain embodiments, one or more of the ABMs of the present disclosure are non-antibody scaffold proteins (e.g., engineered Defective ankyrin repeat proteins (DARPins), avimers (avidity multimers) abbreviations), anticalins / lipocalins, centirins, Kunitz domains, adnexins , affilin, affitin (also known as nonphytin), knottin, pronec including, but not limited to, Chin, Versabody, Duocalin and Finomer), It is derived from a ligand, receptor, cytokine or chemokine.
[0107] Non-immunoglobulin scaffolds that may be used in the TBM of the present disclosure include those described by Mintz et al. nd Crea,2013,Bioprocess International 11 (2):40-48, Tables 3 and 4; Vazquez-Lombardi et al., 2015, Drug Discovery Today 20(10):1271-83 Figure 1, Table 1 and Figure I of Skrlec et al., 2015, Trends in Biotechnology 33(7):408-18, Table 1 and Box 2. Mintz and Crea, 2013, Bioproces s International 11(2):40-48, Tables 3 and 4; Vazque z-Lombardi et al.,2015,Drug Discovery To day 20(10):1271-83, Figure 1, Table 1 and Figure I; Skrlec et al. l.,2015,Trends in Biotechnology 33(7):40 The contents of Table 1 and Box 2 of Parts 8-18 (collectively, the "Scaffolding Disclosure") are incorporated herein by reference. In certain embodiments, the disclosure of scaffolds is incorporated herein by reference. In another embodiment, the scaffold disclosure is They are incorporated by reference for what they disclose regarding avimers. In the present application, the disclosures of scaffolds are incorporated by reference for what they disclose regarding affibodies. In yet another embodiment, the scaffold disclosure relates to anticalins. In yet another embodiment, the development of a scaffold The disclosures in this application are incorporated by reference for what they disclose regarding DARPins. In another embodiment, the disclosure of scaffolds is in accordance with the disclosure of scaffolds as they relate to Kunitz domains. In yet another embodiment, the scaffold disclosure is is incorporated by reference for its disclosure regarding knottins. , the disclosures of scaffolds are incorporated by reference for what they disclose with respect to Pronectin. In yet another embodiment, the scaffold disclosure relates to nanophytin. In yet another embodiment, the development of a scaffold are incorporated by reference for what they disclose regarding affilins. In another embodiment, the disclosure of scaffolds is similar to that of Adnectins. In yet another embodiment, the scaffold disclosure provides that they are In yet another embodiment, The disclosures of Scaffold are incorporated by reference for what they disclose regarding Adviron. In yet another embodiment, the disclosure of scaffolds is inconsistent with that disclosed for Affimers. In yet another embodiment, the scaffold disclosure is is incorporated by reference for its disclosure regarding alpha bodies. In some embodiments, the scaffolds disclosed relate to armadillo repeat proteins. In yet another embodiment, the scaffold disclosure is is incorporated by reference for its disclosure regarding atrimer / tetranectin. In yet another embodiment, the disclosure of scaffolds provides that they are capable of binding to obody / OB-folds. In yet another embodiment, the scaffold The disclosures of which are incorporated by reference for what they disclose regarding centrins. In yet another embodiment, the disclosure of scaffolds is similar to that disclosed for repebodies. In yet another embodiment, the scaffold disclosure provides that they The disclosure regarding anticalin is incorporated by reference. In this application, the disclosures of the scaffolds are incorporated by reference for what they disclose regarding atrimers. In yet another embodiment, the scaffold disclosure relates to bicyclic peptides. In yet another embodiment, the development of a scaffold The disclosures are incorporated by reference for what they disclose regarding cys-knots. In yet another embodiment, the disclosure of scaffolds further provides that they are Fn3 scaffolds (adnectins, centrinoids, erythropoietins, erythrocytic leukemia ... (including Lilin, Pronectin, and Tn3) will be done.
[0108] In one embodiment, the ABM of the present disclosure is an engineered ankyrin repeat protein ( DARPins can be highly specific and high affinity target proteins. Antibody mimetic proteins typically exhibit protein binding. The ankyrin protein is recombinantly derived from a natural ankyrin protein, and at least one of these proteins is They consist of three, usually four or five repeating motifs. Their molecular weight is The repeat DARPins are approximately 14 or 18 kDa (kilodaltons), respectively. Examples of DARPin-containing compounds can be found, for example, in U.S. Patent No. 7,417,130. Multispecific binding molecules comprising a binding module and an immunoglobulin-based binding module are For example, the method disclosed in U.S. Patent Application Publication No. 2015 / 0030596 A1 .
[0109] In another embodiment, the ABM of the present disclosure can be an affibody. , which are well known in the art and are used in the treatment of staphylococcal A 58 amino acid residue protein domain derived from one of the IgG-binding domains of tein A It refers to an affinity protein based on
[0110] In another embodiment, the ABM of the present disclosure can be an anticalin. is well known in the art and refers to another antibody mimetic technology, in which the binding specificity Anticalins are derived from lipocalins. Dual-targeting anticalins are called duocalins. It can also be formatted as a protein.
[0111] In another embodiment, the ABM of the present disclosure can be a Versabody. are well known in the art and refer to other antibody mimetic technologies. forming a high disulfide density scaffold that replaces the hydrophobic core of typical proteins; It is a small protein of 3-5 kDa with more than 15% cysteine.
[0112] Other non-immunoglobulin ABMs include "A" domain oligomers (also known as avimers). known) (see, for example, U.S. Patent Application Publication No. 2005 / 0164301; See Patent Publications 2005 / 0048512 and 2004 / 017576. ), Fn3-based protein scaffolds (e.g., U.S. Patent Application Publication No. 2003 / 017 0753), VASP polypeptide, avian pancreatic polypeptide (a PP), tetranectin (CTLD3-based), affilirin (γB-crystallin) phospho / ubiquitin-based), knottin, SH3 domain, PDZ domain, ten Damistat, neocarzinostatin, protein A domain, lipocalin, transferrin In one embodiment, the TBMs of the present disclosure include those useful in constructing TBMs. A useful ABM is the fibrous ABM exemplified in WO 2011 / 130324. Including nectin-based scaffolds.
[0113] Additionally, in certain embodiments, the ABM is a ligand binding domain of a receptor or a ligand For example, when the TAA is an EGF receptor, ABM3 contains the receptor binding domain: The ABM may contain a portion of EGF that binds to EGFR, and if the TAA is a PDGF receptor, 3 may comprise a portion of PDGF that binds to PDGF, etc. In certain embodiments, ABM1 is a CD2 ligand, and in particular the CD58 portion described in Section 6.6.2. The respective binding domains of many ligand / receptor pairs are well known in the art. are well known and can therefore be readily selected and adapted for use in the TBMs of the present disclosure.
[0114] Connectors The TBMs of the present disclosure may, in some cases, be combined with one another, e.g., as fusion proteins without a linker. ABM or a pair of ABM chains (e.g., VH-CH1 or VL-C of Fab) directly linked to It is contemplated that the TBM of the present disclosure may comprise individual Connector moieties that link ABMs or ABM chains are included. The use of connector moieties can be, for example, Enhance target binding by increasing the flexibility of ABM within the BM, thereby reducing steric hindrance. ABMs can be improved by, for example, Fc domains (each Fc domain is an associated Fc region) The Fc domain may be linked to each other via a nucleotide pair (representing a nucleotide pair) and / or an ABM linker. The use typically involves the use of a hindpeptide as a connector for the ABM or ABM chain for optimal antigen binding. Therefore, the term "connector" includes, but is not limited to, , Fc region, Fc domain, hinge region.
[0115] Fc domain (formed by pairing of two Fc domains), hinge region and ABM link Examples of anchors are given in Sections 6.3.1, 6.3.2 and 6.3.3, respectively.
[0116] Fc Domain The TBM of the present disclosure may comprise an Fc domain from any suitable species. In this case, the Fc domain is derived from a human Fc domain.
[0117] The Fc domain is responsible for IgA (including subclasses IgA1 and IgA2), IgD, and IgE , IgG (including subclasses IgG1, IgG2, IgG3, and IgG4) and IgM In one embodiment, the Fc domain may be derived from any suitable class of antibody, including: It is derived from IgG1, IgG2, IgG3 or IgG4. In one embodiment, the Fc domain In one embodiment, the Fc domain is derived from IgG1. In another embodiment, the Fc domain is derived from IgG4. do.
[0118] The Fc domain contains two polypeptide chains, each called a heavy chain Fc region. The heavy chain Fc regions of the IgG1 and IgG2a dimerize to generate the Fc domain. The Fc regions of the antibodies may be the same or different from each other. In a native antibody, the Fc region is typically For purposes of generating typologically identical, but multispecific, binding molecules, such as the TBMs of the present disclosure, Additionally, the Fc region can be heterodimerized, as described in Section 6.3.1.5 below. may be advantageously different to achieve
[0119] Typically, each heavy chain Fc region comprises or consists of two or three heavy chain constant domains. become.
[0120] In natural antibodies, the heavy chain Fc regions of IgA, IgD, and IgG consist of two heavy chain constant domains. The heavy chain Fc region of IgE and IgM consists of three heavy chains (CH2 and CH3). The Fc domain is composed of the Fc chain constant domains (CH2, CH3, and CH4). dimerize to produce
[0121] In the present disclosure, the heavy chain Fc region may be a region of one or more different classes of antibodies, e.g., one, two, or more. or may comprise heavy chain constant domains from three different classes.
[0122] In one embodiment, the heavy chain Fc region comprises the CH2 and CH3 domains derived from IgG1. Includes:
[0123] In one embodiment, the heavy chain Fc region comprises CH2 and CH3 domains derived from IgG2. Includes:
[0124] In one embodiment, the heavy chain Fc region comprises the CH2 and CH3 domains derived from IgG3. Includes:
[0125] In one embodiment, the heavy chain Fc region comprises CH2 and CH3 domains derived from IgG4. Includes:
[0126] In one embodiment, the heavy chain Fc region comprises a CH4 domain derived from IgM. The M CH4 domain is typically located C-terminal to the CH3 domain.
[0127] In one embodiment, the heavy chain Fc region comprises CH2 and CH3 domains derived from IgG. and the CH4 domain derived from IgM.
[0128] Heavy chain constant domains for use in generating heavy chain Fc regions for TBMs of the present disclosure It will be understood that the constant domains may include variants of the naturally occurring constant domains described above. Such variants may contain one or more amino acid changes compared to the wild-type constant domain. The heavy chain Fc region of the present disclosure comprises at least one constant domain that differs in sequence from a wild-type constant domain. The variant constant domain may be longer or shorter than the wild-type constant domain. It will be appreciated that the variant constant domain may be a variant of the wild-type constant domain. In another example, the variant is at least 60% identical or similar to the domain. Common domains are at least 70% identical or similar. The constant domains are at least 80% identical or similar. The variant constant domains are at least 90% identical or similar. Thus, the variant constant domains are at least 95% identical or similar. Fc variants are described below in Sections 6.3.1.1-6.3.1.5.
[0129] IgM and IgA are naturally occurring in humans as covalently linked multimers of a common H2L2 antibody unit. IgM exists as a pentamer when incorporating a J chain, or as a pentamer when incorporating a J chain. IgA exists as a hexamer when the IgG is absent. IgA exists in both monomeric and dimeric forms. The heavy chains of IgM and IgA consist of a single chain connected to a C-terminal constant domain known as the tail. The tail has an 8 amino acid extension. The tail forms disulfide bonds between the heavy chains in the polymer. The tail contains a cysteine residue that is thought to play an important role in polymerization. It also contains glycosylation sites. In certain embodiments, the TBM of the present disclosure does not include a tail. do not have.
[0130] The Fc domain incorporated into the TBM of the present disclosure alters the functional properties of the protein One or more modifications, such as binding to FcRn or leukocyte receptors (e.g. 6.3.1.1), complement binding (e.g., as described in Section 6.3.1.1), 6.3.1.2), modified disulfide bond structures (e.g., as described in Section 6.3.1.3), ) or modified glycosylation patterns (e.g., as described in Section 6.3.1.4). The Fc domain may comprise, for example, a non-identical Fc region. By enabling heterodimerization, which is the preferential pairing of the c region, asymmetric TBM production is achieved. The heterodimerization can also be performed by combining different AB M are TBMs linked to each other by Fc domains containing Fc regions with different sequences Examples of heterodimerization techniques are provided in Section 6.3.1.5 (and its subsections). This is illustrated in the example below.
[0131] Any of the modifications described in Sections 6.3.1.1 to 6.3.1.5 may be used in any suitable manner. may be combined in a manner to achieve desired functional properties and / or combined with other modifications. It will be appreciated that the properties of the TBM may be modified by the addition of a hydroxyl group.
[0132] 6.3.1.1. Fc Domains with Altered FcR Binding The Fc domain of the TBM of the present disclosure has one or more The antibody may exhibit altered binding to Fc-receptors (FcRs) of any particular Fc-receptor. In one embodiment, the binding to the Fc- It contains one or more modifications that alter the receptor binding profile.
[0133] The human cells are selected from FcαR, FcεR, FcγR, FcRn and glycan receptors. Some cells express soluble (extracellular domain) FcRs. It is also possible to express FcRs (for review, see Fridman et al., 1993, J Leukocyte Biology 54:504-512). Fcγ R is further determined by the affinity of IgG binding (high / low) and biological effect (activation / inhibition). Human FcγRI is widely considered to be the only "high affinity" receptor. whereas all others are thought to have intermediate to low affinity. It is the only receptor with "inhibitory" functionality due to its intracellular ITIM motif, while all others is "activated" by the ITAM motif or pairs with the common FcγR-γ chain FcγRIIIb is active, but it binds to cells via a GPI anchor. Overall, humans have six "canonical" FcγRs: Fc γRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa Fcγ In addition to these sequences, there are multiple sequences spread across these families. Numerous sequence or allotypic variants exist, some of which have important functional consequences. It has been shown that β-glucanase receptors are involved in the expression of β-glucanase receptors, and therefore may be considered to be their own receptor subtype. Examples include FcγRIIa H134R , FcγRIIb I190T , Fcγ RIIIa F158V and FcγRIIIb NA1 , FcγRIIIb NA2 FcγR III SH Each receptor sequence includes IgG: IgG1, IgG2, IgG3, and It has been shown to have different affinities for the four subclasses of IgG4 (Bruhn s, 1993, Blood 113:3716-3725). Other species have some FcγRs. The mouse system is the best studied to date, with four FcγRs, each with different numbers and functionality. , FcγRI FcγRIIb FcγRIII FcγRIV (Bruhns, 2012, Blood 119:5640-5649). Human FcγRI on cells is commonly Usually, its affinity for IgG1 / IgG3 / IgG4 (approximately 10 -8 M) and serum The concentration of these IgGs (approximately 10 mg / ml) is such that they are produced by monomeric IgG under normal serum conditions. Therefore, they are thought to be "occupied" by FcγRI. The cells that respond to the antigen are surrogately screened for their antigen environment by the bound multispecific IgG. It is thought that "sampling" or "scanning" of IgG subclasses is possible. Lower affinity (approximately 10 -5 ~10 -7 Other receptors with receptors in the M range are usually Therefore, low affinity receptors are considered to be the most effective in preventing antibody-mediated immune complexes. The antibody is inherently sensitive to detection and activation by the complex. The added Fc density also results in increased functional affinity of binding to low affinity FcγRs. This has been demonstrated in vitro using several methods (Shields et al., 2004). t al.,2001,J Biol Chem 276(9):6591-6604; Lux et al., 2013, J Immunol 190:4315-4323) It is believed that this is the primary mode of action in the use of anti-RhD to treat ITP in humans. It has also been suggested that this is one of the factors (Crow, 2008, Transfusion Mechanism). dicine Reviews 22:103-116).
[0134] Many cell types express multiple types of FcγR, and therefore, FcγR-bearing cells The binding of IgG or antibody immune complexes to cells can have multiple and complex outcomes depending on the biological context. Most simply, cells can receive either activating, inhibitory, or mixed signals. This includes phagocytosis (e.g., macrophages and neutrophils), antigen processing (e.g., dendritic cells), decreased IgG production (e.g., B cells) or degranulation (e.g., neutrophils) Inhibitory signals from FcγRIIb can lead to events such as activation signals. There is data supporting that it may be superior to the naru one (Proulx, 2010, Clinical Immunology 135:422-429).
[0135] FcRn plays an important role in maintaining the long half-life of IgG in serum in adults and children. The receptor binds to IgG in acidified vesicles (pH < 6.5) and releases IgG molecules. It protects the molecule from degradation and then releases it at the higher pH of 7.4 in the blood.
[0136] FcRn differs from leukocyte Fc receptors, instead sharing structural similarity with MHC class I molecules. It consists of a β2-protein complex non-covalently linked to a membrane-associated chain containing three extracellular domains. It is a heterodimer composed of microglobulin chains. These chains contain carbohydrate chains. The main one, together with β2-microglobulin, is between the CH2 and CH3 domains of Fc. The interaction occurs at pH < 6.5, where the histidine residues on IgG are positively charged. At higher pH, His residues lose their positive charge. This leads to loss of FcRn-IgG interaction, weakening the FcRn-IgG interaction and dissociation of IgG.
[0137] In one embodiment, the TBM of the present disclosure comprises an Fc domain that binds to human FcRn. .
[0138] In one embodiment, the Fc domain also contains a histidine at position 310, preferably at position 435. and one (e.g., one or two) Fc region containing these histidine residues. are important for human FcRn binding. The histidine residues in the nucleotide sequence are natural residues, i.e., positions 310 and 435 are modified. Alternatively, one or both of these histidine residues may be present as a result of modification. .
[0139] The TBMs of the present disclosure may comprise one or more Fc regions that alter Fc binding to FcRn. The altered binding can be increased binding or decreased binding.
[0140] In one embodiment, the TBM comprises at least one (and optionally both) Fc region comprising: It binds to FcRn with higher affinity and avidity than the corresponding native immunoglobulin. The Fc domain comprises one or more modifications to provide a
[0141] In one embodiment, the Fc region replaces the threonine residue at position 250 with a glutamine residue (T250Q).
[0142] In one embodiment, the Fc region modifies the methionine residue at position 252 to a tyrosine residue ( M252Y).
[0143] In one embodiment, the Fc region mutates the serine residue at position 254 to a threonine residue (S 254T).
[0144] In one embodiment, the Fc region replaces the threonine residue at position 256 with a glutamic acid residue. The compound is modified by substituting it with the group (T256E).
[0145] In one embodiment, the Fc region replaces the threonine residue at position 307 with an alanine residue ( T307A).
[0146] In one embodiment, the Fc region mutates the threonine residue at position 307 with a proline residue ( It is modified by substituting with T307P.
[0147] In one embodiment, the Fc region mutates the valine residue at position 308 to a cysteine residue (V 308C).
[0148] In one embodiment, the Fc region replaces the valine residue at position 308 with a phenylalanine residue. It is modified by substituting with the group (V308F).
[0149] In one embodiment, the Fc region is modified by substituting a valine residue at position 308 with a proline residue (V3 08P).
[0150] In one embodiment, the Fc region mutates the glutamine residue at position 311 with an alanine residue ( Q311A).
[0151] In one embodiment, the Fc region replaces the glutamine residue at position 311 with an arginine residue (Q311R).
[0152] In one embodiment, the Fc region comprises a methionine residue at position 428 replaced by a leucine residue ( M428L).
[0153] In one embodiment, the Fc region comprises a histidine residue at position 433 replaced by a lysine residue (H 433K).
[0154] In one embodiment, the Fc region comprises an Fc region in which the asparagine residue at position 434 is replaced by a phenylalanine residue. It is modified by substituting the nin residue (N434F).
[0155] In one embodiment, the Fc region replaces the asparagine residue at position 434 with a tyrosine residue (N434Y).
[0156] In one embodiment, the Fc region comprises an Fc amino acid sequence in which the methionine residue at position 252 is replaced with a tyrosine residue. The serine residue at position 254 is replaced with a threonine residue, and the threonine residue at position 256 is replaced with a threonine residue. by substituting the α-glutamic acid residues (M252Y / S254T / T256E) be qualified.
[0157] In one embodiment, the Fc region comprises a valine residue at position 308 replaced with a proline residue, and and replacing the asparagine residue at position 434 with a tyrosine residue (V308P / N434Y). It is modified by
[0158] In one embodiment, the Fc region comprises an Fc amino acid sequence in which the methionine residue at position 252 is replaced with a tyrosine residue. , the serine residue at position 254 is replaced by a threonine residue, and the threonine residue at position 256 is replaced by a threonine residue. A glutamic acid residue was replaced with a lysine residue at position 433 and a histidine residue at position 434. The asparagine residue in / H433K / N434F).
[0159] It is understood that any of the modifications listed above may be combined to alter FcRn binding. It will be understood.
[0160] In one embodiment, the TBM comprises one or both Fc regions of a corresponding Fc domain. One or more immunoglobulins are designed to bind to FcRn with lower affinity and avidity than native immunoglobulins. The Fc domain contains the above modifications.
[0161] In one embodiment, the Fc region comprises histidine at positions 310 and / or 435. Any amino acid residue other than
[0162] The TBM of the present disclosure comprises one or both Fc regions that have increased binding to FcγRIIb. FcγRIIb may comprise an Fc domain containing one or more modifications that enhance the expression of FcγRIIb. It is the only inhibitory receptor and the only Fc receptor found on B cells.
[0163] In one embodiment, the Fc region replaces the proline residue at position 238 with an aspartic acid residue. The compound is modified by substituting it with the group (P238D).
[0164] In one embodiment, the Fc region replaces the glutamic acid residue at position 258 with an alanine residue (E258A).
[0165] In one embodiment, the Fc region is modified by substituting the serine residue at position 267 with an alanine residue (S2 67A).
[0166] In one embodiment, the Fc region comprises a nucleotide sequence in which the serine residue at position 267 is replaced with a glutamic acid residue ( S267E).
[0167] In one embodiment, the Fc region mutates the leucine residue at position 328 with a phenylalanine It is modified by substituting with residue (L328F).
[0168] In one embodiment, the Fc region replaces the glutamic acid residue at position 258 with an alanine residue and the serine residue at position 267 is replaced with an alanine residue (E258A / S267A). It is modified by
[0169] In one embodiment, the Fc region comprises an Fc amino acid sequence in which the serine residue at position 267 is replaced with a glutamic acid residue. and the leucine residue at position 328 is replaced with a phenylalanine residue (S267E / L328F )
[0170] Any of the modifications listed above may be combined to increase FcγRIIb binding It will be understood that.
[0171] In one embodiment of the present disclosure, a T cell comprising an Fc domain that exhibits reduced binding to FcγRs is provided. BM is provided.
[0172] In one embodiment, the TBM comprises one or both Fc regions that confers Fc binding to FcγR. The Fc domain comprises one or more modifications that reduce the
[0173] The Fc domain may be derived from IgG1.
[0174] In one embodiment, the Fc region mutates the leucine residue at position 234 with an alanine residue (L 234A).
[0175] In one embodiment, the Fc region mutates the leucine residue at position 235 with an alanine residue (L 235A).
[0176] In one embodiment, the Fc region replaces the glycine residue at position 236 with an arginine residue ( G236R).
[0177] In one embodiment, the Fc region replaces the asparagine residue at position 297 with an alanine residue (N297A) or glutamine residue (N297Q).
[0178] In one embodiment, the Fc region is modified by substituting the serine residue at position 298 with an alanine residue (S2 98A).
[0179] In one embodiment, the Fc region mutates the leucine residue at position 328 with an arginine residue ( L328R).
[0180] In one embodiment, the Fc region comprises an Fc amino acid sequence comprising the leucine residue at position 234 replaced by an alanine residue; and replacing the leucine residue at position 235 with an alanine residue (L234A / L235A). It is modified by
[0181] In embodiments, the Fc region replaces the phenylalanine residue at position 234 with an alanine residue. and the leucine residue at position 235 was replaced with an alanine residue (F234A / L235A). It is modified by substitution.
[0182] In one embodiment, the Fc region comprises an Fc amino acid sequence in which the glycine residue at position 236 is replaced with an arginine residue. and replacing the leucine residue at position 328 with an arginine residue (G236R / L328R). It is modified by converting
[0183] It has been found that any of the modifications listed above may be combined to reduce FcγR binding. It will be understood.
[0184] In one embodiment, the TBM of the disclosure has one or both Fc regions responsive to FcγRII. One or more modifications that decrease Fc binding to FcγRIIIa without affecting Fc binding to other Fc. It contains an Fc domain containing a decoration.
[0185] In one embodiment, the Fc region is modified by substituting the serine residue at position 239 with an alanine residue (S2 39A).
[0186] In one embodiment, the Fc region replaces the glutamic acid residue at position 269 with an alanine residue (E269A).
[0187] In one embodiment, the Fc region replaces the glutamic acid residue at position 293 with an alanine residue (E293A).
[0188] In one embodiment, the Fc region comprises a tyrosine residue at position 296 replaced by a phenylalanine It is modified by substituting with residue (Y296F).
[0189] In one embodiment, the Fc region is modified by substituting a valine residue at position 303 with an alanine residue (V3 03A).
[0190] In one embodiment, the Fc region mutates the alanine residue at position 327 with a glycine residue (A 327G).
[0191] In one embodiment, the Fc region is modified by substituting the lysine residue at position 338 with an alanine residue (K3 38A).
[0192] In one embodiment, the Fc region is modified by replacing the aspartic acid residue at position 376 with an alanine residue. The compound is modified by substituting it with the group (D376A).
[0193] Any of the modifications listed above may be combined to reduce FcγRIIIa binding. It will be understood that
[0194] 6.3.1.2. Fc Domain with Altered Complement Binding The TBMs of the present disclosure may comprise one or both Fc regions containing one or more polypeptides that alter Fc binding to complement. The modified complement binding may include an Fc domain containing a modification of The bond may be a bond.
[0195] In one embodiment, the Fc region contains one or more modifications that reduce its binding to C1q. The initiation of the classical complement pathway involves the binding of hexamers to the CH2 domain of antigen-binding IgG and IgM. It starts with the binding of C1q protein.
[0196] In one embodiment, the TBM of the present disclosure comprises one or both Fc regions that are Fc competent to C1q. It comprises an Fc domain containing one or more modifications that decrease binding.
[0197] In one embodiment, the Fc region mutates the leucine residue at position 234 with an alanine residue (L 234A).
[0198] In one embodiment, the Fc region mutates the leucine residue at position 235 with an alanine residue (L 235A).
[0199] In one embodiment, the Fc region replaces the leucine residue at position 235 with a glutamic acid residue (L235E).
[0200] In one embodiment, the Fc region mutates the glycine residue at position 237 with an alanine residue (G 237A).
[0201] In one embodiment, the Fc region is modified by substituting the lysine residue at position 322 with an alanine residue (K3 22A).
[0202] In one embodiment, the Fc region mutates the proline residue at position 331 to an alanine residue (P 331A).
[0203] In one embodiment, the Fc region is modified by substituting the proline residue at position 331 with a serine residue (P3 31S).
[0204] In one embodiment, the TBM of the present disclosure comprises an Fc domain derived from IgG4. IgG4 not only inherently has a lower complement activation profile than IgG1, but also has a lower Fcγ Thus, in one embodiment, the TBM also has weaker binding of IgG4 F c domain and also contain one or more modifications that increase FcγR binding.
[0205] It is understood that any of the modifications listed above may be combined to reduce C1q binding. It will be understood.
[0206] 6.3.1.3. Fc Domains with Engineered Disulfide Structures The TBMs of the present disclosure may contain one or more modifications to create and / or remove cysteine residues. Cysteine residues may be located between each pair of polypeptide monomers. Spontaneous assembly of Fc-based multispecific binding molecules by disulfide bridge formation Therefore, modifying the number and / or position of cysteine residues By doing so, the structure of TBM can be modified to produce proteins with improved therapeutic properties. It is possible to do this.
[0207] The TBM of the present disclosure may comprise one or both Fc regions, preferably both Fc regions, each comprising a nucleotide sequence at position 309. In one embodiment, the Fc domain may comprise a cysteine residue at position 309. The cysteine residues are generated by modifications, e.g., in the Fc domain derived from IgG1. In this case, the leucine residue at position 309 is replaced by a cysteine residue (L309C), resulting in Ig In the case of the Fc domain derived from G2, the valine residue at position 309 is replaced by a cysteine residue (V 309C).
[0208] In one embodiment, the Fc region mutates the valine residue at position 308 to a cysteine residue (V 308C).
[0209] In one embodiment, the two disulfide bonds in the hinge region are CPPC (SEQ ID NO: 2) was removed by mutating it to SPPS (SEQ ID NO: 3). can be.
[0210] 6.3.1.4. Fc Domains with Altered Glycosylation In certain embodiments, the immunoglobulins contain fewer glycosylation sites than the corresponding immunoglobulin. These proteins are more easily translated and therefore more easily adaptable to the TBM. It has a post-glycosylation pattern and is therefore simpler and cheaper to produce. do.
[0211] In one embodiment, the glycosylation site in the CH2 domain is at position 297 The asparagine residue is replaced with an alanine residue (N297A) or a glutamine residue (N297Q). In addition to improved manufacturability, these glycosyl radicals are The variants also reduce FcγR binding as described herein above.
[0212] Fc Heterodimerization Many multispecific molecule formats differ from natural immunoglobulins in that they contain non-identical antigen-binding domains. (or a portion thereof, e.g., VH or VH-CH1 of a Fab), Insufficient Fc regions to form an Fc domain leads to dimerization between the Fc regions of the Unwanted heterodimerization has always been an obstacle to increasing the yield of desired multispecific molecules. Various techniques available in the art include: See, for example, European Patent Application Publication No. 1870459A1; U.S. Patent No. 5,582,999 No. 6; U.S. Patent No. 5,731,168; U.S. Patent No. 5,910,573 Specification; U.S. Patent No. 5,932,448 Specification; U.S. Patent No. 6,833,441 Specification No. 7,183,076; U.S. Patent Application Publication No. 2006204493 A1 specification; and PCT publication number WO 2009 / 089004A1 brochure As disclosed in the present application, the present invention provides a method for promoting dimerization of Fc regions that may be present in the TBM of the present disclosure. It can be used for.
[0213] The present disclosure provides Fc heterodimers, i.e., Fc domains comprising heterologous, non-identical Fc regions. Using heterodimerization techniques, different ABMs (or portions thereof, e.g., promotes dimerization of the Fc region operably linked to the VH or VH-CH1 of the Fab. , reduces dimerization of Fc regions operably linked to the same ABM or portion thereof. Generally, each Fc region in an Fc heterodimer comprises a CH3 domain of an antibody. The antibody may be of any isotype, class or subclass, preferably any of the isotypes, classes or subclasses, as described in the previous section. or derived from the constant region of antibodies of the IgG (IgG1, IgG2, IgG3, and IgG4) class. Coming.
[0214] Typically, TBMs contain CH1 domain, CH2 domain, human IL-1 domain, and human IL-2 domain in addition to the CH3 domain. The VH domain, VL domain, CDR and / or antigen binding domain described herein In one embodiment, two helical fragments are combined to form a single antibody fragment. The polypeptide is two heavy chains that form a bispecific or multispecific molecule. Heterodimerization of two different heavy chains in the α-domain produces the desired antibody or antibody-like molecule. While this results in a decrease in the yield of the desired antibody or molecule, homodimerization of identical heavy chains reduces the yield of the desired antibody or molecule. In an exemplary embodiment, two or more heteropolypeptide chains comprise a CH3 domain. and comprising two chains forming a molecule of any of the above-described multispecific molecule formats of this disclosure. In one embodiment, the two heteropolypeptide chains comprising the CH3 domain are unmodified. Modifications that favor heterodimeric association of the polypeptides relative to the unmodified chains are included. Various examples are shown in Table 2 below and in sections 6.3.1.5.1 to 6.3.1.5.3. .
[0215] [Table 2]
[0216] [Table 3]
[0217] [Table 4]
[0218] [Table 5]
[0219] [Table 6]
[0220] [Table 7]
[0221] [Table 8]
[0222] [Table 9]
[0223] Knob-in-Hole (KIH) The TBMs of the present disclosure may comprise a nucleotide sequence for one or more of the constant domains of the Fc domain, e.g., the CH3 domain. In one example, the TBM of the present disclosure may include one or more, e.g., multiple, modifications to the domain. The antibody heavy chain constant domains, such as the CH2 or CH3 domains, are composed of two polypeptides. In one example, two heavy chain constant domains of TBM, e.g., CH2 or The CH3 domain contains one or more modifications that allow heterodimeric association between the two chains. In one embodiment, the one or more modifications are located on the CH2 domains of the two heavy chains. In such a case, the one or more modifications are made to the CH3 domain of at least two polypeptides of the TBM. In one embodiment, the first polypeptide of the TBM comprising the heavy chain constant domain is located on the One or more modifications to the polypeptide can generate a "knob," which is a second polypeptide of the TBM. One or more modifications to the tide create a "hole" in the TBM containing the heavy chain constant domain. Heterodimerization of polypeptides allows the "knob" to associate with the "hole" (e.g., For example, the CH2 domain of a first polypeptide interacts with the CH2 domain of a second polypeptide. domain or the CH3 domain of the first polypeptide interacts with the second polypeptide. This term is used herein to refer to the interaction of the CH3 domain of the ATP-dependent ATPase. As used herein, "knob" refers to the boundary of the first polypeptide of TBM that contains the heavy chain constant domain. protrude from the nucleus, thus stabilizing the heteromultimer, thereby preventing, for example, homomultimer formation. A second polynucleotide of TBM containing the heavy chain constant domain is added to favor heteromultimer formation. At least one amino acid sequence capable of positioning in a complementary "hole" at the interface with the peptide. The knob may be at the original boundary or may be located at a position (e.g., encoding the boundary). The preferred interface for the formation of the knob is The port residue is generally a natural amino acid residue, preferably arginine (R), phenyl The most preferred are selected from the group consisting of propylamino (F), propylamino (Y ... The preferred amino acids are tryptophan and tyrosine. The original residues for have small side chain volumes, e.g., alanine, asparagine, asparagine The amino acid is guanine, glycine, serine, threonine, or valine.
[0224] The "hole" is recessed from the boundary of the second polypeptide of TBM, which contains the heavy chain constant domain. and thus the first polypeptide of TBM containing the heavy chain constant domain is adjacent to each other. A hole refers to at least one amino acid side chain that fits into a corresponding knob on the interaction surface. The original border may be present, or (e.g., by modifying the nucleic acid encoding the border) ) can be synthetically introduced. Preferred import residues for hole formation are usually naturally occurring amino acid residues, preferably alanine (A), serine (S), threonine (T) and Valine (V), most preferably serine, alanine or threonine. In a preferred embodiment, the original residue for hole formation has a large side chain capacity. For example, tyrosine, arginine, phenylalanine or tryptophan.
[0225] In a preferred embodiment, the first CH3 domain comprises residues 366, 405, or 407 to generate either a "knob" or a "hole" (as described above), The second CH3 domain, which heterodimerizes with the first CH3 domain, has a residue 366 When modified in the first CH3 domain, residues 407 and 405 are When modified in the first CH3 domain, residue 394 or residue 407 is in the first CH3 domain. and modified in the first CH3 domain to form a "hole" complementary to the "knob" or "hole" of the first CH3 domain. " or "knob", it is modified at residue 366.
[0226] In another preferred embodiment, the first CH3 domain is modified at residue 366 The second CH3 domain, which heterodimerizes with the first CH3 domain, has a residue 3 66, 368 and / or 407 to form the "knob" or creates a "hole" or "knob" complementary to the "hole". The modification to the CH3 domain of introduces a tyrosine (Y) residue at position 366. In one embodiment, the modification to the first CH3 is T366Y. The modification to the first CH3 domain is a tryptophan (W) residue at position 366. In one embodiment, the modification to the first CH3 is T366W. In some embodiments, the heterologous sequence is a first CH3 domain modified at position 366. Modifications to the second CH3 domain (e.g., a nucleotide sequence introduced at position 366) that allow dimerization having a tyrosine (Y) or tryptophan (W), e.g., modified T366Y or T36 6W) has a modification at position 366, a modification at position 368, and a modification at position 407. In one embodiment, the modification at position 366 introduces a serine (S) residue. The modification at position 368 introduces an alanine (A), and the modification at position 407 introduces a valine (Va). (V). In one embodiment, the modifications are T366S, L368A and Y40 In one embodiment, the first CH3 domain of the multispecific molecule comprises a modified T3 a second CH3 domain that contains 66Y and heterodimerizes with the first CH3 domain contains the modifications T366S, L368A and Y407V, or vice versa. In one embodiment, the first CH3 domain of the multispecific molecule comprises the modification T366W and the first The second CH3 domain that heterodimerizes with the CH3 domain is modified T366S, Contains L368A and Y407V or vice versa.
[0227] Further steric or "distortion" (e.g., knobs-in-holes) modifications may be made in accordance with the PCT publication number. International Publication No. 2014 / 145806 (e.g., International Publication No. 2014 / 145 806 pamphlet), Figures 3, 4 and 12, PCT Publication No. WO 2014 / 02314 No. 110601 and PCT Publication No. WO 2016 / 086186 Brochure, International Publication No. 2016 / 086189, International Publication No. 2016 / 086196 and WO 2016 / 182751 The contents of which are incorporated herein by reference in their entireties. Examples of KIH mutants include S L368D and K370 paired with a second constant chain containing the 364K and E357Q modifications The first constant chain contains an S modification.
[0228] Additional knob-in-one molecules suitable for use in any of the multispecific molecules of the present disclosure are Hole-modified pairs are described, for example, in WO 1996 / 027011 and Mer chant et al.,1998,Nat.Biotechnol.,16:677 -681, the contents of which are incorporated herein by reference in their entireties. can be.
[0229] In a further embodiment, the CH3 domain is modified to introduce a pair of cysteine residues. Without being bound by theory, it is believed that the disulfide bond formation The introduction of a pair of cysteine residues capable of binding to a heterodimer containing paired CH3 domains allows for the formation of a heterodimer containing ... paired CH3 domain. It is believed that this provides stability to the merized TBM. In one embodiment, the first CH3 The domain contains a cysteine at position 354 and is heterologous with the first CH3 domain. The second CH3 domain that dimerizes contains a cysteine at position 349. In some embodiments, the first CH3 domain contains a cysteine at position 354 (e.g., a modified S3 54C) and tyrosine (Y) at position 366 (including, for example, the modification T366Y) and a second CH3 domain that heterodimerizes with the first CH3 domain, Cysteine at position 49 (including, for example, the modification Y349C), serine at position 366 (e.g., containing the modified T366S), an alanine at position 368 (e.g., containing the modified L368 A) and valine at position 407 (e.g., containing the modification Y407V). In embodiments, the first CH3 domain comprises a cysteine at position 354 (e.g., a modified modified S354C) and tryptophan (W) at position 366 (e.g., modified T36 6W) and a second CH3 domain that heterodimerizes with the first CH3 domain. The main ones are cysteines at position 349 (e.g., containing the modification Y349C), a serine at position 368 (e.g., containing the modification T366S), an alanine at position 368 (e.g., containing the modification T366S), modification L368A) and valine at position 407 (e.g., containing the modification Y407V) Includes:
[0230] 6.3.1.5.2. Alternative Knobs and Holes: IgG Heterodimerization Heterodimerization of TBM polypeptide chains containing paired CH3 domains is essential for the formation of IgG1 Increased antibody activity by introducing one or more modifications into the CH3 domain derived from the antibody class. In one embodiment, the modification is paired with a F405L modification in the second CH3 domain. The modifications further include a K409R modification to one CH3 domain. could alternatively be at positions 366, 368, 370, 399, 405, 407 and 409 Preferably, heterodimerization of polypeptides containing such modifications is carried out under reducing conditions, e.g. For example, 25 to 37°C, for example, 25°C or 37°C for 1 to 10 hours, for example, 1.5 to 5 hours, For example, 10 to 100 mM 2-MEA (e.g., 25, 50, or 100 mM) for 5 hours. The procedure is carried out in a 2-MEA (M).
[0231] The amino acid substitutions described herein can be made by CH synthesis using techniques well known in the art. 3 domains (see, e.g., McPherson, ed., 1991, Dir ected Mutagenesis:a Practical Approach;A (See Delman et al., 1983, DNA, 2:183).
[0232] IgG heterodimerization techniques are described, for example, in WO 2008 / 119353. , International Publication No. 2011 / 131746 and International Publication No. 2013 / 06 No. 0867, the contents of which are incorporated herein by reference in their entirety. The specification is incorporated by reference.
[0233] In any of the embodiments described in this section, the CH3 domain is selected from the group consisting of 6.3.1. It can be further modified to introduce a pair of cysteine residues as described in Section 5.1. .
[0234] 6.3.1.5.3.Polar crosslinking Heterodimerization of TBM polypeptide chains containing the Fc domain is based on the principle of "polar cross-linking." The principle of "polar cross-linking" can be increased by introducing modifications based on the Residues at the binding interface of the peptide chains are similar (or complementary) in the heterodimeric form. While the homodimer form interacts with residues with different physical properties, In particular, these modifications allow polar residues to interact with polar dimers in heterodimer formation. The hydroxyl groups are designed to interact with hydroxyl residues, while hydrophobic residues interact with hydrophobic residues. In contrast, in homodimer formation, residues are arranged such that polar residues interact with hydrophobic residues. The preferred interaction in the heterodimeric form and the The unfavorable interactions may cooperate to cause the Fc region to form heterodimers rather than homodimers. This increases the tendency to form dimers.
[0235] In an exemplary embodiment, the modifications are at residues 364, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, It is generated at one or more of positions 99, 405, 409 and 411.
[0236] In one embodiment, S364L, T366V, L368Q, N399K, F405 one or more modifications selected from S, K409F and R411K in the two CH3 domains One or more modifications selected from Y407F, K409Q and T411N are introduced into the Decorations can be introduced into the second CH3 domain.
[0237] In another embodiment, S364L, T366V, L368Q, D399K, F405 one or more modifications selected from the group consisting of S, K409F and T411K in one CH3 domain, while one selected from Y407F, K409Q and T411D One or more modifications are introduced into the second CH3 domain.
[0238] In one exemplary embodiment, a substitution of the threonine at position 366 of one CH3 domain The original residue is replaced with a valine, while the tyrosine at position 407 in the other CH3 domain The original residue is replaced with phenylalanine.
[0239] In another exemplary embodiment, the residue of serine at position 364 of one CH3 domain is The residue at position 368 of the same CH3 domain is replaced by leucine, while the residue at position 368 of the same CH3 domain is replaced by leucine. The original residue is replaced with glutamine.
[0240] In yet another exemplary embodiment, a phenylalanine amino acid sequence at position 405 of one CH3 domain is The original residue of α-alanine was replaced by serine, and the lysine at position 409 of this CH3 domain The original residue of α-glucan is replaced by phenylalanine, while the residue at position 409 of the CH3 domain is The original lysine residue in is replaced with glutamine.
[0241] In yet another exemplary embodiment, an aspartate amino acid at position 399 of one CH3 domain is The original residue of paragic acid was replaced by lysine, and the trehalose at position 411 of the same CH3 domain The original residue of onine is replaced by lysine, while the other residue at position 411 of the CH3 domain The original threonine residue is replaced with aspartic acid.
[0242] The amino acid substitutions described herein can be made by CH synthesis using techniques well known in the art. 3 domains (see, e.g., McPherson, ed., 1991, Dir ected Mutagenesis:a Practical Approach;A (See Delman et al., 1983, DNA, 2:183). The bridge method is described, for example, in International Publication No. 2006 / 106905 and International Publication No. No. 09 / 089004 Brochure and K. Gunasekaran, et al. (2 010)The Journal of Biological Chemistry, 285:19637-19646, the contents of which are incorporated by reference in their entireties. The present application is incorporated by reference.
[0243] Further polar crosslink modifications are described, for example, in PCT Publication No. WO 2014 / 145806 No. 2014 / 145806 (e.g., Figure 6 in WO 2014 / 145806), PCT Publication Number International Publication No. 2014 / 110601 Pamphlet and PCT Publication Number Country International Publication No. 2016 / 086186 Brochure, International Publication No. 2016 / 086189 Brochure, International Publication No. 2016 / 086196 Brochure and International Publication No. 201 No. 6 / 182751, the contents of which are incorporated herein in their entirety. Examples of polar bridge mutants are N208D, Q295E, N384D, Q418E and a constant chain containing the N421D modification.
[0244] In any of the embodiments described herein, the CH3 domain is selected from the group consisting of 6.3.1 It may be further modified to introduce a pair of cysteine residues as described in Section 5.1. do.
[0245] Further techniques for promoting heterodimerization are described, for example, in WO 2016 / 10 Pamphlet No. 5450, International Publication No. 2016 / 086186, International Publication Pamphlet No. 2016 / 086189, Pamphlet No. WO 2016 / 086196 Lett, International Publication No. 2016 / 141378 and International Publication No. 2014 / 145806 brochure and International Publication No. 2014 / 110601 brochure and the entire contents of which are incorporated herein by reference in their entirety. Any of the above may be used in the TBMs described herein.
[0246] 6.3.2. Hinge Area The TBMs of the present disclosure also include, for example, a hinge region that links the antigen binding module to the Fc region. The hinge region may be a natural or modified hinge region. The hinge region typically comprises It is found at the N-terminus of the Fc region.
[0247] A native hinge region is the hinge region that can normally be found between the Fab and Fc domains in a natural antibody. A modified hinge region is any hinge region that differs in length and / or composition from the native hinge region. Such hinges are found in humans, mice, rats, rabbits, sharks, pigs, and hamsters. The hinge region may include hinge regions from other species, such as rabbit, camel, llama, or goat hinge regions. The modified hinge region is derived from an antibody of a different class or subclass than that of the heavy chain Fc region. Alternatively, the modified hinge region may comprise a portion or repeat of the natural hinge. Each unit in the repeat may comprise a repeat unit derived from a natural hinge region. In this case, the native hinge region may contain one or more cysteine or other residues substituted with serine or alanine, etc. by converting a neutral residue to a cysteine residue, or by converting a suitably placed residue to a cysteine residue. By such means, the number of cysteine residues in the hinge region can be modified. Other modified hinge regions may be entirely synthetic, and may vary in length, structure, or function. It can be designed to have desired properties, such as composition and flexibility.
[0248] Some modified hinge regions are described, for example, in U.S. Pat. No. 5,677,425; Publication No. 9915549, International Publication No. 2005003170 , International Publication No. 2005003169 Brochure, International Publication No. 2005003170 Pamphlet, International Publication No. 9825971 and International Publication No. 2005003171 , which are incorporated herein by reference.
[0249] Examples of suitable hinge sequences are shown in Table 3.
[0250] [Table 10]
[0251] In one embodiment, the heavy chain Fc region has an intact hinge region at its N-terminus. .
[0252] In one embodiment, the heavy chain Fc region and hinge region are derived from IgG4, and the hinge region contains the modified sequence CPPC (SEQ ID NO: 2). The core hinge region of human IgG4 contains the sequence C containing the sequence CPSC (SEQ ID NO: 12) compared to IgG1 containing PPC (SEQ ID NO: 2). The serine residues present in the IgG4 sequence also allow for increased flexibility in this region. Thus, part of the molecule is in the IgG molecule to form interchain disulfides. Disulfide bonds within the same protein chain (intrachain disulfides) rather than cross-linking to other heavy chains in the chain. (Angel et al., 1993, Mol lmmunol 30(1):105-108). The serine residue was changed to proline, resulting in the same chain structure as IgG1. Obtaining the IgG4 hinge sequence allows for the complete formation of interchain disulfides in the IgG4 hinge region. This modified isotype results in a reduced heterogeneity in the purified product. It is called IgG4P.
[0253] ABM Linker In certain embodiments, the present disclosure provides a TBM comprising at least three ABMs, wherein and two or more components of the ABM (e.g., VH and VL of an scFv), two or more AB The peptide is composed of an M or ABM and a non-ABM domain (e.g., a dimerization domain such as an Fc region). Such linkers are, for example, those described in Section 6.9.2. In contrast to the ADC linkers used to attach drugs to TBMs, as described in Sect. , herein referred to as an "ABM linker."
[0254] Peptide linkers can range from 2 amino acids to 60 or more amino acids, and certain In embodiments, the peptide linker is between 3 amino acids and 50 amino acids, between 4 and 30 amino acids, Amino acids, 5 to 25 amino acids, 10 to 25 amino acids, or 12 to 20 amino acids In certain embodiments, the peptide linker is in the range of 2 amino acids, 3 amino acids, Amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids Amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids Amino acids, 18 amino acids, 19 amino acids, 20 amino acids, 21 amino acids , 22 amino acids, 23 amino acids, 24 amino acids, 25 amino acids, 26 27 amino acids, 28 amino acids, 29 amino acids, 30 amino acids Acid, 31 amino acids, 32 amino acids, 33 amino acids, 34 amino acids, 35 36 amino acids, 37 amino acids, 38 amino acids, 39 amino acids 40 amino acids, 41 amino acids, 42 amino acids, 43 amino acids, 4 4 amino acids, 45 amino acids, 46 amino acids, 47 amino acids, 48 amino acids amino acids, 49 amino acids or 50 amino acids in length.
[0255] Charged and / or flexible linkers are particularly preferred.
[0256] Examples of flexible ABM linkers that can be used in the TBMs of the present disclosure include those described by Chen et al. al.,2013,Adv Drug Deliv Rev.65(10):1357- 1369 and Klein et al., 2014, Protein Engineer ing,Design&Selection 27(10):325-330 Particularly useful flexible linkers include those shown in (GGGGS)n (SEQ ID NO: 25) (also referred to as (G4S)n (SEQ ID NO: 25)). In one embodiment, n is any number from 1 to 10, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Any range bounded by any two of the above numbers, e.g., 1-5, 2-5, 3 ~6, 2~4, 1~4, etc. and others.
[0257] Other examples of TBM linkers suitable for use in the TBMs of the present disclosure are shown in Table 4 below. .
[0258] [Table 11]
[0259] [Table 12]
[0260] In various embodiments, the present disclosure provides a TBM comprising one or more ABM linkers. Each ABM linker optionally comprises two to six amino acids selected from Table 4 above. 0 amino acid length, preferably 4 to 30 amino acids, 5 to 25 amino acids, 10 to 2 It can range from 5 amino acids or 12 to 20 amino acids in length. Thus, the TBM comprises two, three, four, five, or six ABM linkers. - may be on one, two, three, four or more polypeptide chains of the TBM obtain.
[0261] 6.4. Exemplary Trispecific Binding Molecules An exemplary TBM configuration is shown in Figure 1. Figure 1A illustrates the TBM configuration shown in Figures 1B-1Z. scFv, Fab, non-immunoglobulin-based ABM and Fc are Each may have the properties described for these components in Sections 6.2 and 6.3. The components of the TBM configuration shown in Figure 1 are the means described in Sections 6.2 and 6.3. By any of the following (e.g., direct conjugation, ABM linker, disulfide bond, knob-in These can be associated with each other (e.g., by Fc domains modified with hole interactions). The orientation and association of the various components shown is exemplary only; As will be appreciated, other orientations and associations may be suitable (e.g., see Sections 6.2 and 6.3). as described in Sect.
[0262] The TBM of the present disclosure is not limited to the configuration shown in Figure 1. Other configurations that may be used are well known in the art. For example, International Publication No. 2014 / 145806; International Publication No. No. 2017 / 124002 Brochure; Liu et al., 2017, Fron t Immunol.8:38;Brinkmann&Kontermann,2017 , mAbs 9:2,182-212; U.S. Patent Application Publication No. 2016 / 0355600 Specification; Klein et al., 2016, MAbs 8(6):1010-20; and U.S. Patent Application Publication No. 2017 / 0145116.
[0263] 6.4.1. Exemplary Trivalent TBM The TBMs of the present disclosure can be trivalent, i.e., they have three antigen-binding domains. These bind to CD2, a component of the TCR complex, and one of the TAAs, respectively.
[0264] Exemplary trivalent TBM forms are shown in Figures 1B-1O and 1V-1Z.
[0265] As shown in Figures 1B-1K, 1O, and 1V-1Z, the TBM contains two half antibodies. The two half antibodies are obtained, one containing two ABMs and the other containing one ABM, and the two half antibodies are separated by an Fc domain. They are paired via the in.
[0266] In the embodiment of FIG. 1B, the first (or left) half antibody comprises an scFv and an Fc region. The first and second half antibodies comprise the Fab, scFv, and Fc regions. The half antibodies are associated via their Fc regions to form an Fc domain.
[0267] In the embodiment of FIG. 1C, the first (or left) half antibody comprises two Fab and Fc regions. and the second (or right) half antibody comprises the Fab and Fc regions. The antibodies associate via the Fc region to form an Fc domain.
[0268] In the embodiment of FIG. 1D, the first (or left) half antibody comprises Fab, scFv, and Fc The first and second half antibodies comprise a Fab and Fc region, and the second (or right) half antibody comprises a Fab and Fc region. The half antibodies are associated via their Fc regions to form an Fc domain.
[0269] In the embodiment of FIG. 1E, the first (or left) half antibody comprises an scFv and an Fc region. The first and second halves comprise two Fab and Fc regions. Antibodies associate via their Fc regions to form Fc domains.
[0270] In the embodiment of FIG. 1F, the first (or left) half antibody comprises an scFv, an Fc region, and an F ab, and the second (or right) half antibody comprises the Fab and Fc regions. The half antibodies are associated via their Fc regions to form an Fc domain.
[0271] In the embodiment of FIG. 1G, the first (or left) half antibody comprises an scFv and an Fc region. The first and second (or right) half antibodies comprise a Fab, an Fc region, and an scFV. The half antibodies are associated via their Fc regions to form an Fc domain.
[0272] In the embodiment of FIG. 1H, the first (or left) half antibody comprises two Fab and Fc regions. and the second (or right) half antibody comprises a non-immunoglobulin-based ABM and an Fc region. The first and second half antibodies are associated via their Fc regions to form an Fc domain.
[0273] In the embodiment of FIG. 1I, the first (or left) half antibody comprises Fab, scFv, and Fc The second (or right) half antibody comprises a non-immunoglobulin-based ABM and an Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain. do.
[0274] In the embodiment of FIG. 1J, the first (or left) half antibody comprises a Fab and an Fc region. The second (or right) half antibody comprises an scFv, a non-immunoglobulin-based ABM, and an Fc region. The first and second half antibodies are associated via the Fc region to form an Fc domain. do.
[0275] In the embodiment of FIG. 1K, the first (or left) half antibody comprises an scFv and an Fc region. The second (or right) half antibody comprises an scFv, an Fc region and a second scFv. and the second half antibody are associated via their Fc regions to form an Fc domain.
[0276] In the embodiment of FIG. 1N, the first (or left) half antibody comprises a Fab, an Fc region, and a sc The first and second half antibodies comprise an Fv region, and the second (or right) half antibody comprises an Fab and an Fc region. The half antibodies are associated via their Fc regions to form an Fc domain.
[0277] In the embodiment of FIG. 10, the first (or left) half antibody comprises a Fab, an Fc region, and a sc The first and second half antibodies comprise a Fab region, and the second (or right) half antibody comprises a Fab and an Fc region. The half antibodies are associated via their Fc regions to form an Fc domain.
[0278] In the embodiment of FIG. 1V, the first (or left) half antibody is a non-immunoglobulin-based antibody. the ABM, Fab and Fc regions, and the second (or right) half antibody comprises the Fab and Fc regions The first and second half antibodies are associated via the Fc region to form an Fc domain. .
[0279] In the embodiment of FIG. 1W, the first (or left) half antibody is a non-immunoglobulin-based antibody. The second (or right) half antibody comprises the Fab and Fc regions. The first and second half antibodies are associated via the Fc region to form an Fc domain. do.
[0280] In the embodiment of FIG. 1X, the first (or left) half antibody comprises an scFv, an Fc region, and an F The second (or right) half antibody contains a non-immunoglobulin-based ABM at the C-terminus of the c region. The first and second half antibodies comprise Fab and Fc regions. The first and second half antibodies are associated via the Fc region to form F Forms the c domain.
[0281] In the embodiment of FIG. 1Y, the first (or left) half antibody comprises an scFv, an Fc region, and an F The second (or right) half antibody contains an scFv at the C-terminus of the c region, and the second (or right) half antibody contains a non-immunoglobulin-based antibody. The first and second half antibodies are associated via the Fc region. Forms the Fc domain.
[0282] In the embodiment of FIG. 1Z, the first (or left) half antibody comprises an scFv, an Fc region, and an F The second (or right) half antibody comprises a non-immunoglobulin-based Fab at the C-terminus of the c region. The first and second half antibodies are associated via the Fc region to form an F Forms the c domain.
[0283] Alternatively, as shown in Figure 1L, a trivalent TBM can contain two half antibodies and one full antibody. It contains a complete ABM and a portion of another ABM (one is VH, the other is VL). As soon as the half antibodies are paired via the Fc domain, the VH and VL associate to form a complete Forms the antigen-binding Fv domain.
[0284] As shown in Figure 1M, the TBM can be single-stranded. It comprises three scFv domains linked via
[0285] In each of the embodiments shown in FIGS. 1B to 1O and 1V to Z, the Each of the domains listed, not necessarily in that order, is a TCR ABM , CD2 ABM or TAA ABM. In other words, X represents TCR ABM, CD2 ABM or TAA ABM, and Y can be a TCR ABM, a CD2 ABM, or a TAA ABM. ABM, and Z can be a CD2 ABM, a TCR ABM, or a TAA ABM. However, the TBM must contain at least one TCR ABM and at least one CD2 ABM. The BM comprises at least one TAA ABM.
[0286] Therefore, in the present disclosure, as shown in any one of FIGS. 1B-1O and 1V-Z, and providing a trivalent TBM such that X is a CD2 ABM and Y is a TCR ABM. and Z is a TAA ABM (this form of ABM is conveniently designated "T1"). ).
[0287] The present disclosure also provides trivalent TBMs as shown in any one of Figures 1B-1O and 1V-Z. wherein X is a CD2 ABM, Y is a TAA ABM, and Z is a TCR ABM. BM (this form of ABM is conveniently designated as "T2").
[0288] The present disclosure further provides a trivalent TBM as shown in any one of Figures 1B-1O and 1V-Z. wherein X is a TCR ABM, Y is a CD2 ABM, and Z is a TA A ABM (this form of ABM is conveniently designated as "T3").
[0289] The present disclosure further provides a trivalent TBM as shown in any one of Figures 1B-1O and 1V-Z. Also provided is a method for the preparation of a medicament ... CD2 ABM (this form of ABM is conveniently designated as "T4").
[0290] The present disclosure further provides a trivalent TBM as shown in any one of Figures 1B-1O and 1V-Z. Also provided is a method for the preparation of a medicament ... TCR ABM (this form of ABM is conveniently designated as "T5").
[0291] The present disclosure further provides a trivalent TBM as shown in any one of Figures 1B-1O and 1V-Z. Also provided is a method for the preparation of a medicament ... CD2 ABM (this form of ABM is conveniently designated "T6").
[0292] 6.4.2. Exemplary Tetravalent TBM The TBMs of the present disclosure can be tetravalent, i.e., they have four antigen binding domains. One or two of them bind to CD2, and one or two of them bind to the TCR complex. components, one or two of which bind to the TAA.
[0293] Exemplary tetravalent TBM forms are shown in Figures 1P-1R.
[0294] As shown in Figures 1P-1R, a tetravalent TBM can contain two half antibodies, each containing 2 It contains one complete ABM and two half antibodies paired via their Fc domains.
[0295] In the embodiment of FIG. 1P, the first (or left) half antibody comprises a Fab, an Fc region, and a second the second (or right) half antibody comprises a Fab, an Fc region, and a second Fab. The first and second half antibodies are associated via their Fc regions to form an Fc domain.
[0296] In the embodiment of FIG. 1Q, the first (or left) half antibody comprises a Fab, an Fc region, and a sc The first (or right) half antibody comprises an Fab, an Fc region, and an scFv. and the second half antibody are associated via their Fc regions to form an Fc domain.
[0297] In the embodiment of FIG. 1R, the first (or left) half antibody comprises a Fab, an Fc region, and a sc The first (or right) half antibody comprises an Fv, and the second (or right) half antibody comprises an scFv, an Fc region, and an Fab. and the second half antibody are associated via their Fc regions to form an Fc domain.
[0298] In the embodiments shown in FIGS. 1P to 1R, each of X, Y, Z, and A does not necessarily represent the Representing, but not necessarily in order, TCR ABM, CD2 ABM, or TAA ABM. , wherein the TBM comprises at least one TCR ABM, one CD2 ABM, and one Thus, the tetravalent ABM of the present disclosure comprises a component of the TCR complex. , CD2 and two ABMs for one of the TAA. Preferably, the tetravalent TBM is It has two TAA ABMs.
[0299] Therefore, in the present disclosure, a tetravalent TB as shown in any one of Figures 1P-1R M, where X is a CD2 ABM, Y is a TCR ABM, and Z and A Both are TAA ABMs (this form of ABM is conveniently designated "Tv 1"). (will be done).
[0300] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X is CD2 ABM, Y and A are both TAA ABM, and Z is T CR ABM (this form of ABM is conveniently designated as "Tv 2").
[0301] The present disclosure also provides a tetravalent TBM as shown in any one of Figures 1P-1R. where X is a TCR ABM, Y is a CD2 ABM, and Z and A are both is also a TAA ABM (this form of ABM is conveniently designated "Tv 3") .
[0302] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X is a TCR ABM, Y and A are both TAA ABM, and Z is C D2 ABM (this form of ABM is conveniently designated as "Tv 4").
[0303] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X and A are both TAA ABM, Y is CD2 ABM, and Z is T CR ABM (this form of ABM is conveniently designated as "Tv 5").
[0304] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X and A are both TAA ABM, Y is TCR ABM, and Z is C D2 ABM (this form of ABM is conveniently designated as "Tv 6").
[0305] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X is CD2 ABM, Y and Z are both CD2 ABM, and Z is T CR ABM (this form of ABM is conveniently designated as "Tv 7").
[0306] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X and Z are both TAA ABM, Y is CD2 ABM, and A is T CR ABM (this form of ABM is conveniently designated as "Tv 8").
[0307] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X is a TCR ABM, Y and A are both TAA ABM, and Z is C D2 ABM (this form of ABM is conveniently designated as "Tv 9").
[0308] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X and Y are both TAA ABM, Z is CD2 ABM, and A is T CR ABM (this form of ABM is conveniently designated as "Tv 10").
[0309] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X and Z are both TAA ABMs, Y is a TCR ABM, and A is a C D2 ABM (this form of ABM is conveniently designated as "Tv 11").
[0310] The present disclosure further provides a tetravalent TBM as shown in any one of Figures 1P-1R, where X and Y are both TAA ABMs, Z is a TCR ABM, and A is a C D2 ABM (this form of ABM is conveniently designated as "Tv 12").
[0311] 6.4.3. Exemplary Pentavalent TBM The TBMs of the present disclosure can be pentavalent, i.e., they have five antigen-binding domains. and one, two, or three of them bind to CD2, and one, two, or three of them They bind to components of the TCR complex, one, two or three of which bind to the TAA.
[0312] An exemplary pentavalent TBM form is shown in Figure 1S.
[0313] As shown in Figure 1S, a pentavalent TBM can contain two half antibodies, one of which binds two full antibodies. The two half antibodies are connected via the Fc domain, one containing an ABM and the other containing one complete ABM. are paired.
[0314] In the embodiment of FIG. 1S, the first (or left) half antibody comprises Fab, scFv, and Fc The first (or right) half antibody comprises a Fab, an Fc region, and an scFv. and the second half antibody are associated via their Fc regions to form an Fc domain.
[0315] In the embodiment shown in FIG. 1S, X, Y, Z, A, and B are not necessarily in that order. represents, but is not limited to, a TCR ABM, a CD2 ABM, or a TAA ABM; However, the TBM must contain at least one TCR ABM, one CD2 ABM, and one Thus, the pentavalent TBM of the present disclosure comprises the components of the TCR complex: Two ABMs or TCR complexes for CD2 and TAA, CD2 and TAA structure Preferably, the pentavalent TBM contains two or three ABMs. In certain embodiments, the pentavalent TBM has three TAAs. Has ABM.
[0316] Thus, the present disclosure provides a pentavalent TBM as shown in FIG. 1S, where X, Y , Z, A, and B are CD2, components of the TCR complex, and TAAs, as shown in Table 5. This is ABM for
[0317] [Table 13]
[0318] [Table 14]
[0319] [Table 15]
[0320] 6.4.4. Exemplary Hexavalent TBM The TBMs of the present disclosure can be hexavalent, i.e., they have six antigen-binding domains. and one, two, three or four of them bind to CD2, and one, two, three or four of them bind to CD2. One or four of these bind to components of the TCR complex, and one, two, three, or four of these bind to Binds to TAA.
[0321] Exemplary hexavalent TBM forms are shown in Figures 1T-1U.
[0322] As shown in Figures 1T-1U, a pentavalent TBM can contain two half antibodies, one of which binds two The two half antibodies, one containing a complete ABM and the other containing one complete ABM, have the Fc domain are paired via
[0323] In the embodiment of FIG. 1T, the first (or left) half antibody comprises a Fab, a second Fab, a F The second (or right) half antibody comprises a Fab, a second Fab, an Fc region, and an scFv. The first and second half antibodies are associated via the Fc region to form an Fc domain. Form the main.
[0324] In the embodiment of FIG. 1U, the first (or left) half antibody comprises a first Fv, a second Fv, The third half antibody comprises a first Fv and a second Fc region, and the second (or right) half antibody comprises a first Fv, a second Fv, and a third Fc region. The first and second half antibodies are associated via the Fc region. The Fc domain is formed by
[0325] In the embodiments shown in FIGS. 1T to 1U, each of X, Y, Z, A, B, and C must be TCR ABM, CD2 ABM, or TAA AB, although not necessarily in that order. M, where the TBM comprises at least one TCR ABM, one CD2 ABM, and and one TAA ABM. Thus, the hexavalent TBM of the present disclosure comprises: (i) a TCR complex; (ii) two ABMs for each of the combined components, CD2 and TAA; (iii) three ABMs against one of the combined components, CD2 and TAA, or TCR It may contain four ABMs for the components of the complex, CD2 and one of the TAAs. For example: The hexavalent ABM consists of three ABMs for TAA, two ABMs for CD2, and a TCR complex. As another example, a hexavalent ABM may comprise one ABM per TAA Three ABMs for the IL-1 receptor, two ABMs for components of the TCR complex, and one for CD2. Preferably, the hexavalent TBM comprises two, three, or four TAAs. In certain embodiments, the hexavalent TBM has three TAA ABMs. In another embodiment, the hexavalent TBM has four TAA ABMs.
[0326] Therefore, in the present disclosure, a hexavalent TB as shown in any one of Figures 1T-1U M, where X, Y, Z, A, B, and C are selected from the group consisting of CD2, T Components of the CR complex and ABMs for TAAs.
[0327] [Table 16]
[0328] [Table 17]
[0329] [Table 18]
[0330] [Table 19]
[0331] [Table 20]
[0332] [Table 21]
[0333] [Table 22]
[0334] 6.5.TCR ABM The TBM of the present disclosure contains an ABM that specifically binds to a component of the TCR complex. CRs are highly variable antigens that are normally expressed as part of a complex with the non-mutated CD3 chain molecules. Disulfide-linked membrane-anchored heterodimer consisting of alpha (α) and beta (β) chains It is a dimeric protein. T cells that express this receptor are called α:β (or αβ) T cells. Although a small number of T cells express different receptors, called gamma (γ) and delta (δ) receptors, These are formed by the γδ T-cell chain and are called γδ T-cells.
[0335] In a preferred embodiment, the TBM of the present disclosure comprises an ABM that specifically binds to CD3. Has.
[0336] 6.5.1.CD3 ABM The TBM of the present disclosure may contain an ABM that specifically binds to CD3. The term refers to the three differentiated coreceptors (or coreceptor complexes) of the T cell receptor. The amino acid sequence of the polypeptide chain of human CD3 is NCB I. The methods shown in Accessions P04234, P07766 and P09693 The CD3 protein may also include variants. The CD3 protein may also include fragments. The CD3 protein may also include post-translational modifications of the CD3 amino acid sequence. These include, but are not limited to, N-linked and O-linked glycosylation.
[0337] In one embodiment, the TBM of the present disclosure comprises an anti-CD3 antibody (e.g., U.S. Patent Application Publication No. 2016 / 0355600, International Publication No. Pamphlet No. 2014 / 110601 and International Publication No. 2014 / 145806 The present invention may include a nucleotide sequence (as described in FRET) or an antigen-binding domain thereof, the ABM. Exemplary anti-CD3 VH, VL and scFV sequences that can be used in the indicated TBMs are listed in Table 7. Shown in A.
[0338] [Table 23]
[0339] [Table 24]
[0340] [Table 25]
[0341] [Table 26]
[0342] [Table 27]
[0343] [Table 28]
[0344] Kabat numbering scheme (Kabat et al., 1991, Sequence s of Proteins of Immunological Interest, 5 th Ed.Public Health Service,National In Institutes of Health, Bethesda, Md.), Chothia The numbering scheme (Al-Lazikani et al., 1997, J. Mol. B iol 273:927-948) and the Kabat and Chothia numbering combination The CDR sequences of several CD3 binding agents defined by the formula are shown in Tables 7B to 7D, respectively. will be done.
[0345] [Table 29]
[0346] [Table 30]
[0347] [Table 31]
[0348] Table 32
[0349] Table 33
[0350] Table 34
[0351] Table 35
[0352] Table 36
[0353] Table 37
[0354] Table 38
[0355] Table 39
[0356] Table 40
[0357] Table 41
[0358] [Table 42]
[0359] [Table 43]
[0360] [Table 44]
[0361] [Table 45]
[0362] [Table 46]
[0363] [Table 47]
[0364] [Table 48]
[0365] [Table 49]
[0366] In one embodiment, the TBM of the present disclosure is a TBM having a Kabat numbering system (e.g., as set forth in Table 7B). The CDR of any one of CD3-1 to CD3-128 as defined by In other embodiments, the TBM of the present disclosure may comprise a CD3 ABM comprising Choth CD3-1 to CD3-C as defined by ia numbering (e.g., as described in Table 7C) The present invention may further comprise a CD3 ABM comprising any of the CDRs of D3-128. In the present disclosure, the TBMs are represented by a combination of Kabat and Chothia numbering (e.g. Any of CD3-1 to CD3-128 as defined by the markers (as described in Table 7D) The CD3 ABM may comprise any of the CDRs.
[0367] In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-1. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-2. Thus, the CD3 ABM comprises the CDR sequences of CD3-3. The ABM comprises the CDR sequences of CD3-4. In one embodiment, the CD3 ABM In one embodiment, the CD3 ABM comprises the CDR sequences of CD3- In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-7. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-8. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-9. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-10. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-11. The D3 ABM comprises the CDR sequences of CD3-12. The BM comprises the CDR sequences of CD3-13. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-14. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-16. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-17. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-18. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-19. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-20. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-21. The D3 ABM comprises the CDR sequences of CD3-22. The BM comprises the CDR sequences of CD3-23. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-24. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-26. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-27. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-28. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-29. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-30. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-31. The D3 ABM comprises the CDR sequences of CD3-32. The BM comprises the CDR sequences of CD3-33. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-34. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-36 and CD3-35. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-37. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-38. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-39. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-40. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-41. The D3 ABM comprises the CDR sequences of CD3-42. The BM comprises the CDR sequences of CD3-43. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3- In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-46 and CD3-45. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-47. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-48. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-49. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-50. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-51. The D3 ABM comprises the CDR sequences of CD3-52. The BM comprises the CDR sequences of CD3-53. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-54. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-56. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-57. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-58. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-59. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-60. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-61. The D3 ABM comprises the CDR sequences of CD3-62. The BM comprises the CDR sequences of CD3-63. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-64. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-66. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-67. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-68. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-69. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-70. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-71. The D3 ABM comprises the CDR sequences of CD3-72. The BM comprises the CDR sequences of CD3-73. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3- In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-76. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-77. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-78. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-79. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-80. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-81. The D3 ABM comprises the CDR sequences of CD3-82. The BM comprises the CDR sequences of CD3-83. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3- In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-86. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-87. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-88. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-89. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-90. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-91. The D3 ABM comprises the CDR sequences of CD3-92. The BM comprises the CDR sequences of CD3-93. In one embodiment, the CD3 ABM comprises: In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-94. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-96. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-97. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-98. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-99. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-100. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-101. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-102. The CD3 ABM comprises the CDR sequences of CD3-103. The BM comprises the CDR sequences of CD3-104. In one embodiment, the CD3 ABM , CD3-105. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-105. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-1 In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-108. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-109. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-110. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-111. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-112. In some embodiments, the CD3 ABM comprises the CDR sequences of CD3-113. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-114. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-115. The CD3 ABM comprises the CDR sequences of CD3-116. The ABM comprises the CDR sequences of CD3-117. comprises the CDR sequences of CD3-118. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-D3-119. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-121 In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-122. In one embodiment, the CD3 ABM comprises the CDR sequence of CD3-123. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-124. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-125. In an embodiment, the CD3 ABM comprises the CDR sequences of CD3-126. In one embodiment, the CD3 ABM comprises the CDR sequences of CD3-127. In this case, the CD3 ABM comprises the CDR sequences of CD3-128.
[0368] The TBM of the present disclosure comprises a complete heavy and light chain variable region of any one of CD3-1 to CD3-128. In one embodiment, the TBM of the present disclosure may comprise the VH and VL sequences of CD3-1. In one embodiment, the TBM of the present disclosure comprises a CD3 ABM comprising the sequence In one embodiment, the T The BM comprises a CD3 ABM comprising the VH and VL sequences of CD3-2. In this regard, the TBM of the present disclosure comprises a CD3 ABM comprising the VH and VL sequences of CD3-3. In one embodiment, the TBM of the present disclosure comprises a CD3 TBM comprising the VH and VL sequences of CD3-4. In one embodiment, the TBM of the present disclosure comprises a CD3-5 VH and VL. In one embodiment, the TBM of the present disclosure comprises a CD3 ABM comprising the sequence In one embodiment, the T The BM comprises a CD3 ABM comprising the VH and VL sequences of CD3-7. In this regard, the TBM of the present disclosure comprises a CD3 ABM comprising the VH and VL sequences of CD3-8. In one embodiment, the TBM of the present disclosure comprises a CD3 T cell comprising the VH and VL sequences of CD3-9. In one embodiment, the TBM of the present disclosure comprises a CD3-10 VH and VH. In one embodiment, the TBM of the present disclosure comprises a CD3 ABM comprising a CD3 L sequence. In one embodiment, the present disclosure provides a CD3 ABM comprising the VH and VL sequences of α-11. The TBM comprises a CD3 ABM comprising the VH and VL sequences of CD3-12. In one embodiment, the TBM of the present disclosure is a CD3 ABM comprising the VH and VL sequences of CD3-13. In one embodiment, the TBM of the present disclosure comprises the VH and VL sequences of CD3-14. In one embodiment, the TBM of the present disclosure comprises a CD3 ABM comprising CD3-15. In one embodiment, the TBM of the present disclosure comprises a CD3 ABM comprising a VH and a VL sequence. In one embodiment, the antibody comprises a CD3 ABM comprising the VH and VL sequences of CD3-16. Thus, the TBM of the present disclosure comprises a CD3 ABM comprising the VH and VL sequences of CD3-17. In one embodiment, the TBM of the present disclosure comprises a CD3-18 VH and VL sequence. In one embodiment, the TBM of the present disclosure comprises a VH of CD3-19 and In one embodiment, the TBM of the present disclosure comprises a CD3 ABM comprising a CD4 VL sequence. In one embodiment, the present invention comprises a CD3 ABM comprising a VH and VL sequence of 3-20. The TBM shown contains a CD3 ABM containing the VH and VL sequences of CD3-21. In one embodiment, the TBM of the present disclosure comprises a CD3 AB antibody comprising the VH and VL sequences of CD3-22. In one embodiment, the TBM of the present disclosure comprises the VH and VL sequences of CD3-23. In one embodiment, the TBM of the present disclosure comprises a CD3 ABM comprising CD3-24 In one embodiment, the TB antibody of the present disclosure comprises a CD3 ABM comprising the VH and VL sequences of M comprises a CD3 ABM comprising the VH and VL sequences of CD3-25. In this regard, the TBM of the present disclosure comprises a CD3 ABM comprising the VH and VL sequences of CD3-26. In one embodiment, the TBM of the present disclosure comprises a CD3-27 VH and VL sequence. In one embodiment, the TBM of the present disclosure comprises a VH of CD3-28 and a D3 ABM. and VL sequences.
[0369] TCR-α / β ABM The TBM of the present disclosure specifically binds to the TCR-α chain, the TCR-β chain, or the TCR-αβ dimer. Exemplary anti-TCR-α / β antibodies include those known in the art. are well known (see, for example, U.S. Patent Application Publication Nos. 2003 / 0109990, 2003 / 0109992 ... Specification No. 2012 / 0034221; Borst et al., 1990, Hum See Immunol. 29(3):175-88 (describing antibody BMA031) (See U.S. Patent Application Publication No. 2012 / 0034221). The VH, VL and Kabat CDR sequences of antibody BMA031 are shown in Table 8.
[0370] [Table 50]
[0371] In one embodiment, the TCR ABM may comprise the CDR sequences of antibody BMA031. In another embodiment, the TCR ABM comprises the VH and VL sequences of antibody BMA031. obtain.
[0372] TCR-γ / δ ABM The TBM of the present disclosure specifically binds to the TCR-γ chain, the TCR-δ chain, or the TCR-γδ dimer. Exemplary anti-TCR-γ / δ antibodies include those known in the art. (See, for example, U.S. Pat. No. 5,980,899, the contents of which are incorporated herein by reference. 2 (hybridoma deposited with ATCC under accession number HB 9578) (See, e.g.,
[0042] , which describes δTCS1 produced by
[0373] 6.6.CD2 ABM Immunoglobulin-based CD2 ABM In one embodiment, the TBM of the present disclosure is an anti-CD2 antibody or an antigen-binding domain thereof. Exemplary anti-CD2 antibodies are known in the art (e.g., For example, U.S. Patent No. 6,849,258, CN102827281A, U.S. Patent Application Publication No. 2003 / 0139579 A1 and U.S. Pat. No. 5,795, (See US Pat. No. 5,572.) Table 9 lists anti-CD2 antibodies for use in the TBM of the present disclosure. Exemplary CDR, VH, and VL sequences that may be included in an antibody or antigen-binding fragment thereof are shown. vinegar.
[0374] [Table 51]
[0375] In one embodiment, the CD2 ABM comprises the CDR sequences of CD2-1 (SEQ ID NO: 247 In one embodiment, the CD2 ABM comprises the heavy and light chains of CD2-1. In one embodiment, the CD2 ABM comprises a chain variable sequence (SEQ ID NOs: 253-254). The antibody contains the heavy and light chain variable sequences of hu1CD2-1 (SEQ ID NOs: 255 to 256). In an embodiment, the CD2 ABM comprises the heavy and light chain variable sequences of hu2CD2-1 (which (SEQ ID NOs: 257 and 256, respectively).
[0376] In another embodiment, the CD2 ABM is identified as CGMCC 6132, accessed 2012. Chinese Culture Collection Commit on May 16th Deposited by the General Microbiology Center, C The hybridomas described in US Pat. No. 6,282,7281A are In another embodiment, the CD2 ABM may comprise the CDR sequences of antibody 9D1. The American Type Culture Collection (ATC) issued the following notice on June 22, 1999, under the number PTA-802: Deposited by the National Type Culture Collection and filed for U.S. patent application By hybridomas as described in Publication No. 2003 / 0139579 A1 In yet another embodiment, the CDR sequences of the antibody LO-CD2b to be produced may be included. The CD2 ABM was deposited with the ATCC on April 9, 1993 under accession number 69277. , and recombinant E. coli ( ) CD2 SFv-Ig CD produced by expression of constructs cloned in It may contain an R sequence.
[0377] In other embodiments, the CD2 ABM may comprise the VH and VL sequences of antibody 9D1. In another embodiment, the CD2 ABM comprises the VH and VL sequences of antibody LO-CD2b. In yet another embodiment, the CD2 ABM may comprise ATCC Accession No. 6927 For expression of constructs cloned in recombinant E. coli with The VH and VL sequences of the CD2 SFv-Ig thus produced may be included.
[0378] CD58-based CD2 ABM In certain embodiments, the present disclosure provides a TBM that includes a CD2 ABM that is a ligand. CD2 ABM specifically binds to human CD2, the natural ligand of which is L CD58, also known as FA-3. The CD58 / LFA-3 protein is It is a glycoprotein expressed on the surface of various cell types (Dustin et al. , 1991, Annu.Rev.Immunol.9:27), antigen-dependent and antigen-independent They play a role in mediating T cell interactions with APCs in both a structural and functional manner (Walln er et al., 1987, J. Exp. Med. 166:923). In certain embodiments, the CD2 ABM is a CD58 portion. When combined, the CD58 portion has at least 70% sequence identity to the CD2-binding portion of CD58. identity to the CD2-binding portion of CD58, e.g., at least 70%, 71%, 72%, 7 3%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 8 3%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 9 Amino acid sequences with 3%, 94%, 95%, 96%, 97%, 98% or 99% identity The sequence of human CD58 is available under Uniprot identification number P19256 (www.uniprot.org). prot.org / uniprot / P19256). containing acid residues 30 to 123 (i.e., the sequence shown as CD58-4 in Table 10 below). It has been established that a CD58 fragment containing α-CD58 is sufficient for binding to CD2. Wang et al., 1999, Cell 97:791-803. In certain embodiments, the CD58 portion comprises at least amino acids 30-123 of CD58. At least 70% sequence identity, e.g., to the amino acid sequence designated CD58-4. Both 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79 %, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9 It contains an amino acid sequence with 9% identity.
[0379] The interaction between CD58 and CD2 was confirmed by X-ray crystallography and molecular modeling. Residues E25, K29, K30, K32, D33, K34, E37, and D8 Substitutions at positions 4 and K87 (where the numbering indicates the mature polypeptide) conferred binding to CD2. Ikemizu et al., 1999, Proc. Natl. Ac Ad.Sci.USA 96:4289-94. Therefore, in a preferred embodiment The CD58 portion of the present disclosure comprises E25, K29, K30, K32, D33, K34, E37 , D84 and K87 retain the wild-type residues.
[0380] In contrast, the following substitutions (where the numbering indicates the full-length polypeptide) :F29S;V37K;V49Q;V86K;T113S; and L121G. Thus, the CD58 moiety of the present disclosure may have one, two, three or more of the above substitutions. It may include one, four, five or all six.
[0381] Exemplary CD58 moieties are shown in Table 10 below.
[0382] [Table 52]
[0383] CD48-based CD2 ABM In certain embodiments, the present disclosure provides a TBM comprising a CD2 ABM that is a CD48 portion. As used herein, a CD48 portion refers to the CD2-binding portion of CD48. At least 70% sequence identity to, e.g., the CD2-binding portion of CD48 Both 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79 %, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9 The amino acid sequence of human CD48 contains 9% identity. The sequence of human CD48 is identified by Uniprot identifier no. No. P09326 (www.uniprot.org / uniprot / P09326) It has a signal peptide (amino acids 1 to 26) and a GPI anchor (amino acids 2 In certain embodiments, the CD48 portion comprises Uniprot identification numbers 21-243. At least 70% of the amino acid sequence consisting of amino acids 27 to 220 of P09326 Sequence identity (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 6%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 8 6%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 9 Human CD48 contains an amino acid sequence that is identical to the amino acid sequence of the target gene (6%, 97%, 98% or 99% identity). , Ig-like C2 type I domain (amino acids 29 to 30 of Uniprot identification number P09326) 127) and Ig-like C2 type 2 domain (Uniprot identification number P09326) Thus, in one embodiment, the CD48 portion comprises: The amino acid sequence consisting of amino acids 29 to 212 of Uniprot ID number P09326 and amino acids 29 to 1 of the C2 type I domain (Uniprot identification number P09326). 27) and / or the Ig-like C2 type 2 domain (Uniprot identification number P0 9326) (amino acids 132-212) with at least 70% sequence identity (e.g. , at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78 %, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 In some embodiments, the CD48 portion comprises an amino acid sequence that contains at least one amino acid sequence identical to the CD48 portion of the CD48 polypeptide (at least 99% or 99% identity). and contains one or more naturally occurring variants relative to the sequence of Uniprot identification number P09326. For example, the CD48 portion can include an E102Q substitution. The moiety may be a CD-48 isoform or a CD2-binding portion thereof, e.g., a CD48 isoform having a Uniprot identifier number No. P09326-2 or the amino acid corresponding to the CD2-binding portion thereof It may contain sequences.
[0384] 6.7. Tumor-associated antigen ABM The TBM of the present disclosure comprises at least one AB that specifically binds to a tumor-associated antigen (TAA). Preferably, the TAA is a human TAA. The antigen is present in normal cells. In certain embodiments, the TAA may or may not exhibit a specific phenotype compared to normal cells. In another embodiment, the TAA is preferentially expressed or downregulated in tumor cells. , a cell lineage marker.
[0385] Any type of tumor and any type of TAA may be targeted by the TBM of the present disclosure. Exemplary types of cancer that may be targeted include acute lymphoblastic leukemia. , acute myeloid leukemia, cholangiocarcinoma, B-cell leukemia, B-cell lymphoma, cholangiocarcinoma, bone cancer , brain tumor, Breast cancer, triple-negative breast cancer, cervical cancer, Burkitt's lymphoma, chronic lymphocytic leukemia, Chronic myeloid leukemia, colon cancer, endometrial cancer, esophageal cancer, gallbladder cancer, stomach cancer, gastrointestinal cancer, glioma, Hairy cell leukemia, head and neck cancer, Hodgkin's lymphoma, liver cancer, lung cancer, medullary thyroid cancer, melanoma, Multiple myeloma, ovarian cancer, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, respiratory tract cancer, kidney cancer, sarcoma However, those skilled in the art will recognize that cancers include, but are not limited to, skin cancer, testicular cancer, urothelial cancer, and other bladder cancers. It will be appreciated that TAAs are known for virtually every type of cancer.
[0386] Exemplary TAAs from which TBMs of the present disclosure can be generated include ABCF1;ACVR1;A CVR1B;ACVR2;ACVR2B;ACVRL1;ADORA2A;ADRB3; アグリカン;AGR2;AICDA;AIF1;AIG1;AKAP1;AKAP2;A LK;AMH;AMHR2;ANGPT1;ANGPT2;ANGPTL3;ANGPT L4;ANPEP;APC;APOC1;AR;AZGP1 ;B7.1;B7.2;BAD;BAFF;BAG1;BAI1;BCL2;BCL6; BDNF;BLNK;BLR1(MDR15);BlyS;BMP1;BMP2;BMP 3B(GDF10);BMP4;BMP6;BMP8;BMPR1A;BMPR1B;B MPR2;BPAG1(プレクチン);BRCA1;C19orf10(IL27w); C3;C4A;C5;C5R1;カドヘリン17;CANT1;CASP1;CASP4 ;CAV1;CCBP2(D6 / JAB61);CCL1(1-309);CCL11( エオタキシン);CCL13(MCP-4);CCL15(MIP-1d);CCL16 (HCC-4);CCL17(TARC);CCL18(PARC);CCL19(MI P-3b);CCL2(MCP-1);MCAF;CCL20(MIP-3a);CCL 21(MIP-2);SLC;EXODUS(exodus)-2;CCL22(MDC / STC-1);CCL23(MPIF-1);CCL24(MPIF-2 / エオタキシン -2);CCL25(TECK);CCL26(エオタキシン-3);CCL27(CT ACK / ILC);CCL28;CCL3(MIP-1a);CCL4(MIP-1b) ;CCL5(RANTES);CCL7(MCP-3);CCL8(mcp-2);CC NA1;CCNA2;CCND1;CCNE1;CCNE2;CCR1(CKR1 / HM 145);CCR2(mcp-1RB / RA);CCR3(CKR3 / CMKBR3); CCR4;CCR5(CMKBR5 / ChemR13);CCR6(CMKBR6 / CK R-L3 / STRL22 / DRY6);CCR7(CKR7 / EBI1);CCR8(C MKBR8 / TER1 / CKR-L1);CCR9(GPR-9-6);CCRL1(V SHK1);CCRL2(L-CCR);CD164;CD19;CD1C;CD20; CD200;CD-22;CD24;CD28;CD3;CD37;CD38;CD3E ;CD3G;CD3Z;CD4;CD32b;CD40;CD40L;CD44;CD4 5RB;CD52;CD69;CD72;CD74;CD79A;CD79B;CD8; CD80;CD81;CD83;CD86;CD97;CD179a;CDH1(E-ka CDH10;CDH12;CDH13;CDH18;CDH19;CDH2 0;CDH5;CDH7;CDH8;CDH9;CDK2;CDK3;CDK4;CDK 5;CDK6;CDK7;CDK9;CDKN1A(p21Wap1 / Cip1);CD KN1B(p27Kip1);CDKN1C;CDKN2A(p16INK4a);CD KN2B;CDKN2C;CDKN3;CEBPB;CER1;CHGA;CHGB;Ki Chinase;CHST10;CKLFSF2;CKLFSF3;CKLFSF4;CKLF SF5;CKLFSF6;CKLFSF7;CKLFSF8;CLDN3;CLDN6; CLDN7 (claudin-7); CLN3; CLU (clusterin); CMKLR1; CMKOR1(RDC1);CNR1;COL18A1;COL1A1;COL4A3; COL6A1;CR2;CRP;CSF1(M-CSF);CSF2(GM-CSF); CSF3(GCSF);CTLA4;CTNNB1(b-カテニン);CTSB(カテプ シンB);CX3CL1(SCYD1);CX3CR1(V28);CXCL1(GRO 1);CXCL10(IP-10);CXCL11(1-TAC / IP-9);CXCL 12(SDF1);CXCL13;CXCL14;CXCL16;CXCL2(GRO2 );CXCL3(GRO3);CXCL5(ENA-78 / LIX);CXCL6(GC P-2);CXCL9(MIG);CXCR3(GPR9 / CKR-L2);CXCR4 ;CXCR6(TYMSTR / STRL33 / Bonzo);CYB5;CYC1;CY SLTR1;CGRP;C1q;C1r;C1;C4a;C4b;C2a;C2b;C3 a;C3b;DAB2IP;DES;DKFZp451J0118;DNCL1;DPP 4;E-セレクチン;E2F1;ECGF1;EDG1;EFNA1;EFNA3;EF NB2;EGF;EGFR;EGFRvIII;ELAC2;ENG;ENO1;ENO 2;ENO3;EPHB4;EPO;ERBB2(Her-2);EREG;ERK8; ESR1;ESR2;F3(TF);Factor VII;Factor IX;Factor V;Factor VIIa Factor; Factor X; Factor XII; Factor XIII; FADD; FasL; FASN; FC ER1A;FCER2;Fc gamma receptor;FCGR3A;FCRL5;FGF;FGF1 (aFGF);FGF10;FGF11;FGF12;FGF12B;FGF13;FG F14;FGF16;FGF17;FGF18;FGF19;FGF2(bFGF);F GF20;FGF21;FGF22;FGF23;FGF3(int-2);FGF4( HST);FGF5;FGF6(HST-2);FGF7(KGF);FGF8;FGF 9; FGFR3; FIGF(VEGFD); FIL1(EPSILON); FIL1(Z ETA); FLJ12584; FLJ25530; FLRT1(Fibronectin); F LT1; Folic acid receptor α; Folic acid receptor β; FOS; FOSL1(FRA-1); Fucosyl G M1; FY(DARC); GABRP(GABAa); GAGEB1; GAGEC1; G ALNAC4S-6ST; GATA3; GDF5; GFI1; GGT1; GM-CSF; GloboH; GNAS1; GNRH1; GPNMB; GPR2(CCR10); GPR 20; GPR31; GPR44; GPR64; GPR81(FKSG80); GPRC5 D; GRCC10(C10); GRP; GSN(Gelsolin); GSTP1; Glycoprotein (gP)IIb / IIIa; HAVCR1; HAVCR2; HDAC4; HDAC5; HDAC7A; HDAC9; Her2; HER3; HGF; HIF1A; HIP1; Histamine and histamine receptor; HLA-A; HLA-DRA; HM74; HMGB1; H MOX1; HMWMAA; HUMCYT2A; ICEBERG; ICOSL; ID2; I MOX1; HMWMAA; HUMCYT2A; ICEBERG; ICOSL; ID2; I FN-a; IFNA1; IFNA2; IFNA4; IFNA5; IFNA6; IFNA7 ; IFNB1; IFN-γ; IFNW1; IGBP1; IGF1; IGF1R; IGF2 ; IGFBP2; IGFBP3; IGFBP6; IL-1; IL-α; IL-1-β; I L10; IL10RA; IL10RB; IL11; IL11RA; IL-12; IL12 A; IL12B; IL12RB1; IL12RB2; IL13; IL13RA1; IL1 3RA2; IL14; IL15; IL15RA; IL16; IL17; IL17B; IL 17C;IL17R;IL18;IL18BP;IL18R1;IL18RAP;IL1 9;IL1A;IL1B;IL1F10;IL1F5;IL1F6;IL1F7;IL1 F8;IL1F9;IL1HY1;IL1R1;IL1R2;IL1RAP;IL1RA PL1;IL1RAPL2;IL1RL1;IL1RL2;IL1RN;IL2;IL2 0;IL20RA;IL21R;IL22;IL22R;IL22RA2;IL23;I L24;IL25;IL26;IL27;IL28A;IL28B;IL29;IL2R A;IL2RB;IL2RG;IL3;IL30;IL3RA;IL4;IL4R;IL 5;IL5RA;IL6;IL6R;IL6ST(protein130);IL7;IL 7R;IL8;IL8RA;IL8RB;IL8RB;IL9;IL9R;ILK;IN HA;INHBA;INSL3;INSL4;IRAQ1;IRAQ2;ITGA1;I TGA2;ITGA3;ITGA6(a6β);ITGAV;ITGB3;I TGB4(b 4cap);JAG1;JAK1;JAK3;JUN;K6HF; KAI1;KDR;KITLG;KLF5(GC Box BP);KLF6;KLK1 0;CLOCK12;CLOCK13;CLOCK14;CLOCK15;CLOCK3;CLOCK4;CLOCK5 ;KLK6;KLK9;KRT1;KRT19(KRT19);KRT2A;KRTH B6(Light-fingered II strainer);L-strainer;LAMAS;LEP(strainer) ;Lingo-p75;Lingo-Troy;LRP6;LPS;LTA(TNF-b). );LTB;LTB4R(GPR16);LTB4R2;LTBR;LY6K;LYPD 8;MACMARCKS;MAG isOmgp;MAP2K7(c-Jun);MDK; Mesothelin; MIB1; Midkine; MIF; MIP-2; MKI67 (Ki-67) ;MMP2;MMP9;MS4A1;MSMB;MT3 (metallothionectin-III) ;MTSS1;MUC1 (mucin);MYC;MYD88;NCK2;Neurocan;N KG2D;NFKB1;NFKB2;NGF;NGFB(NGF);NGFR;NgR- Lingo;NgR-Nogo66(Nogo);NgR-p75;NgR-Troy; NME1(NM23A);NOX5;NPPB;NR0B1;NR0B2;NR1D1; NR1D2;NR1H2;NR1H3;NR1H4;NRII2;NRII3;NR2C 1;NR2C2;NR2E1;NR2E3;NR2F1;NR2F2;NR2F6;NR 3C1;NR3C2;NR4A1;NR4A2;NR4A3;NR5A1;NR5A2; NR6A1;NRP1;NRP2;NT5E;NTN4;NY-BR-1;o-acetyl -GD2;ODZ1;OPRD1;OR51E2;P2RX7;PANX3;PAP;P ART1;PATE;PAWR;PCA3;PCNA;PDGFA;PDGFB;PEC AM1;PF4(CXCL4);PGE2;PGF;PGR;Phosphacan;PIAS2 ;PIK3CG;PLAC1;Plasminogen activator;PLAU(uPA);PL G;PLXDC1;Polysialic acid;PPBP(CXCL7);PPID;PR1;PRK CQ;PRKD1;PRL;PROC;Protein C;PROK2;PSAP;PSCA ;PTAFR;PTEN;PTGS2(COX-2);PTN;RAC2(p21Rac 2);RAGE;RARB;RGS1;RGS13;RGS3;RNF110(ZNF1 44);ROBO2;SIO0A2;SCGB1D2(shellB);SCGB2A 1(shell2);SCGB2A2(shell1);SCYE1(supernatural SDF2;SERPIN1;SERPIN3;SERPIN B5(ツ);SERPINE1(PAI-1);SERPINF1;SHBG;S LA2;SLC2A2;SLC33A1;SLC34A2;SLC39A6;SLC43 A1;SLIT2;SLITRK6;SPP1;SPRR1B(Spr1);ST6GA L1;STAB1;STAT6;STEAP;STEAP2;LAXP;TACS TD2;TB4R2;TBX21;TCP10;TDGF1;TEK;TEM1 / CD2 48;TEM7R;TGFA;TGFB1;TGFB111;TGFB2;TGFB3; TGFBI;TGFBR1;TGFBR2;TGFBR3;TH1L;THBS1(THB THBS2;THBS4;THPO;TIE(Tie-1);T IMP3;promoter;TLR10;TLR2;TLR3;TLR4;TLR5;TLR6 ;TLR7;TLR8;TLR9;TNF;TNF-A;TNFAIP2(B94);T NFAIP3;TNFRSF11A;TNFRSF1A;TNFRSF1B;TNFRS F21;TNFRSF5;TNFRSF6(Fas);TNFRSF7;TNFRSF8 ; TNFRSF9;TNFSF10(TRAIL);TNFSF11(TRANCE);T NFSF12(APO3L);TNFSF13(Apr);TNFSF13B;TN FSF14(WHO-L);TNFSF15(VEGI);TNFSF18;TNFS F4 (OX40 ligand); TNFSF5 (CD40 ligand); TNFSF6 (Fas L);TNFSF7 (CD27 ligand);TNFSF8 (CD30 ligand);TNF SF9 (4-1BB ligand); TOLLIP; Toll-like receptor; TOP2A (Topoisomerase II A) somerase ha);TP53;TPM1;TPM2;TRADD;TRAF1;TRAF 2;TRAF3;TRAF4;TRAF5;TRAF6;TREM1;TREM2;TR PC6;TSHR;TSLP;TWEAK;Thrombomodulin;Thrombin;UPK2 ;VEGF;VEGFB;VEGFC;Versican;VHL C5;VLA-4;XCL 1 (lymphotactin); XCL2 (SCM-1b); XCR1 (GPRS / CCXCR1 );YY1; and ZFPM2.
[0387] In one embodiment, the TAA is ADRB3. In one embodiment, the TAA is ALK. In one embodiment, the TAA is an androgen receptor. In one embodiment, the TAA is BCMA. In one embodiment, the TAA is BORIS. In one embodiment, the TAA is BST2. In one embodiment, the TAA is cadherin 17. In one embodiment, the TAA is CAIX. In one embodiment, the TAA is CD171. In one embodiment, the TAA is CD179a. In one embodiment, the TAA is CD20. In one embodiment, the TAA is CD22. In another embodiment, the TAA is CD24. In some embodiments, the TAA is CD30. In one embodiment, the TAA is CD32b. In one embodiment, the TAA is CD33. In one embodiment, the TAA is CD38. In one embodiment, the TAA is CD44v6. The TAA is CD72. In one embodiment, the TAA is CD79a. In an embodiment, the TAA is CD79b. In one embodiment, the TAA is CEA. In one embodiment, the TAA is CLDN6. In one embodiment, the TAA is CLEC12A. In one embodiment, the TAA is CLL-1. A is CS-1. In one embodiment, the TAA is CXORF61. In an embodiment, the TAA is cyclin B1. , CYP1B1. In one embodiment, the TAA is EGFR. In one embodiment, the TAA is EGFRvIII. In one embodiment, the TAA is EPCAM. In one embodiment, the TAA is EphA2. In one embodiment, the TAA is EphB2. In one embodiment, the TAA is ERBB2. A is ERG (TMPRSS2 ETS fusion gene). In one embodiment, the AA is ETV6-AML. In another embodiment, the TAA is FAP. In some embodiments, the TAA is FCAR. In one embodiment, the TAA is CRL5. In one embodiment, the TAA is FLT3. In one embodiment, the TAA is FLT3. In one embodiment, the TAA is folate receptor alpha. In one embodiment, the TAA is folate receptor β. AA is Fos-related antigen 1. In one embodiment, the TAA is fucosyl-GM1. In one embodiment, the TAA is GD2. In one embodiment, the TAA is GD2. In one embodiment, the TAA is GD3. In one embodiment, the TAA is GloboH. In one embodiment, the TAA is GM3. In one embodiment, the TAA is gp100Tn. In one embodiment, the AA is GPC3. In one embodiment, the TAA is GPNMB. In an embodiment, the TAA is GPR20. In one embodiment, the TAA is GPR64. In one embodiment, the TAA is HAVCR1. In one embodiment, the TAA is HER3. In some embodiments, the TAA is HMWMAA. The TAA is hTERT. In one embodiment, the TAA is an Igf-I receptor. In one embodiment, the TAA is IGLL1. A is IL-11Ra. In one embodiment, the TAA is IL-13Ra2. In one embodiment, the TAA is KIT. In one embodiment, the TAA is In one embodiment, the TAA is LCK. In one embodiment, the TAA is Lewis Y. In one embodiment, the TAA is LILRA2. In one embodiment, the TAA is LMP2. A is LRP6. In one embodiment, the TAA is LY6K. In one embodiment, the TAA is LY75. In one embodiment, the TAA is LYPD8 In one embodiment, the TAA is MAD-CT-1. In one embodiment, the TAA is MAD-CT-2. In one embodiment, the TAA is ML-IAP. In one embodiment, the TAA is MUC1. In another embodiment, the TAA is MYCN. In some embodiments, the TAA is NA17. In one embodiment, the TAA is NKG2D. In one embodiment, the TAA is o-acetyl. In one embodiment, the TAA is OR51E2. In one embodiment, the TAA is OY-TES1. In one embodiment, the TAA is PANX3. In one embodiment, the TAA is PAX3. In one embodiment, the TAA is PAX5. In one embodiment, the TAA is PDGFR-β. In one embodiment, the TAA is PLAC1. In one embodiment, the TAA is polysialic acid. In one embodiment, the TAA is PRSS21. A is PSCA. In one embodiment, the TAA is RhoC. In one embodiment, the TAA is ROR1. In one embodiment, the TAA is SART3. In one embodiment, the TAA is SLC34A2. In one embodiment, the TAA is LC39A6. In one embodiment, the TAA is sLe. In one embodiment, the TAA is SLITRK6. In one embodiment, the TAA is protein 17. In one embodiment, the TAA is SSEA-4. In one embodiment, the TAA is SSX2. In one embodiment, the TAA is TAAG7 2. In one embodiment, the TAA is TAARP. In one embodiment, the TAA is TACSTD2. In one embodiment, the TAA is TEM1 / CD 248. In one embodiment, the TAA is TEM7R. In one embodiment, the TAA is TGS5. In one embodiment, the TAA is Tie 2. In one embodiment, the TAA is Tn Ag. In one embodiment, the TAA is tyrosinase. In one embodiment, the TAA is UPK2. In one embodiment, the TAA is WT1. TAA is XAGE1.
[0388] TAA ABMs can include, for example, ligand-based or antibody-based moieties. For example, in the case of BCMA as a TAA, the ABM may be APRIL, a BCMA ligand, or B or an anti-BCMA antibody or antigen-binding fragment thereof that binds to BCMA. Ligands and antibodies that bind to TAAs are well known in the art. In the case of the base moiety, the anti-TAA antibody or antigen-binding fragment may be, for example, any of those listed in Table 11. In one embodiment, the anti-TAA antibody or its antigen may comprise the CDR sequences of the antibody to be targeted. The binding domains have the heavy and light chain variable region sequences of the antibodies listed in Table 11.
[0389] [Table 53]
[0390] [Table 54]
[0391] [Table 55]
[0392] [Table 56]
[0393] BCMA In certain embodiments, the present disclosure provides methods for detecting ABM3 BCMA expression in cells of the B cell lineage. TBM, a tumor necrosis family receptor (TNFR) member expressed in BC MA expression includes plasma cells, plasmablasts, and subpopulations of activated and memory B cells. It is highest in terminally differentiated B cells that assume a long-lived plasma cell fate. Involved in mediating plasma cell survival to maintain humoral immunity. BCMA expression BCMA has recently been linked to many cancers, autoimmune diseases, and infectious diseases. Cancers with high expression include some hematological cancers, such as multiple myeloma and Hodgkin's lymphoma. and non-Hodgkin's lymphoma, various leukemias, and glioblastoma.
[0394] A TBM that includes an ABM that binds BCMA can be, for example, an anti-BCMA antibody or its antigen-binding The anti-BCMA antibody or antigen-binding domain thereof may comprise, for example, any of the antibodies listed in Tables 12A-12C. The fragment may comprise the CDR, VH, VL or scFV sequences described in 12G.
[0395] [Table 57]
[0396] [Table 58]
[0397] [Table 59]
[0398] [Table 60]
[0399] [Table 61]
[0400] [Table 62]
[0401] [Table 63]
[0402] Table 64
[0403] Table 65
[0404] Table 66
[0405] Table 67
[0406] Table 68
[0407] Table 69
[0408] Table 70
[0409] Table 71
[0410] Table 72
[0411] Table 73
[0412] [Table 74]
[0413] [Table 75]
[0414] [Table 76]
[0415] [Table 77]
[0416] [Table 78]
[0417] [Table 79]
[0418] [Table 80]
[0419] In some embodiments, the ABM comprises the CDR sequences of BCMA-1. In one embodiment, the ABM comprises the CDR sequences of BCMA-2. In one embodiment, the ABM comprises the CDR sequences of BCMA-4. In one embodiment, the ABM comprises the CDR sequences of BCMA-5. In some embodiments, the ABM comprises the CDR sequences of BCMA-6. In one embodiment, the ABM comprises the CDR sequences of BCMA-7. In one embodiment, the ABM comprises the CDR sequences of BCMA-9. In one embodiment, the ABM comprises the CDR sequences of BCMA-10. In one embodiment, the ABM comprises the CDR sequences of BCMA-11. In one embodiment, the ABM comprises the CDR sequences of BCMA-12. The BM comprises the CDR sequences of BCMA-13. In one embodiment, the ABM comprises the CDR sequences of BCMA-15. In one embodiment, the ABM comprises the CDR sequences of BCMA-16. In some embodiments, the ABM comprises the CDR sequences of BCMA-17. In one embodiment, the ABM comprises the CDR sequences of BCMA-18. comprises the CDR sequences of BCMA-19. In one embodiment, the ABM comprises the CDR sequences of BCMA-21. In one embodiment, the ABM comprises the CDR sequences of BCMA-22. In an embodiment, the ABM comprises the CDR sequences of BCMA-23. In one embodiment, the ABM comprises the CDR sequences of BCMA-24. In one embodiment, the ABM comprises the CDR sequences of BCMA-25. In one embodiment, the ABM comprises the CDR sequences of BCMA-27. In one embodiment, the ABM comprises the CDR sequences of BCMA-28. In one embodiment, the ABM comprises the CDR sequences of BCMA-29. The ABM comprises the CDR sequences of BCMA-30. In one embodiment, the ABM comprises the CDR sequences of BCMA-31. In one embodiment, the ABM comprises the CDR sequences of BCMA-33. In some embodiments, the ABM comprises the CDR sequences of BCMA-34. In one embodiment, the ABM comprises the CDR sequences of BCMA-35. M comprises the CDR sequences of BCMA-36. In one embodiment, the ABM comprises the CDR sequences of BCMA-38. In one embodiment, the ABM comprises the CDR sequences of BCMA-39. In some embodiments, the ABM comprises the CDR sequences of BCMA-40.
[0420] In one embodiment, the CDRs are selected from the group consisting of Kaba, as set forth in Tables 12B and 10E. In other embodiments, the CDRs are defined by the t numbering in Tables 12C and 10F. Further embodiments are defined by Chothia numbering as described in In the above, the CDRs are selected from the Kabat and Chot It is defined by the combination of hia numbering.
[0421] In one embodiment, the TBM comprising an ABM that binds to BCMA is BCMA-1 to BCMA-B It may comprise any of the heavy and light chain variable sequences of CMA-40.
[0422] In one embodiment, the ABM comprises the heavy and light chains of BCMA-1 listed in Table 12A. In one embodiment, the ABM comprises a BCMA-2 sequence listed in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-3 as set forth in Table 1. In one embodiment, the BCMA-4 heavy and light chain variable sequences are as set forth in 2A. The ABM comprises the heavy and light chain variable sequences of BCMA-5 set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-6 set forth in Table 12A. In one embodiment, the ABM comprises a BCMA-7 heavy chain and a BCMA-7 heavy chain as described in Table 12A. In one embodiment, the ABM comprises a BCMA light chain variable sequence as set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of ATP-8. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-9. In one embodiment, the heavy and light chain variable sequences of BCMA-10 are set forth in Table 12A. wherein the ABM comprises the heavy and light chain variable sequences of BCMA-11 set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chains of BCMA-12 listed in Table 12A. In one embodiment, the ABM comprises a BCMA-1 sequence listed in Table 12A. In one embodiment, the ABM comprises a heavy and light chain variable sequence of any one of the sequences set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-14. In one embodiment, the heavy and light chain variable sequences of BCMA-15 are set forth in Table 12A. wherein the ABM comprises the heavy and light chain variable sequences of BCMA-16 set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chains of BCMA-17 listed in Table 12A. In one embodiment, the ABM comprises a BCMA-1 sequence listed in Table 12A. In one embodiment, the ABM comprises a heavy and light chain variable sequence of any of the eight heavy and light chain variable sequences set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-19. In one embodiment, the heavy and light chain variable sequences of BCMA-20 are set forth in Table 12A. wherein the ABM comprises the heavy and light chain variable sequences of BCMA-21 as set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chains of BCMA-22 listed in Table 12A. In one embodiment, the ABM comprises a BCMA-2 sequence listed in Table 12A. In one embodiment, the ABM comprises a heavy and light chain variable sequence of any one of the sequences set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-24. In one embodiment, the heavy and light chain variable sequences of BCMA-25 are set forth in Table 12A. wherein the ABM comprises the heavy and light chain variable sequences of BCMA-26 set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chains of BCMA-27 listed in Table 12A. In one embodiment, the ABM comprises a BCMA-2 sequence listed in Table 12A. In one embodiment, the ABM comprises a heavy and light chain variable sequence of any of the eight heavy and light chain variable sequences set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-29. In one embodiment, the heavy and light chain variable sequences of BCMA-30 are set forth in Table 12A. wherein the ABM comprises the heavy and light chain variable sequences of BCMA-31 as set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chains of BCMA-32 listed in Table 12A. In one embodiment, the ABM comprises a BCMA-3 sequence listed in Table 12A. In one embodiment, the ABM comprises a heavy and light chain variable sequence of any one of the sequences set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-34. In one embodiment, the heavy and light chain variable sequences of BCMA-35 are set forth in Table 12A. wherein the ABM comprises the heavy and light chain variable sequences of BCMA-36 as set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chains of BCMA-37 listed in Table 12A. In one embodiment, the ABM comprises a BCMA-3 sequence listed in Table 12A. In one embodiment, the ABM comprises a heavy and light chain variable sequence of any of the eight heavy and light chain variable sequences set forth in Table 12A. In one embodiment, the ABM comprises the heavy and light chain variable sequences of BCMA-39. The heavy and light chain variable sequences of BCMA-40 are listed in Table 12A.
[0423] 6.7.2.CD19 B cells express cell surface proteins that can be used as markers for differentiation and identification. One such human B cell marker is the CD19 antigen, which is expressed on mature B cells. CD19 is expressed during early pre-B cell development and is not found on plasma cells. CD19 is expressed on normal B cells and on B cell lymphomas where abnormal proliferation leads to B cell lymphomas. For example, CD19 is expressed on both non-Hodgkin's and malignant B cells. lymphoma (B-NHL), chronic lymphocytic leukemia, and acute lymphocytic leukemia, but these It is expressed in B-cell lineage malignancies, not limited to:
[0424] In certain embodiments, the TBM of the present disclosure comprises ABM3 that specifically binds to CD19. Exemplary CDRs and variable domains that can be incorporated into ABM3 that specifically binds CD19. The sequences are listed in Table 13 below.
[0425] [Table 81]
[0426] [Table 82]
[0427] [Table 83]
[0428] In certain embodiments, ABM3 is selected from the group consisting of CD19-H1, CD19-H, and CD19-H 2A and CD19-H3 and the heavy chain CDRs having the amino acid sequences of C19-H3 and C2A and C3A and C4A and C5A and C6A and C7A and C8A and C9A and C9A and C1A and C1B and C1C and C1C and C2A and C3A and C4A and C5A and C6A and C7 ...8A and C9A and C a light chain CDR having the amino acid sequences of CD19-L1, CD19-L2, and CD19-L3; In certain embodiments, ABM3 comprises the amino acid sequence of a VHA listed in Table 13. and a light chain variable region having the amino acid sequence of a VLA listed in Table 13. Includes the area.
[0429] In other embodiments, ABM3 is selected from the group consisting of CD19-H1, CD19-H2, and CD19-H3. heavy chain CDRs having the amino acid sequences of B and CD19-H3 and the CDRs listed in Table 13 and a light chain CDR having the amino acid sequences of CD19-L1, CD19-L2, and CD19-L3. In certain embodiments, the ABM3 comprises the amino acid sequence of a VHB listed in Table 13. and a light chain variable region having the amino acid sequence of a VLB listed in Table 13. Includes:
[0430] In a further embodiment, ABM3 is selected from the group consisting of CD19-H1, CD19- Heavy chain CDRs having the amino acid sequences of H2C and CD19-H3 and listed in Table 13 Light chain CDRs having the amino acid sequences of CD19-L1, CD19-L2, and CD19-L3 In certain embodiments, ABM3 comprises the amino acid sequence of a VHC set forth in Table 13. and a heavy chain variable region having the amino acid sequence of VLB listed in Table 13. Includes the area.
[0431] In a further embodiment, ABM3 is selected from the group consisting of CD19-H1, CD19- Heavy chain CDRs having the amino acid sequences of H2D and CD19-H3 and listed in Table 13 Light chain CDRs having the amino acid sequences of CD19-L1, CD19-L2, and CD19-L3 In certain embodiments, ABM3 comprises the amino acid sequence of a VHD set forth in Table 13. and a heavy chain variable region having the amino acid sequence of VLB listed in Table 13. Includes the area.
[0432] In still other embodiments, ABM3 is in the form of an scFV. The scFv is any one of CD19-scFv1 to CD19-scFv12 listed in Table 13. It contains one of the amino acid sequences.
[0433] 6.8. Nucleic Acids and Host Cells In another embodiment, the disclosure provides a nucleic acid encoding a TBM of the disclosure. In some embodiments, the TBM is encoded by a single nucleic acid. The BM is encoded by multiple (e.g., two, three, four or more) nucleic acids. do.
[0434] A single nucleic acid is a TBM containing a single polypeptide chain, a TBM containing two or more polypeptide chains It may encode a TBM or a portion of a TBM comprising three or more polypeptide chains (e.g., a single The nucleic acid is a fragment of two polypeptides of TBM containing three, four or more polypeptide chains. The polypeptide chains encoding the three polypeptide chains of TBM containing four or more polypeptide chains are For separate control of expression, open loops encoding two or more polypeptide chains can be used. A reading frame is a sequence of distinct transcriptional regulatory elements (e.g., promoter and / or enhancer). An open reading frame encoding two or more polypeptides may be under the control of a gene encoding the open reading frame. The frame is also controlled by the same transcriptional regulatory element, the internal ribosome entry site (IRE). S) sequences to allow translation into separate polypeptides.
[0435] In one embodiment, a TBM comprising two or more polypeptide chains is linked to two or more nucleic acids. The number of nucleic acids encoding TBM is equal to or greater than the number of polypeptide chains in TBM. may be lower (e.g., when two or more polypeptide chains are encoded by a single nucleic acid). ).
[0436] The nucleic acids of the present disclosure can be DNA or RNA (e.g., mRNA).
[0437] In another aspect, the disclosure provides host cells and vectors containing the nucleic acids of the disclosure. The nucleic acids may be cultured in the same host cell or in another host cell, as described in more detail herein below. The vectors may be present in a single vector or in separate vectors present in a single host cell.
[0438] Vectors The present disclosure provides nucleotide sequences encoding the TBM or TBM components described herein. In one embodiment, the vector comprises a sequence as described herein. In one embodiment, the immunoglobulin-based ABM comprises nucleotides encoding the The vector comprises nucleotides encoding the Fc domain described herein. In embodiments, the vector is a recombinant non-immunoglobulin-based vector as described herein. The vectors of the present disclosure comprise nucleotides encoding one or more ABMs, one or more Fc domains, one or more non-immunoglobulin-based ABMs, or a combination thereof can encode (e.g., multiple components or subcomponents can be expressed as a single polypeptide chain) In one embodiment, the vector is encoded by a nucleic acid sequence described herein. Vectors include, but are not limited to, viruses, plasmids, cos mid, lambda phage or yeast artificial chromosome (YAC).
[0439] Many vector systems can be used. For example, one type of vector is, for example, a vector for the expression of bovine papillomavirus (BOV). Romanovirus, polyomavirus, adenovirus, vaccinia virus, baculovirus Virus, retrovirus (Rous sarcoma virus, MMTV or MOMLV) or SV4 Another type of vector uses DNA elements derived from animal viruses, such as the HIV virus. RNA viruses such as Semliki Forest virus, Eastern equine encephalitis virus, and flaviviruses It uses RNA elements derived from viruses.
[0440] Furthermore, cells that have stably integrated the DNA into their chromosomes are transfected hosts. Selection can be achieved by introducing one or more markers that allow for the selection of cells. Cars can be used to confer, for example, prototrophy to an auxotrophic host, biocide resistance (e.g., antibiotics) or may provide resistance to heavy metals such as copper. either directly linked to the DNA sequence to be transfected or introduced into the same cell by cotransformation. Additional elements may also be required for optimal synthesis of mRNA. It may contain price signals as well as transcription promoters, enhancers and termination signals.
[0441] Once the expression vector or DNA sequence containing the construct is prepared for expression, the expression vector The vector can be transfected or introduced into a suitable host cell, for example, by protoplast fusion, Calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection transfection, gene gun, lipid-based transfection or other conventional techniques. A variety of techniques can be used to do this. The resulting transfected cells are cultured. Methods and conditions for culturing and recovering expressed polypeptides are known to those skilled in the art. Based on this specification, the expression vectors and mammalian host cells used will vary. Or it can be optimized.
[0442] 6.8.2.Cells The present disclosure also provides a host cell comprising a nucleic acid of the present disclosure.
[0443] In one embodiment, the host cell is adapted to contain one or more nucleic acids described herein. It is genetically modified.
[0444] In one embodiment, the host cell is genetically engineered by using an expression cassette. The term "expression cassette" refers to the expression of a gene in a host compatible with such sequences. Such a cassette refers to a nucleotide sequence capable of affecting the expression of a gene. promoter, open reading frame with or without introns and termination sequence For example, a promoter may be an inducible promoter, or other signal necessary or useful to effect expression. Additional factors may also be used.
[0445] The present disclosure also provides host cells comprising the vectors described herein.
[0446] The cell can be, but is not limited to, a eukaryotic cell, a bacterial cell, an insect cell, or a human cell. Suitable eukaryotic cells include, but are not limited to, Vero cells, HeLa cells, and COS cells. , CHO cells, HEK293 cells, BHK cells and MDCKII cells. Suitable insect cells include, but are not limited to, Sf9 cells.
[0447] 6.9. Antibody-Drug Conjugates The TBMs of the present disclosure can be conjugated to a drug moiety, for example, via a linker. Such conjugates may be constructed such that one or more (or all) of the ABMs are attached to a non-immunoglobulin scaffold. Although the term may be used interchangeably, for convenience, antibody-drug conjugates ( or "ADC").
[0448] In certain embodiments, the drug moiety exerts a cytotoxic or cytostatic effect. In embodiments, the drug moiety is a maytansinoid, a kinesin-like protein KIF11 inhibitor. agent, V-ATPase (vacuolar H+-ATPase) inhibitor, apoptosis promoter, B cl2 (B-cell lymphoma 2) inhibitor, MCL1 (myeloid cell leukemia 1) inhibitor, HSP90 (heat shock protein 90) inhibitors, IAP (inhibitors of apoptosis) inhibitors, mTO R (mechanistic target of rapamycin) inhibitors, microtubule stabilizers, microtubule destabilizers, aurystine tin, dolastatin, MetAP (methionine aminopeptidase), CRM1 (chromosome Maintenance 1) inhibitors, DPPIV (dipeptidyl peptidase IV) inhibitors, proteasome inhibitors inhibitors, inhibitors of phosphoryl transfer reactions in mitochondria, protein synthesis inhibitors, Kinase inhibitors, CDK2 (cyclin-dependent kinase 2) inhibitors, CDK9 (cyclin Kinase-dependent kinase 9 inhibitors, kinesin inhibitors, HDAC (histone deacetylase) inhibitors toxicants, DNA damaging agents, DNA alkylating agents, DNA intercalators, DNA minor groove binders, RNA polymerases lysomerase inhibitors, topoisomerase inhibitors or DHFR (dihydrofolate reductase) inhibitors.
[0449] In one embodiment, the linker is a cleavable linker, a non-cleavable linker, a hydrophilic linker, or a The linker is selected from a dicarboxylic acid-based linker, a procharged linker, or a dicarboxylic acid-based linker.
[0450] In certain embodiments, the ADC has structural formula (I): [DL-XY] n -Ab or a salt thereof, wherein each "D" independently represents a cytotoxic and and / or a cytostatic drug ("drug"); each "L" independently represents a linker; "Ab" represents a TBM as described herein; each "XY" represents a Functional group R x and a "complementary" functional group R on the antibody y and n represents the connection formed between It represents the number of drugs linked to the ADC or the drug-to-antibody ratio (DAR) of the ADC.
[0451] Specific embodiments of the various antibodies (Abs) that may comprise the ADC include those of the various TBMs described above. Including embodiments.
[0452] In certain embodiments of an ADC and / or salt of Structural Formula (I), each D is the same and , and / or each L is the same.
[0453] A cytotoxic and / or cytostatic drug (D) and linker (B) that may comprise the ADCs of the disclosure. -Specific embodiments of (L) and cytotoxic and / or cytostatic agents linked to ADCs A number of the active ingredients are described in more detail below.
[0454] 6.9.1. Cytotoxic and / or Cytostatic Agents Cytotoxic and / or cytostatic agents are agents that inhibit the growth of cells, particularly cancer cells and / or tumor cells. inhibiting growth and / or replication and / or killing cells, particularly cancer cells and / or tumor cells; The agent may be any agent known to have cytotoxic and / or cytostatic properties. Many drugs are known in the literature that have cytotoxic and / or cytostatic properties. Non-limiting examples of drug classes include, by way of example and not limitation, radionuclides, alkyl groups, lysing agents, topoisomerase I inhibitors, topoisomerase II inhibitors, DNA intercalators (e.g. (e.g., groove binders such as minor groove binders), RNA / DNA antimetabolites, cell cycle regulators, kinases enzyme inhibitors, protein synthesis inhibitors, histone deacetylase inhibitors, mitochondrial inhibitors agents and antimitotic agents.
[0455] Specific non-limiting examples of agents within some of these various classes are provided below.
[0456] Alkylating agent: asaley ((L-leucine, N-[N-acetyl-4-methyl ... -[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester NSC 167780; CAS Registry Number 3577897); AZQ((1,4-silyl) Chlohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3, 6-Dioxo-, diethyl ester; NSC 182986; CAS Registry Number 57998 682));BCNU((N,N'-bis(2-chloroethyl)-N-nitrosourea; NSC 409962; CAS Registry Number 154938); Busulfan (1,4-butadiene Dimethylmethanesulfonate; NSC 750; CAS Registry Number 55981; (C (Carboxyphthalato)platinum (NSC 27164; CAS Registry Number 65296813); C BDCA ((cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)) ;NSC 241240;CAS Registry Number 41575944));CCNU((N-(2 -chloroethyl)-N'-cyclohexyl-N-nitrosourea;NSC 79037; CAS Registry Number 13010474); CHIP (Iproplatin; NSC 25692) 7); Chlorambucil (NSC 3088; CAS Registry Number 305033); Chlorozote Syn((2-[[[(2-chloroethyl)nitrosamino]carbonyl]amino]-2- Deoxy-D-glucopyranose; NSC 178248; CAS Registry Number 547499 05); cis-platinum (cisplatin; NSC 119875; CAS Registry Number 1566) 3271); clomesone (NSC 338947; CAS Registry Number 88343720); Cyanomorpholinodoxorubicin (NCS 357704; CAS Registry Number 882540 73); Cyclodison (NSC 348948; CAS Registry Number 99591738); Di Anhydrogalactitol (5,6-diepoxydulcitol; NSC 132313; CAS Registry Number 23261203; Fluoro dopan (( 5-[(2-chloroethyl)-(2-fluoroethyl)amino]-6-methyl-uracil ;NSC 73754; CAS Registry Number 834913; Hepsulfam (NSC 32 9680; CAS Registry Number 96892578); Hycanthone (NSC 142982; C AS Registry No. 23255938); melphalan (NSC 8806; CAS Registry No. 3 223072; Methyl CCNU((1-(2-chloroethyl)-3-(trans-4- Methylcyclohexane)-1-nitrosourea; NSC 95441; 13909096 ); Mitomycin C (NSC 26980; CAS Registry Number 50077); Mitozolami mitozolamide (NSC 353451; CAS Registry Number 856229 53); Nitrogen mustard ((bis(2-chloroethyl)methylamine hydrochloride; NSC 762; CAS Registry Number 55867; PCNU((1-(2-chloroethyl) -3-(2,6-dioxo-3-piperidyl)-1-nitrosourea; NSC 9546 6; CAS Registry Number 13909029); Piperazine alkylating agent ((1-(2-chloro (3-chloroethyl)-4-(3-chloropropyl)-piperazine dihydrochloride; NSC 344007 ));Piperazinedione (NSC 135758; CAS Registry Number 41109802); Pipobroman ((N,N-bis(3-bromopropionyl)piperazine; NSC 251 54; CAS Registry Number 54911); Porfiromycin (N-methylmitomycin C; NSC 56410; CAS Registry Number 801525); Spirohydantoin Master (NSC 172112; CAS Registry Number 56605164); Teroxylon (Isothiocyanate) Triglycidyl anurate; NSC 296934; CAS Registry Number 2451629); Te Traplatin (NSC 363812; CAS Registry Number 62816982); Thiotepa (N,N',N''-tri-1,2-ethanediylthiophosphoramide; NSC 6396 ;CAS Registry Number 52244); Triethylenemelamine (NSC 9706;CAS Registry Number No. 51183); uracil nitrogen mustard (desmethyl dopant (desm ethyldopan); NSC 34462; CAS Registry Number 66751); Yosh I-864 ((Bis(3-mesyloxypropyl)amine hydrochloride; NSC 102627 ;CAS Registry Number 3458228).
[0457] Topoisomerase I inhibitor: Camptothecin (NSC 94600; CAS Registry Number 7 689-03-4); various camptothecin derivatives and analogues (e.g., NSC 100 880, NSC 603071, NSC 107124, NSC 643833, NSC 629971, NSC 295500, NSC 249910, NSC 606985 , NSC 74028, NSC 176323, NSC 295501, NSC 606 172, NSC 606173, NSC 610458, NSC 618939, NSC 610457, NSC 610459, NSC 606499, NSC 610456 , NSC 364830 and NSC 606497); morpholine isoxorubicin (m orpholinisoxorubicin) (NSC 354646; CAS Registry Number 89196043); SN-38 (NSC 673596; CAS Registry Number 86639- 52-3).
[0458] Topoisomerase II inhibitor: doxorubicin (NSC 123127; CAS Registry No. No. 25316409); Amonafide (benzisoquinolinedione; NSC 30884 7; CAS Registry Number 69408817; m-AMSA ((4'-(9-acridinyl acridinyl ester) (amino)-3'-methoxymethanesulfonanilide; NSC 249992; CAS Registry Number No. 51264143); Anthrapyrazole derivatives ((NSC 355644); Ethyl Poside (VP-16; NSC 141540; CAS Registry Number 33419420); Pyra Pyrazolo[3,4,5-kl]acridine-2(6H)-propanediol amine, 9-methoxy-N,N-dimethyl-5-nitro-, monomethanesulfonate; NS C 366140; CAS Registry Number 99009219; Bisantrene hydrochloride (NSC 337766; CAS Registry Number 71439684; Daunorubicin (NSC 8211 51; CAS Registry Number 23541506; Deoxydoxorubicin (NSC 2674 69; CAS Registry Number 63950061); mitoxantrone (NSC 301739; CAS Registry Number 70476823); Menogaril (NSC 269148; CAS Registry Number No. 71628961); N,N-dibenzyl daunomycin (NSC 268242; C AS Registration No. 70878512); Oxanthrazole (NSC 349174; CAS Registration No. 105118125); Rubidazone (NSC 164011; CAS Registration No. 3 6508711); Teniposide (VM-26; NSC 122819; CAS Registry Number 2 9767202).
[0459] DNA intercalators: anthramycin (CAS Registry Number 4803274); ticamycin A (CAS Registry Number 89675376); tomaymycin (CAS Registry Number 3505055 6); DC-81 (CAS Registry Number 81307246); Sibiromycin (CAS Registry Number No. 12684332); Pyrrolobenzodiazepine derivatives (CAS Registry No. 9454900 95);SGD-1882((S)-2-(4-aminophenyl)-7-methoxy-8- (3-4(S)-7-Methoxy-2-(4-methoxyphenyl)-5-oxo-5,1 1a-Dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-8- (yl)oxy)propoxy)-1H-benzo[e]pyrrolo[1,2-a][1,4]diazo[2-methyl-2- ... Zepin-5(11aH)-one; SG2000 (SJG-136; (11aS, 11a 'S)-8,8'-(propane-1,3-diylbis(oxy))bis(7-methoxy- 2-Methylene-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4 ]diazepin-5(11aH)-one; NSC 694501; CAS Registry Number 232 931576).
[0460] RNA / DNA antimetabolite: L-alanosine (NSC 153353; CAS Registry Number 59163416); 5-azacytidine (NSC 102816; CAS Registry Number 320 672);5-fluorouracil (NSC 19893; CAS Registry Number 51218); Acivicin (NSC 163501; CAS Registry Number 42228922); Aminopteri N-[2-chloro-5-[[(2,4-diamino-5-methyl-6-quinazolinyl] (I)methyl]amino]benzoyl-]L-aspartic acid (NSC 132483); Minopterin derivative N-[4-[[(2,4-diamino-5-ethyl-6-quinazolinyl )Methyl]amino]benzoyl]L-aspartic acid (NSC 184692); Amino Pterin derivative N-[2-chloro-4-[[(2,4-diamino-6-pteridinyl)methyl]methyl [Cycitrimethyl]amino]benzoyl]L-aspartic acid monohydrate (NSC 134033); Antifo ((N α -(4-amino-4-deoxypteroyl)-N 7 - Hemiphthaloyl-L-ornithine; NSC 623017); Baker's soluble anti- Fol (Baker's soluble antifol) (NSC 139105; CAS Registry Number 41191042; Dichloroallyl Lawsone (lawsone) ((2 -(3,3-Dichloroallyl)-3-hydroxy-1,4-naphthoquinone; NSC 12 6771; CAS Registry Number 36417160); brequinar (NSC 368390; C AS Registration No. 96201886; Futorafur ((prodrug; 5-fluoro-1-( Tetrahydro-2-furyl)-uracil; NSC 148958; CAS Registry Number 370 76689); 5,6-dihydro-5-azacytidine (NSC 264880; CAS reg. Registry No. 62402317); methotrexate (NSC 740; CAS Registry No. 590 52); Methotrexate derivative (N-[[4-[[(2,4-diamino-6-pteridinyl) N-(methyl)methylamino)-1-naphthalenyl]carbonyl]L-glutamic acid;N SC 174121; PALA((N-(phosphonoacetyl)-L-aspartate; NSC 224131; CAS Registry Number 603425565; pyrazofurin (NSC 143095; CAS Registry Number 30868305; Trimetrexate (NSC 35 2122; CAS Registry Number 82952645).
[0461] DNA antimetabolite: 3-HP (NSC 95678; CAS Registry Number 3814797) 2'-Deoxy-5-fluorouridine (NSC 27640; CAS Registry Number 509 19);5-HP(NSC 107392;CAS registration number 19494894);α-T GDR (α-2'-deoxy-6-thioguanosine; NSC 71851 CAS Registry Number No. 2133815); Aphidicolin glycinate (NSC 303812; CAS Registry Number Accession No. 92802822);ara C (cytosine arabinoside; NSC 63878; CAS Registry Number 69749); 5-Aza-2'-deoxycytidine (NSC 12771 6; CAS Registry Number 2353335; β-TGDR (β-2'-deoxy-6-thioglycol) Anosine; NSC 71261; CAS Registry Number 789617; Cyclocytidine (NS C 145668; CAS Registry Number 10212256; Guanazole (NSC 189 5; CAS Registry Number 1455772); Hydroxyurea (NSC 32065; CAS Registration No. 127071); inosine glicodialdehyde (NSC 118994; CAS Registration No. 23590990); Macbecin II (NSC 330500; CAS Registration No. 73341738); pyrazoloimidazole (NSC 51143; CAS Registry Number 67 14290); Thioguanine (NSC 752; CAS Registry Number 154427); Thiopro Phosphorus (NSC 755; CAS Registry Number 50442).
[0462] Cell cycle regulators: silibinin (CAS reg. no. 22888-70-6); epigallocatechin EGCG (EGCG; CAS Registry Number 989515); procyanidin derivatives (e.g. For example, procyanidin A1 [CAS registration number 103883030], procyanidin B1 [ CAS Registry Number 20315257], Procyanidin B4 [CAS Registry Number 291065 12], areca tannin B1 [CAS Registry Number 79763283]); isoflavones (e.g. For example, genistein [4',5,7-trihydroxyisoflavone; CAS Registry Number 44 6720], daidzein [4',7-dihydroxyisoflavone, CAS Registry Number 486 668]; indole-3-carbinol (CAS Registry Number 700061); quercetin (NSC 9219; CAS Registry Number 117395); estramustine (NSC 89 201; CAS Registry Number 2998574; nocodazole (CAS Registry Number 314301 89); Podophyllotoxin (CAS Registry Number 518285); Vinorelvintertray (NSC 608210; CAS Registry Number 125317397); cryptophycin ( NSC 667642; CAS Registry Number 124689652).
[0463] Kinase inhibitors: Afatinib (CAS Registry Number 850140726); Axitinib (CAS Registry Number 319460850); ARRY-438162 (binimetinib) (C AS Registry Number 606143899); bosutinib (CAS Registry Number 380843754) Cabozantinib (CAS Registry Number 1140909483); Ceritinib (CAS Registry Number No. 1032900256); crizotinib (CAS Registry Number 877399525); Dub Rafenib (CAS Registry Number 1195765457); Dasatinib (NSC 73251 7; CAS Registry Number 302962498); erlotinib (NSC 718781; CA S Registry No. 183319699); everolimus (NSC 733504; CAS Registry No. No. 159351696); fostamatinib (NSC 745942; CAS Registry Number 90 1119355); gefitinib (NSC 715055; CAS Registry Number 184475 352); ibrutinib (CAS Registry Number 936563961); imatinib (NSC 716051; CAS Registry Number 220127571; lapatinib (CAS Registry Number 38 8082788); lenvatinib (CAS Registry Number 857890392); mubritinib (CAS 366017096);nilotinib (CAS Registry Number 923288953); Nintedanib (CAS Registry Number 656247175); Palbocyclib (CAS Registry Number No. 571190302); pazopanib (NSC 737754; CAS Registry No. 6357 02646); pegaptanib (CAS Registry Number 222716861); ponatinib (CA S registration number 1114544318); rapamycin (NSC 226080; CAS registration number No. 53123889); regorafenib (CAS Registry Number 755037037); AP 23573 (Ridaforolimus) (CAS Registry Number 572924540); INCB0 18424 (ruxolitinib) (CAS Registry Number 1092939177); ARRY-1 42886 (selumetinib) (NSC 741078; CAS Registry Number 606143-5 2-6); sirolimus (NSC 226080; CAS Registry Number 53123889); Rafenib (NSC 724772; CAS Registry Number 475207591); sunitinib (NSC 736511; CAS Registry Number 341031547); tofacitinib (CA S registration number 477600752); temsirolimus (NSC 683864; CAS registration No. 163635043); trametinib (CAS Registry Number 871700173); Detanib (CAS Registry Number 443913733); Vemurafenib (CAS Registry Number 91 8504651); SU6656 (CAS Registry Number 330161870); CEP-70 1 (resaurtinib) (CAS Registry Number 111358884); XL019 (CAS Registry Number No. 945755566);PD-325901 (CAS Registry No. 391210109) ;PD-98059 (CAS registration number 167869218);PI-103 (CAS registration No. 371935749), PP242 (CAS Registry Number 1092351671), PP 30 (CAS Registry Number 1092788094), Trin 1 (CAS Registry Number 122299 8368), LY294002 (CAS Registry Number 154447366), XL-147( CAS Registry Number 934526893), CAL-120 (CAS Registry Number 8702813 48), ETP-45658 (CAS Registry Number 1198357797), PX 866( CAS Registry Number 502632668), GDC-0941 (CAS Registry Number 957054 307), BGT226 (CAS registration number 1245537681), BEZ235 (CA S registration number 915019657), XL-765 (CAS registration number 934493762) ATP-competitive TORC1 / TORC2 inhibitors, including
[0464] Protein synthesis inhibitor: Acriflavine (CAS Registry Number 65589700); Amica cin (NSC 177001; CAS Registry Number 39831555); arbekacin (CA S Registry No. 51025855); astromycin (CAS Registry No. 55779061) ;Azithromycin (NSC 643732; CAS Registry Number 83905015); Beca Namycin (CAS Registry Number 4696768); Chlortetracycline (NSC 13 252; CAS Registry Number 64722; Clarithromycin (NSC 643733; C AS Registration No. 81103119); clindamycin (CAS Registration No. 18323449 ); chromocycline (CAS Registry Number 1181540); cycloheximide (CAS Registry Number Registry No. 66819); dactinomycin (NSC 3053; CAS Registry No. 50760 ); Dalfopristin (CAS Registry Number 112362502); Demeclocycline (C AS Registration No. 127333); Dibekacin (CAS Registration No. 34493986); Dihydrazide Rostreptomycin (CAS Registry Number 128461); Dirithromycin (CAS Registry Number No. 62013041); doxycycline (CAS Registry Number 17086281); emmeline cin (NSC 33669; CAS Registry Number 483181); erythromycin (NSC 55929; CAS Registry Number 114078; flurithromycin (CAS Registry Number 8 3664208); framycetin (neomycin B; CAS Registry Number 119040); Gentamicin (NSC 82261; CAS Registry Number 1403663); Tigecycline glycylcyclines such as hygromycin (CAS Registry Number 220620097); B (CAS Registry Number 31282049); isepamicin (CAS Registry Number 678147 60); josamycin (NSC 122223; CAS Registry Number 16846245); Kanamycin (CAS Registry Number 8063078); Telithromycin (CAS Registry Number 1 91114484), cethromycin (CAS Registry Number 205110481) and Solis Ketolides such as thromycin (CAS Registry Number 760981837); Lincomycin ( CAS Registry Number 154212); Lymecycline (CAS Registry Number 992212); Mec Isocycline (NSC 78502; CAS Registry Number 2013583); Methacycline Londomycin (NSC 356463; CAS Registry Number 914001); Midecama Isin (CAS Registry Number 35457808); minocycline (NSC 141993; CAS Registry Number 10118908); Miocamycin (CAS Registry Number 55881077 ); neomycin (CAS Registry Number 119040); netilmicin (CAS Registry Number 5 6391561); oleandomycin (CAS Registry Number 3922905); eperezoli methadone (CAS Registry Number 165800044), linezolid (CAS Registry Number 1658000 33), pocizolid (CAS Registry Number 252260029), radezolid (CAS Registry Number No. 869884786), lambezolid (CAS Registry Number 392659380), stezo tetrazolid (CAS Registry Number 168828588), tedizolid (CAS Registry Number 856867 oxazolidinones such as oxytetracycline (NSC 9169; CAS Registration No. 2058460); Paromomycin (CAS Registration No. 7542372); Penime Picycline (CAS Registry Number 4599604); a peptidyl transferase inhibitor chloramphenicol (NSC 3069; CAS Registry Number 56757) and Azidamfenicol (CAS registration number 13838089), Florfenicol (CA S registration number 73231342) and thiamphenicol (CAS registration number 1531845 3) and its derivatives, as well as retapamulin (CAS registration number 224452668), thiamri valnemulin (CAS Registry Number 1013129 29) such as pleuromutilins; pirlimycin (CAS Registry Number 79548735); Puromycin (NSC 3055; CAS Registry Number 53792); quinupristin ( CAS Registry Number 120138503); ribostamycin (CAS Registry Number 537973 56); Rokitamycin (CAS Registry Number 74014510); Rolitetracycline ( CAS Registry Number 751973); roxithromycin (CAS Registry Number 80214831 ); Sisomycin (CAS Registry Number 32385118); Spectinomycin (CAS Registry Number spiramycin (CAS Registry Number 8025818); pristine Namycin (CAS Registry Number 270076603), quinupristin / dalfopristin (CAS Registry Number 126602899) and virginiamycin (CAS Registry Number 11 streptogramins such as streptomycin (CAS Registry Number 579 21); Tetracycline (NSC 108579; CAS Registry Number 60548); Tob ramycin (CAS Registry Number 32986564); troleandomycin (CAS Registry Number No. 2751099); tylosin (CAS Registry No. 1401690); verdamycin ( CAS Registry Number 49863481).
[0465] Histone deacetylase inhibitor: abexinostat (CAS Registry Number 7833556 02); Belinostat (NSC 726630; CAS Registry Number 414864009) ; Chidamide (CAS Registry Number 743420022); Entinostat (CAS Registry Number 209783802); gibinostat (CAS Registry Number 732302997); moceti nostat (CAS Registry Number 726169739); panobinostat (CAS Registry Number 404950807); Xinostat (CAS Registry Number 875320299); Resmi nostat (CAS Registry Number 864814880); romidepsin (CAS Registry Number 12 8517077); sulforaphane (CAS Registry Number 4478937); thioureide Butyronitrile (Kevetrin®; CAS Registry Number 6659890); Valp rotic acid (NSC 93819; CAS Registry Number 99661); vorinostat (NSC 7 01852; CAS Registry Number 149647789; ACY-1215 (Rossilinost CUDC-101 (CAS Registry Number 10) 12054599); CHR-2845 (tefinostat); CAS Registry Number 914382608); CHR-3996 (CAS Registry Number 123585 9138);4SC-202 (CAS Registry Number 910462430);CG200745 (CAS Registry Number 936221339); SB939 (prasinostat; CAS Registry Number No. 929016966).
[0466] Mitochondrial inhibitor: Pancratistatin (NSC 349156; CAS Registry Number 96281311); Rhodamine-123 (CAS Registry Number 63669709); Edel Phocin (NSC 324368; CAS Registry Number 70641519); d-α-Tocopherol Ferrol succinate (NSC 173849; CAS Registry Number 4345033); Compound 11β (CAS Registry Number 865070377); aspirin (NSC 406186; CAS Registry Number 50782); Ellipticine (CAS Registry Number 519233); Berberis Cerulenin (CAS Registry Number 633658); Cerulenin (CAS Registry Number 17397896); GX015-070 (Obatoclax®); 1H-indole, 2-(2- ((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H- Pyrrol-5-yl)-; NSC 729280; CAS Registry Number 803712676) ; Celastrol (tripterine; CAS registration number 34157830); Metformin ( NSC 91485; CAS Registry Number 1115704; Brilliant Green (Bri lliant green) (NSC 5011; CAS Registry Number 633034); ME -344 (CAS Registry Number 1374524556).
[0467] Antimitotic agents: Allocolchicine (NSC 406042); MMAE (monomethyl esters of methylaminobenzoates); Ristatin E; CAS registration number 474645-27-7 and MMAF (monomethyl ester) Auristatins such as auristatin F; CAS Registry Number 745017-94-1; Halicon Dolin B (NSC 609395); Colchicine (NSC 757; CAS Registry Number 64 868); Colchicine derivative (N-benzoyl-deacetylbenzamide; NSC 33 410; CAS Registry Number 63989753; Dolastatin 10 (NSC 376128 ;CAS Registry Number 110417-88-4); Maytansine (NSC 153858;C AS registration number 35846-53-8); lozoxin (NSC 332598; CAS registration No. 90996546); Taxol (NSC 125973; CAS Registry No. 3306 9624; Taxol derivative ((2'-N-[3-(dimethylamino)propyl]glucan Thalamate Taxol; NSC 608832; Thiocolchicine (3-demethylthiocolchicine) Luchtin (NSC 361792); Trityl cysteine (NSC 49842; CAS Registry No. 2799077); vinblastine sulfate (NSC 49842; CAS Registry No. No. 143679); Vincristine sulfate (NSC 67574; CAS Registry No. 206 8782).
[0468] Any of these agents that contain or can be modified to contain a binding site for a TBM include: may be included in the ADCs disclosed herein.
[0469] In certain embodiments, the cytotoxic and / or cytostatic agent is an antimitotic agent. is.
[0470] In another specific embodiment, the cytotoxic and / or cytostatic agent is auritis. statins, such as monomethylauristatin E (MMAE) or monomethylauristatin Chin F ("MMAF").
[0471] ADC Linker In the ADCs of the disclosure, the cytotoxic and / or cytostatic agent is attached to the ADC linker. The cytotoxic and / or cytostatic drug is linked to the TBM by the T The ADC linker that connects to the BM can be short, long, hydrophobic, hydrophilic, flexible, or rigid. or the linker may comprise segments with different properties, Independently, the linker may be composed of segments having one or more of the properties described above. , may be multivalent so as to covalently attach two or more agents to a single site on the TBM; or It can be monovalent so as to covalently attach a single agent to a single site on the TBM.
[0472] As will be appreciated by one of skill in the art, an ADC linker may contain cytotoxic and / or cytotoxic groups at one position. or form a covalent bond to the cytostatic drug and a covalent bond to the TBM at another location. The cytotoxic and / or cytostatic drug is linked to the TBM by covalent bonding. is formed by reaction between functional groups on the ADC linker and functional groups on the drug and TBM As used herein, the term "ADC linker" refers to: (i) an AD Functional groups capable of covalently linking the C linker to a cytotoxic and / or cytostatic drug A non-conjugated AD containing a functional group capable of covalently attaching the ADC linker to the TBM. (ii) a C linker containing a functional group capable of covalently attaching the ADC linker to the TBM; , a moiety that is covalently attached to a cytotoxic and / or cytostatic agent, or vice versa a conjugated ADC linker; and (iii) a cytotoxic and / or cytostatic drug, and The present invention is intended to include fully conjugated ADC linkers that are covalently attached to both the TBM and the ADC. The disclosed ADC linkers and ADCs and linker-drugs are used to attach them to TBMs. In certain embodiments of the synthon, the moiety comprising the functional group on the ADC linker and the A The covalent bond formed between the DC linker and the TBM is R x and XY It is shown explicitly.
[0473] The ADC linker is preferably chemically stable to extracellular conditions, but may also be It need not be specifically degraded, cleaved, sacrificed, and / or otherwise degraded within the cell. Alternatively, they may be designed to be specifically cleaved or degraded within the cell. ADC linkers that are not stable may be used. The choice of stable or unstable ADC linker depends on the cell This may depend on the toxicity of the cytotoxic and / or cytostatic drug. Drugs that are toxic to normal cells For selective or targeted and normal cells, stable linkers are preferred. Drugs with lower toxicity can be used, and the chemical stability of the ADC linker to the extracellular environment is improved. The nature of the ADC is not critical. ADC linkers are known in the art. These ADC linkers and other ADC linkers are well known in the art. Any of the C linkers may be used to link a cytotoxic and / or cytostatic agent to the ADC of the disclosure. It can be used to link to a TBM.
[0474] It can be used to link multiple cytotoxic and / or cytostatic drugs to a single TBM molecule. Exemplary multivalent ADC linkers that can be used are described, for example, in WO 2009 / 073445 No. brochure; International Publication No. 2010 / 068795 brochure; International Publication No. 201 Pamphlet No. 0 / 138719; Pamphlet No. WO 2011 / 120053; International Publication No. 2011 / 171020; International Publication No. 2013 / 096901 No. brochure; International Publication No. 2014 / 008375 brochure; International Publication No. 201 4 / 093379; International Publication No. 2014 / 093394; The contents of this patent are described in International Publication No. 2014 / 093640. The entirety of which is incorporated herein by reference. For example, the method developed by Mersana et al. Fleximer linker technology enables the production of high-DAR ADCs with favorable physicochemical properties. As shown below, Mersana's technology has the potential to It is based on incorporating drug molecules into a solubilizing polyacetal backbone via ether bonds. This method allows the production of highly loaded ADCs (up to 20 DAR) while maintaining good physicochemical properties. provide.
[0475] Further examples of dendritic linkers are described in U.S. Patent Application Publication No. 2006 / 116422. ;U.S. Patent Application Publication No. 2005 / 271615; de Groot et al. .,2003,Angew.Chem.Int.Ed.42:4490-4494;Am ir et al.,2003,Angew.Chem.Int.Ed.42:4494 -4499;Shamis et al.,2004,J.Am.Chem.Soc.1 26:1726-1731;Sun et al.,2002,Bioorganic& Medicinal Chemistry Letters 12:2213-2215 ;Sun et al.,2003,Bioorganic&Medicinal Ch emistry 11:1761-1768;King et al.,2002,Te trahedron Letters 43:1987-1990, which Each is incorporated herein by reference.
[0476] Exemplary monovalent ADC linkers that can be used are described, for example, in Nolting, 2013, A ntibody-Drug Conjugates,Methods in Molec ular Biology 1045:71-100;Kitson et al.,2 013,CROs-MOs--Chemica-ggi--Chemistry Tod ay 31(4):30-38;Ducry et al.,2010,Bioconj ugate Chem.21:5-13;Zhao et al.,2011,J.Me d. Chem. 54:3606-3623; U.S. Pat. No. 7,223,837; U.S. Pat. US Patent No. 8,568,728; US Patent No. 8,535,678; and These are described in the pamphlet of International Publication No. 2004010957, and these are referred to by reference. The present application is incorporated by reference.
[0477] By way of example, and not limitation, some cleavable and non-cleavable ADCs that can be included in the ADCs of the present disclosure include: Determinative ADC linkers are described below.
[0478] Cleavable ADC Linkers In certain embodiments, the ADC linker selected is cleavable in vivo. Cleavable ADC linkers can include chemically or enzymatically labile or degradable linkages. Cleavable ADC linkers generally respond to the reducing conditions in the cytoplasm and the acidic conditions in the lysosome. The drug is released by exposure to light or by cleavage by specific proteases or other enzymes within the cell. Cleavable ADC linkers generally rely on chemical processes within the cell to or incorporate one or more chemical bonds that are enzymatically cleavable, while the remainder of the ADC linker In certain embodiments, the ADC linker is a hydrazone or a hydroxyl group. and / or containing chemically unstable groups such as disulfide groups. Carr exploits the differences in properties between the protoplasm and some cytoplasmic fractions. For DC linkers, the intracellular conditions that promote drug release are endosomes and lysosomes. While disulfide-containing ADC linkers are suitable for use in acidic environments with high thiol concentrations, e.g. It is reduced in the cytosol containing glutathione. In certain embodiments, it is chemically unstable. Cytostability of ADC linkers containing chemically unstable groups can be improved by using substituents near the chemically labile group. This can be increased by introducing steric hindrance into the
[0479] Acid-labile groups such as hydrazones are stable in the neutral pH environment of blood (pH 7.3-7.5). The ADC remains intact during systemic circulation and enters the weakly acidic endosomes (pH 5.0– When taken up into the lysosomal (pH 4.5-5.0) and lysosomal (pH 6.5) fractions, hydrolysis occurs. This pH-dependent release mechanism was associated with nonspecific drug release. To enhance the stability of the hydrazone group of the ADC linker, the ADC linker is chemically modified. , e.g., by substitution to minimize loss in circulation and maintain in lysosomes. This may allow for adjustment to achieve a more efficient release.
[0480] Hydrazone-containing ADC linkers may also contain additional acid-labile cleavage sites and / or enzymatically It may contain additional cleavage sites, such as labile cleavage sites. Exemplary Hydrazone-Containing ADCs The ADC including the linker has the following structure: [ka] wherein D and Ab are each a cytotoxic and / or cytostatic agent (drug). and Ab, and n represents the number of drug-ADC linkers linked to the TBM. In certain ADC linkers, such as (Ig), the ADC linker contains two cleavable groups-di For such ADC linkers, unmodified free radicals are used. Effective release of the drug requires acidic pH or disulfide reduction and acidic pH. Linkers such as (Ii) and (II) have been shown to be effective at a single hydrazone cleavage site. are.
[0481] It remains intact during systemic circulation and undergoes hydrolysis when the ADC is taken up into acidic cellular compartments. Further ADC linkers that release drugs include carbonates. ADC linkers such as It may be useful if it can be covalently linked.
[0482] Other acid-labile groups that can be included in the ADC linker include cis-aconityl-containing ADs. The cis-aconityl chemistry involves amide hydrolysis under acidic conditions. For speed, a carboxylic acid juxtaposed to the amide bond is used.
[0483] Cleavable ADC linkers can also contain disulfide groups. Disulfides are cleavable at physiological pH. thermodynamically stable in the cytosol, making the cytosol a significantly more reducing environment compared to the extracellular environment. It is designed to release the drug upon entry into the cell, providing a barrier between the nuclei and the nuclei. Cleavage of the disulfide bond is generally considered to be a catalyzed event when disulfide-containing ADC linkers are reasonably stable in circulation. and (reduced) glutathione (GS) to selectively release the drug in the cytosol. Requires the presence of cytoplasmic thiol cofactors such as hydroxylase (H). Disulfide isomerases or similar enzymes capable of cleaving disulfide bonds are also known to act intracellularly. GSH is the most abundant GSH in the circulation. The concentration of 0.5–1000 mg / L is higher than that of cysteine, a common low-molecular-weight thiol. It is reported to exist in cells at a concentration of 10 mM. The tumor cells that cause this have increased activity of reductases and therefore higher glutathione concentrations. In certain embodiments, the in vivo stability of disulfide-containing ADC linkers is improved. Qualitative studies have demonstrated the use of chemical modifications of the ADC linker, such as steric hindrance adjacent to the disulfide bond. This can be facilitated by:
[0484] Exemplary ADCs containing disulfide-containing ADC linkers have the following structure: [ka] wherein D and Ab represent a drug and a TBM, respectively, and n is linked to the TBM. represents the number of drug-ADC linkers, and each occurrence of R is independently selected from, for example, hydrogen or alkyl. In certain embodiments, the sterically hindered alkyl groups adjacent to the disulfide bond are selected from the group consisting of: The increase in the valence increases the stability of the ADC linker. Structures such as (Ij) and (Il) are When one or more R groups are selected from lower alkyl, such as methyl, increased in vivo stability is achieved. show.
[0485] Another type of cleavable ADC linker that can be used is one that is specifically cleaved by an enzyme. Such ADC linkers are typically peptide-based or or a peptide region that serves as a substrate for an enzyme. Linkers tend to be more stable in the plasma and extracellular environment than chemically unstable ADC linkers. Lysosomal protease activity is higher in the blood than in endogenous inhibitors and lysosomes. The peptide bond is a soluble form of ATP, which has very low activity in blood due to the unfavorably high pH value of the solution. Generally, it has good serum stability. Drug release from TBM is mediated by lysosomal proteases. These proteases are specifically caused by the action of proteases such as cathepsins and plasmin. may be present at elevated levels in certain tumor cells.
[0486] In an exemplary embodiment, the cleaving peptide has the sequence Gly-Phe-Leu-Gly (SEQ ID NO: 1). tetrapeptides such as Ala-Leu-Ala-Leu (sequence number 716), Ala-Leu-Ala-Leu (sequence number 717), Tide or Val-Cit, Val-Ala, Met-(D)Lys, Asn-(D)Ly s, Val-(D)Asp, Phe-Lys, Ile-Val, Asp-Val, His -Val, NorVal-(D)Asp, Ala-(D)Asp 5, Met-Lys, Asn-Lys, Ile-Pro, Me3Lys-Pro, PhenylGly-(D) Lys, Met-(D)Lys, Asn-(D)Lys, Pro-(D)Lys, Met -(D)Lys, Asn-(D)Lys, AM Met-(D)Lys, Asn-(D) Selected from dipeptides such as Lys, AW Met-(D)Lys and Asn-(D)Lys In certain embodiments, the hydrophobicity of the longer peptides may result in the longer polypeptides being selected. Dipeptides are preferred over peptides.
[0487] Doxorubicin, mitomycin, camptothecin, pyrrolobenzodiazepines, taliso Drugs such as mycin and auristatins / auristatin family members to TBM A variety of dipeptide-based cleavable ADC linkers useful for linking have been described ( Dubowchik et al., 1998, each of which is incorporated herein by reference. ,J.Org.Chem.67:1866-1872;Dubowchik et al. .,1998,Bioorg.Med.Chem.Lett.8(21):3341-3 346;Walker et al.,2002,Bioorg.Med.Chem.L ett.12:217-219;Walker et al.,2004,Bioorg .Med.Chem.Lett.14:4323-4327;Sutherland e t al., 2013, Blood 122:1455-1463; and Francis See co et al., 2003, Blood 102:1458-1465 These dipeptide ADC linkers or modifications of these dipeptide ADC linkers All of these forms may be used in the ADCs of the present disclosure. Other dipeptide ADC phosphoryl groups that may be used include: As for the car, Seattle Genetics' Brentuximab Ven dotin SGN-35 (Adcetris(TM)), Seattle Genet ics SGN-75 (anti-CD-70, Val-Cit-monomethyl auristatin F ( MMAF), Seattle Genetics SGN-CD33A (anti-CD-33, Val-Ala-(SGD-1882)), Celldex Therapeutics Glenbatumumab (CDX-011) (anti-NMB, Val-Cit-monomethylalanine Tatin E (MMAE) and Cytogen PSMA-ADC (PSMA-ADC-13 01) (anti-PSMA, Val-Cit-MMAE) and other ADCs. Examples include:
[0488] Enzymatically cleavable ADC linkers spatially separate the drug from the site of enzymatic cleavage The direct attachment of a drug to a peptide ADC linker may include a self-immolative spacer for Causes proteolytic release of the drug's amino acid adduct, thereby increasing its activity The use of a self-immolative spacer can result in a fully active chemical structure after hydrolysis of the amide bond. This allows for efficient release of the unmodified drug.
[0489] One self-immolative spacer is a bifunctional para-aminobenzyl alcohol group, It is linked to the peptide via the amino group, forming an amide bond, while amine-containing drugs The product is attached to the benzylic hydroxyl group of the ADC linker (PABC) via the carbamate functional group. The resulting prodrug is activated after protease-mediated cleavage. A 1,6-elimination reaction occurs to leave the unmodified drug, carbon dioxide, and the residue of the ADC linker group. The following scheme illustrates the cleavage of the p-aminobenzyl ether and release of the drug: [ka] where XD represents the unmodified drug.
[0490] Heterocyclic forms of this self-immolative group have also been described, see, for example, See U.S. Patent No. 7,989,434.
[0491] In one embodiment, the enzymatically cleavable ADC linker is a β-glucuronic acid-based The ADC linker is a soluble form of the lysosomal enzyme β-glucuronidase. This can be achieved by cleavage of the β-glucuronide glycosidic bond by the enzyme It is abundant in the endothelium and is overexpressed in some tumor types, but the enzyme is not expressed extracellularly. The ADC is β-glucuronic acid-based ADC linker, and the ADC is β-glucuronic acid-based ADC linker. This avoids the tendency of lonide to aggregate due to its hydrophilicity. A uronic acid-based ADC linker is an ADC linker for ADCs that are linked to hydrophobic drugs. The following scheme illustrates a preferred ADC linker containing a β-glucuronic acid-based ADC linker: 1 shows the release of drug from an ADC having [ka]
[0492] Auristatins, camptothecin and doxorubicin analogues, CBI minor groove binders and protease inhibitors Various cleavable β-glucuronic acid bases useful for linking drugs such as cymbeline to TBMs ADC linkers of the same type have been described (Nol ting,Chapter 5“Linker Technology in Anti Body-Drug Conjugates”,In:Antibody-Drug C onjugates:Methods in Molecular Biology,v ol.1045,pp.71-100,Laurent Ducry(Ed.),Spr. inger Science&Business Medica,LLC,2013;J effrey et al.,2006,Bioconjug.Chem.17:831 -840;Jeffrey et al.,2007,Bioorg.Med.Chem .Lett.17:2278-2280; and Jiang et al., 2005, J (See Am. Chem. Soc. 127:11254-11255). All of the above β-glucuronic acid-based ADC linkers may be used in the ADCs of the disclosure.
[0493] Additionally, cytotoxic and / or cytostatic drugs containing a phenol group may be It can be covalently attached to an ADC linker via a hydroxyl oxygen. WO 2007 / 0891 One such ADC linker described in Issue 49 is a diamino- The "SpaceLink" tandem with the conventional "PABO"-based self-immolation group was used to Cleavage of the ADC linker is shown schematically below and is dependent on the method of delivering the phenol. wherein D is a cytotoxic and / or cytostatic drug having a phenolic hydroxyl group Represents the agent. [ka]
[0494] Cleavable ADC linkers may include non-cleavable portions or segments and / or may be cleavable. The functional segment or moiety is included in an otherwise non-cleavable ADC linker and is cleaved. By way of example only, polyethylene glycol (PEG) and related polymers The polymer may contain cleavable groups in the polymer backbone. The ADC linker may comprise one or more cleavable groups such as a disulfide, hydrazone, or dipeptide. It may contain functional groups.
[0495] Other degradable linkages that can be included in the ADC linker are PEG carboxylic acid or activated PE G. Ester bonds formed by reaction of a carboxylic acid with an alcohol group on a bioactive agent wherein such ester groups generally hydrolyze under physiological conditions to become bioactive. Hydrolytically degradable linkages include, but are not limited to, carbon phosphate bond; imine bond obtained from the reaction of an amine with an aldehyde; alcohol with a phosphate group Phosphate ester bond formed by reaction with ; reaction product of aldehyde and alcohol Acetal bonds, which are products of the reaction of formates with alcohols; orthoesters, which are products of the reaction of formates with alcohols and phosphoramidite groups and, but not limited to, oligonucleotides at the ends of the polymers. The oligonucleotide bond formed by the 5' hydroxyl group of the oligonucleotide is do.
[0496] In certain embodiments, the ADC linker comprises an enzymatically cleavable peptide moiety, e.g., For example, structural formula (IVa) or (IVb): [ka] or a salt thereof, wherein the peptide is cleaved by a lysosomal enzyme. represents a cleavable peptide (denoted C→N, without the carboxy and amino "termini"). T contains one or more ethylene glycol units or alkylene chains or combinations thereof R represents a polymer; a is selected from hydrogen, alkyl, sulfonate and methylsulfonate p is an integer ranging from 0 to 5; q is 0 or 1; x is 0 or 1; and y is is 0 or 1; [ka] represents the point of attachment of the ADC linker to the cytotoxic and / or cytostatic agent; * A represents the point of attachment to the remainder of the DC linker.
[0497] In certain embodiments, the peptide is selected from a tripeptide or a dipeptide. In certain embodiments, the dipeptide is Val-Cit; Cit-Val; Ala-A la;Ala-Cit;Cit-Ala;Asn-Cit;Cit-Asn;Cit-C it;Val-Glu;Glu-Val;Ser-Cit;Cit-Ser;Lys-C it;Cit-Lys;Asp-Cit;Cit-Asp;Ala-Val;Val-A la;Phe-Lys;Val-Lys;Ala-Lys;Phe-Cit;Leu-C It is selected from Ile-Cit; Phe-Arg; and Trp-Cit. In an embodiment, the dipeptide is selected from Cit-Val; and Ala-Val.
[0498] Specific Examples of ADC Linkers Represented by Structural Formula (IVa) That May Be Included in the ADCs of the Disclosure Typical embodiments include the ADC linkers shown below (as shown): The ADC linker comprises a group suitable for covalently attaching the ADC linker to the TBM). [ka] [ka]
[0499] Specific Examples of ADC Linkers Represented by Structural Formula (IVb) That May Be Included in the ADCs of the Disclosure Typical embodiments include the ADC linkers shown below (as shown): The ADC linker comprises a group suitable for covalently attaching the ADC linker to the TBM). [ka] [ka] [ka] [ka] [ka] [ka]
[0500] In certain embodiments, the ADC linker comprises an enzymatically cleavable peptide moiety, e.g., For example, structural formula (IVc) or (IVd): [ka] or a salt thereof, wherein the peptide is cleaved by a lysosomal enzyme. represents a cleavable peptide (denoted C→N, without the carboxy and amino "termini"). T contains one or more ethylene glycol units or alkylene chains or combinations thereof R represents a polymer; a is selected from hydrogen, alkyl, sulfonate and methylsulfonate p is an integer ranging from 0 to 5; q is 0 or 1; x is 0 or 1; and y is is 0 or 1; [ka] represents the point of attachment of the ADC linker to the cytotoxic and / or cytostatic agent; * A represents the point of attachment to the remainder of the DC linker.
[0501] Specific Examples of ADC Linkers Represented by Structural Formula (IVc) That May Be Included in the ADCs of the Disclosure Typical embodiments include the ADC linkers shown below (as shown): The ADC linker comprises a group suitable for covalently attaching the ADC linker to the TBM). [ka]
[0502] Specific examples of ADC linkers represented by structural formula (IVd) that may be included in the ADCs of the disclosure Typical embodiments include the ADC linkers shown below (as shown): The ADC linker comprises a group suitable for covalently attaching the ADC linker to the TBM). [ka] [ka]
[0503] In certain embodiments, a compound represented by structural formula (IVa), (IVb), (IVc), or (IVd) ADC linkers containing the carboxyl group exhibit a carbonate moiety that is cleavable upon exposure to acidic medium. In certain embodiments, the ADC linker provides cytotoxicity and / or cytotoxicity via oxygen. or conjugated to a cytostatic drug.
[0504] 6.9.2.2. Non-cleavable Linkers While cleavable ADC linkers may offer several advantages, ADs, including the ADCs of the present disclosure, The C linker does not need to be cleavable. For non-cleavable ADC linkers, release of the drug occurs The release of drugs does not depend on the difference in properties between the cytoplasm and some cytoplasmic fractions. The ADC is taken up by endocytosis and delivery to the lysosomal compartment, where it TBM is produced after being decomposed to the amino acid level by intracellular proteolysis. This process is hypothesized to involve the covalent bonding of the drug, the ADC linker, and the ADC linker. The non-cleavable ADC linker releases the drug derivative formed by the amino acid residue. Amino acid drug metabolites from conjugates with cleavable ADC linkers It is more hydrophilic compared to the gate and generally has a lower membrane permeability, thereby Generally, ADCs with non-cleavable linkers have a lower under-reaction effect and lower non-specific toxicity. The ADCs have greater stability in circulation than ADCs with cleavable ADC linkers. The cleavable ADC linker can be an alkylene chain or, for example, a polyalkylene glyco. They may be polymeric in nature, such as based on alcohol polymers, amide polymers, etc., or may be alkyl. The polymer may contain segments of olefin chains, polyalkylene glycols and / or amide polymers. do.
[0505] A variety of non-cleavable ADC linkers have been described that can be used to link drugs to TBMs. Jeffrey et al., 2006, each of which is incorporated herein by reference. ,Bioconjug.Chem.17;831-840;Jeffrey et al .,2007,Bioorg.Med.Chem.Lett.17:2278-2280 ; and Jiang et al., 2005, J.Am.Chem.Soc.127:1 See, e.g., pp. 1254-11255. All of these ADC linkers are contemplated as ADCs of the present disclosure. may be included in
[0506] In certain embodiments, the ADC linker is not cleavable in vivo, e.g., ADC linkers represented by formula (VIa), (VIb), (VIc), or (VId) (as shown): As such, the ADC linker may comprise a group suitable for covalently attaching the ADC linker to the TBM. (including [ka] or a salt thereof, wherein R a is hydrogen, alkyl, sulfonate and methylsulfonate Selected from;R x However, it contains a functional group that allows the covalent attachment of the ADC linker to the TBM. It is the part that [ka] represents the point of attachment of the ADC linker to the cytotoxic and / or cytostatic agent.
[0507] ADC linkers represented by structural formulas (VIa) to (VId) that may be included in the ADCs of the present disclosure Specific exemplary embodiments include the ADC linkers shown below (as shown): As shown, the ADC linker contains a group suitable for covalently attaching the ADC linker to the TBM. Including, [ka] represents the point of attachment to the cytotoxic and / or cytostatic agent). [ka]
[0508] 6.9.2.3. Groups Used to Attach the Linker to the TBM Various groups can be used to attach the ADC linker-drug synthon to the TBM to yield the ADC. The linking group can be electrophilic in nature, such as a maleimide group, an activated disulfide, Active esters such as NHS esters and HOBt esters, haloformates, and acid halides Examples of suitable halides include alkyl and benzyl halides such as acetamides and haloacetamides. As will be seen, the "self-stabilizing" maleimides and "bridged disulfides" that may be used in accordance with the present disclosure are There is also emerging technology related to "fides." The specific groups used are partially dependent on the binding to the TBM. Depends on the area.
[0509] A, which spontaneously hydrolyzes under TBM conjugation conditions and has improved stability An example of a "self-stabilizing" maleimide group that results in a DC species is shown in the following schematic diagram: Publication No. 20130309256 A1; Lyon et al., Nature re Biotech published online,doi:10.1038 / See also nbt.2968. [ka] [ka]
[0510] Polytherics are paired strands derived from the reduction of the native hinge disulfide bonds. discloses a method for cross-linking alkylhydryl groups. 2014, Bioconjugate Chem. 25:1124-1136 The reaction is shown in the following schematic diagram. The advantage of this method is the complete reduction of IgG (four pairs of (generating sulfhydryls) followed by reaction with four equivalents of an alkylating agent The ability to synthesize DAR4 ADCs containing "bridged disulfides" is It is also believed to have great stability. [ka]
[0511] Similarly, maleic acid capable of bridging paired sulfhydryl groups, as shown below, The amide derivative (1, below) was also developed. Please refer to the following. [ka]
[0512] ADC Linker Selection Considerations As known by those of skill in the art, the ADC linker selected for a particular ADC will depend on the , binding site to TBM (e.g., lys, cys or other amino acid residue), drug pharmacopoeia This is due to various factors, including but not limited to the structural constraints of the cophore and the lipophilicity of the drug. The particular ADC linker selected for an ADC can be influenced by the specific TBM / Drug combinations should attempt to balance these different factors. For a review of factors influenced by the choice of ADC linker in ADCs, see Nol ting,Chapter 5“Linker Technology in Anti Body-Drug Conjugates”,In:Antibody-Drug C onjugates:Methods in Molecular Biology,v ol.1045,pp.71-100,Laurent Ducry(Ed.),Spr. See Inger Science & Business Medica, LLC, 2013 I want to be illuminated.
[0513] For example, ADCs can target bystander antigen-negative cells that are present near antigen-positive tumor cells. The mechanism of bystander cell killing by ADCs is These results indicate that metabolites formed during the intracellular processing of C may play a role. Neutral cytotoxic metabolites generated by metabolism of ADCs in antigen-positive cells are bioactive. While it appears to play a role in standard cell death, charged metabolites are transported across membranes. This may prevent diffusion into the medium and thus affect bystander killing. In certain embodiments, the ADC linker is not catalyzed by intracellular metabolic products of the ADC. In certain embodiments, the IL-16 receptor is selected to attenuate the bystander killing effect caused by the IL-16 receptor. Thus, the ADC linker is selected to increase the bystander killing effect.
[0514] The properties of the ADC linker also influence the aggregation of the ADC under conditions of use and / or storage. Typically, ADCs reported in the literature have no more than 3-4 antibodies per antibody molecule. containing drug molecules (see, e.g., Chari, 2008, Acc Chem Res 41 Attempts to obtain a higher drug-to-antibody ratio ("DAR") have been Failure can occur due to aggregation of the ADC, especially when both the drug and the ADC linker are hydrophobic. (King et al., 2002, J Med Chem 45:43 36-4343;Hollander et al.,2008,Bioconjuga te Chem 19:358-361;Burke et al.,2009 Bio conjugate Chem 20:1242-1250). In many cases, A high DAR can be beneficial as a means of increasing efficacy. If the inhibitory agent is hydrophobic in nature, especially if a DARS greater than 3-4 is desired Therefore, it is desirable to select a relatively hydrophilic ADC linker as a means of reducing ADC aggregation. Thus, in certain embodiments, the ADC linker may be used for storage and / or The ADC linker incorporates a chemical moiety that reduces aggregation of the ADC during use. To reduce aggregation, polar or hydrophilic groups, such as charged groups or groups that are charged at physiological pH, are incorporated. For example, the ADC linker may contain charged groups such as salts or groups that are soluble at physiological pH, e.g., carboxylates. It may incorporate groups that deprotonate the carboxylate or protonate, for example, the amine. do.
[0515] Many cytotoxic and / or cytostatic drugs can be used to link TBM Exemplary multivalent ADC linkers that have been reported to yield DARs as high as 20 are available from the International Publication No. 2009 / 073445; International Publication No. 2010 / 068795 Brochure; International Publication No. 2010 / 138719 Brochure; International Publication No. 2011 / 120053 Brochure; International Publication No. 2011 / 171020 Brochure; International Publication No. 2013 / 096901 Pamphlet; International Publication No. 2014 / 008375 Pamphlet Brochure; International Publication No. 2014 / 093379 Brochure; International Publication No. 2014 / No. 093394; described in International Publication No. 2014 / 093640 and the contents of which are incorporated herein by reference in their entireties.
[0516] In certain embodiments, aggregation of ADCs during storage or use can be detected by size exclusion chromatography. In certain embodiments, the percentage of the total amount of the SEC's stock that is used for the purpose of the present invention is less than about 10% as determined by the Securities and Exchange Commission (SEC). Aggregation of ADCs during storage or use was determined by size exclusion chromatography (SEC). When determining the concentration, it is less than 10%, for example, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1 %, less than about 0.5%, less than about 0.1% or even lower.
[0517] 6.9.3. Methods for Making ADCs The ADCs of the present disclosure can be synthesized using well-known chemistries. The chemistry chosen is particularly The identity of the cytotoxic and / or cytostatic drug, the ADC linker, and the ADC linker Generally, ADCs of formula (I) are: Below scheme: DLR x +Ab-R y →[DL-XY] n -Ab(I) wherein D, L, Ab, XY and n are as previously defined; R x and R yare complementary groups capable of forming covalent bonds with each other, as described above. Represents.
[0518] base R x and R y The identity of the synthon DLR x Used to connect to the TBM Generally, the chemistry used will depend on the integrity of the TBM, e.g., its ability to bind to its target. Preferably, the binding properties of the conjugated antibody should not be altered. The results are very similar to those of unconjugated TBM. conjugated to globulin (the components of which are typically the building blocks of TBMs of the present disclosure) Various chemistries and techniques for this purpose are well known. See, for example, Amon et al., "Mo Noclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”,in:Monoclona l Antibodies And Cancer Therapy,Reisfeld et al.Eds.,Alan R.Liss,Inc.,1985;Hellst rom et al., “Antibodies For Drug Delivery ”,in:Controlled Drug Delivery,Robinson e t al.Eds.,Marcel Dekker,Inc.,2nd Ed.1987 ;Thorpe,“Antibody Carriers Of Cytotoxic Agents In Cancer Therapy:A Review”,in:Mo noclonal antibodies'84:Biological And Cl inical Applications,Pinchera et al.,Eds. ,1985;“Analysis,Results,and Future Prosp. ective of the Therapeutic Use of Radiola "belled Antibody In Cancer Therapy",in:Mon Oclonal Antibodies For Cancer Detection And Therapy,Baldwin et al.,Eds.,Academic Press,1985;Thorpe et al.,1982,Immunol.R ev.62:119-58; PCT Publication WO 89 / 12624 pamphlet Any of these chemistries can be used to link the synthon to the TBM. .
[0519] Several functional groups R useful for linking synthons to available lysine residues x and Chemistry are known, examples of which include, but are not limited to, NHS-esters and isothiocyanates. Examples include:
[0520] It is useful for linking synthons to the available free sulfhydryl groups of cysteine residues. Some functional groups R x and chemistry is known, examples of which include, but are not limited to, haloacetyl and maleimides.
[0521] However, the conjugation chemistry is not limited to the available side chain groups. Side chains such as hydroxyl can be substituted for other functional groups such as hydroxyl by linking an appropriate small molecule to the amine. Using this approach, multifunctional small molecules can be attached to the available amino groups of TBM. Conjugation to the side chains of amino acid residues increases the number of available attachment sites on the antibody. Synthons can then be covalently attached to these "converted" functional groups. Suitable functional group R x is included in the synthon.
[0522] TBMs can also be engineered to contain amino acid residues for conjugation. Non-genetically encoded amino acids useful for conjugating drugs in the context of DCs The strategy for engineering TBM to contain acid residues is to convert synthons into unencoded amino acids. As well as chemistries and functional groups useful for linking to carboxylic acids, Axup et al., 2012 ,Proc Natl Acad Sci USA.109(40):16101-16 106.
[0523] Typically, the synthon is a nucleotide that is linked to, for example, the primary amino group of an available lysine residue or an available linked to the side chains of amino acid residues of TBM, including the sulfhydryl groups of the cysteine residues Free sulfhydryl groups can be obtained by reducing interchain disulfide bonds. Cut.
[0524] R y For linkages where R is a sulfhydryl group (e.g., R x is maleimide) TBM is generally first fully or partially reduced to remove interchain disulfides between cysteine residues. Cleavage of sulfide bridges.
[0525] Cysteine residues not involved in disulfide bridges can be converted to T by one or more codon modifications. These unpaired cysteines can be engineered into the BM. This creates a sulfhydryl group suitable for the synthesis of engineered cysteines. Positions include, but are not limited to, positions S112C, S113C, S114C, S115C, S116C, S117C, S118C, S119C, S120C, S121D, S122D, S123C, S124C, S125C, S126C, S127C, S128C, S129C, S130C, S1 113C, A114C, S115C, A176C, 5180C, S252C, V286C , V292C, S357C, A359C, S398C, S428C (Kabat numbering ) and positions V110C, S114C, S121C, S127C, S on the human Ig kappa light chain 168C, V205C (Kabat numbering) (see, e.g., U.S. Pat. Nos. 7,545,562, 7,545,565 ... 21,541, U.S. Pat. No. 7,855,275 and U.S. Pat. No. 8,455 (See US Pat. No. 5,622).
[0526] As will be appreciated by those skilled in the art, the cytotoxic and / or cytotoxic molecules linked to the TBM molecule may be The number of antiproliferative agents may vary such that the population of ADCs may be heterogeneous in nature, Some TBMs contain one linked drug, others two, three, etc. (and (Some do not include cytotoxic and / or cytostatic drugs.) Heterogeneity is particularly pronounced in It depends on the chemistry used to link the molecules. For example, TBM may be reduced to form a stalk for conjugation. For hydroxyl groups, 0, 2, 4, 6, or 8 linked drugs per molecule can be used. In addition, the molar ratio of the binding compounds is often inconsistent with the TBM. By limiting the number of linked amino acids per molecule, 0, 1, 2, 3, 4, 5, 6, 7 or 8 can be obtained. Therefore, depending on the situation, TBM containing prescribed drugs may be generated. It will be appreciated that the TBM ratio (DTR) may be an average of a population of TBMs, e.g. "DTR4" has not been subjected to purification to isolate a specific DTR peak, and Different numbers of cytostatic and / or cytotoxic drugs per TBM (e.g., one Heterogeneous mixtures of ADC molecules conjugated with 0, 2, 4, 6, or 8 drugs per TBM Although the term "antibody" may refer to an ADC formulation having an average drug-to-TBM ratio of 4, it may also refer to an ADC formulation having an average drug-to-TBM ratio of 4. In this formulation, "DTR2" refers to a heterogeneous ADC formulation with an average drug-to-TBM ratio of 2. vinegar.
[0527] If an enriched preparation is desired, a defined number of linked cytotoxic and / or cytoproliferative agents may be added. TBM with antiproliferative drugs can be purified from heterogeneous mixtures, e.g., by column chromatography. The hydroxybenzoates can be obtained by chromatography, for example, hydrophobic interaction chromatography.
[0528] Purity can be assessed by a variety of methods, as known in the art. As a specific example, an ADC preparation can be analyzed by HPLC or other chromatography: Purity can be assessed by analyzing the area under the curve of the resulting peaks.
[0529] 6.10. Preparations The present disclosure provides a plurality of TBMs and / or a plurality of TBM conjugates, e.g., at least one 00, at least 1,000, at least 10,000 or at least 100,000 The present invention provides a formulation comprising TBM and / or TBM conjugates of the formula (I). Compositions of M molecules and enriched or purified TBM molecules (e.g., fractionated or purified from cell culture supernatants) Contains cell culture supernatant containing purified TBM.
[0530] The formulation can include, for example, multiple TBMs or conjugates, where At least 50% (e.g., at least 50%, at least 60%, At least 70%, at least 80%, at least 90%, at least 95%, at least At least 97%, at least 98%, at least 99% of the total amino acids have the same primary amino acid sequence. In various embodiments, between 50% and 99% of the trispecific molecules in the formulation have the same primary amino acid sequence. columns (e.g., 50% to 95%, 50% to 80%, 50% to 70%, 60% to 95%) %, 60%~80%, 60%~70%, 70%~95%, 70%~80%, 80%~95 %, 95%-99%, or any range bounded by any two of the above values).
[0531] In some embodiments, a majority of the trispecific molecules in the formulation have the same inter-strand bridges (e.g., For example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98% or at least As used herein, an "interchain bridge" refers to a cross-link between two linear polypeptides. The term "crosslinks" refers to crosslinks between amino acid chains, for example crosslinks formed by disulfide bridges. In a formulation, 50% to 99% of the trispecific molecules have the same interstrand crosslinks (e.g., 50%~95%, 50%~80%, 50%~70%, 60%~95%, 60%~80%, 60%~70%, 70%~95%, 70%~80%, 80%~95%, 95%~99% or is any range bounded by any two of the above values).
[0532] In one embodiment, the majority of the trispecific molecules in the formulation are of the same ABM1:ABM2: ABM3 ratio (e.g., at least 50%, at least 60%, at least 70%) , at least 80%, at least 90%, at least 95%, at least 97%, less In various embodiments, the trispecific molecule in the formulation 50%–99% of the cells have the same ABM1:ABM2:ABM3 ratio (e.g., 50%–9 5%, 50%~80%, 50%~70%, 60%~95%, 60%~80%, 60%~7 0%, 70% to 95%, 70% to 80%, 80% to 95%, 95% to 99% or any of the above values any range bounded by any two of
[0533] Pharmaceutical Compositions The TBMs of the present disclosure (as well as conjugates thereof; references to TBMs in this disclosure include Unless the context requires otherwise, this also refers to conjugates containing TBM, such as ADCs. ) includes, for example, TBM, containing one or more pharmaceutically acceptable excipients or carriers. It can be formulated as a pharmaceutical composition. Preparing a pharmaceutical or sterile composition comprising the TBM of the present disclosure To achieve this, the TBM formulation may be combined with one or more pharmaceutically acceptable excipients or carriers. do.
[0534] For example, formulations of TBM may include combining TBM with a physiologically acceptable carrier, excipient, or stabilizer. For example, by mixing in the form of a lyophilized powder, a slurry, an aqueous solution, a lotion, or a suspension. (e.g., Hardman et al., 2001, Goodman et al., 2002). n and Gilman's The Pharmacological Basis of Therapeutics,McGraw-Hill,New York,N. Y.; Gennaro, 2000, Remington: The Science an d Practice of Pharmacy,Lippincott,Willia ms, and Wilkins, New York, NY; Avis, et al. (eds.), 1993, Pharmaceutical Dosage Forms: General Medications,Marcel Dekker,NY;Lie berman, et al. (eds.), 1990, Pharmaceutical Dosage Forms:Tablets,Marcel Dekker,NY;Li eberman,et al.(eds.),1990,Pharmaceutical Dosage Forms:Disperse Systems,Marcel De kker, NY; Weiner and Kotkoskie, 2000, Excipi ent Toxicity and Safety,Marcel Dekker,In c., New York, NY).
[0535] The choice of dosing regimen for TBM depends on the serum or tissue turnover rate of TBM, the level of symptoms, and other factors. The specificity of the TBM depends on several factors, including the immunogenicity of the TBM and the accessibility of the target cells. In an embodiment, the dosing regimen is consistent with an acceptable level of side effects and allows TB to be delivered to the subject. M. Thus, the amount of TBM delivered depends, in part, on the specific TBM The dosage of antibodies and small molecules depends on the patient's condition and the severity of the condition being treated. Needles are available (e.g., Wawrzynczak, 1996, Antibody Therapy,Bios Scientific Pub.Ltd,Oxfordsh ire, UK; Kresina (ed.), 1991, Monoclonal Anti bodies,Cytokines and Arthritis,Marcel De kker, New York, NY; Bach (ed.), 1993, Monocl. onal Antibodies and Peptide Therapy in A autoimmune diseases, Marcel Dekker, New York k,NY;Baert et al.,2003,New Engl.J.Med. 348:601-608;Milgrom et al.,1999,New Engl. .J.Med.341:1966-1973;Slamon et al.,2001, New Engl.J.Med.344:783-792;Beniaminovitz et al.,2000,New Engl.J.Med.342:613-619; Ghosh et al.,2003,New Engl.J.Med.348:24- 32;Lipsky et al.,2000,New Engl.J.Med.343 :1594-1602).
[0536] Determining the appropriate dosage is known in the art to affect treatment, e.g. parameters known or suspected to affect treatment or predicted to affect treatment The dosage is generally somewhat less than the optimal dose. Start with a dose and then gradually increase it until the desired or optimal effect is achieved relative to negative side effects. Important diagnostic measures are, for example, measures of the symptoms of inflammation or the amount of inflammatory cytokines produced. Including tocainine levels.
[0537] The actual dosage level of TBM in the pharmaceutical compositions of the present disclosure may be any dosage level that is not harmful to the subject and is not particularly The subject matter, compositions and methods of administration include an amount of TBM effective to achieve the desired therapeutic response. The selected dosage level will depend on the activity of the particular TBM, the route of administration, Timing of administration, excretion rate of the specific TBM used, duration of treatment, specific TB Other agents used in combination with M (e.g., active agents such as therapeutic agents or compounds and / or Inert materials used as carriers), the age, sex, weight, condition, and overall condition of the subject to be treated Various pharmacokinetic factors, including general health and past medical history and similar factors known in the medical field, Depends on factors.
[0538] Compositions comprising TBM of the present disclosure can be administered by continuous infusion or by infusion over a period of time, e.g., daily, weekly, or weekly. It may be administered in 1 to 7 separate doses. Administration may be intravenous, subcutaneous, topical, oral, or nasal. The administration may be given intravenously, rectally, intramuscularly, intracerebrally, or by inhalation. This includes the maximum dose or frequency of administration that avoids significant undesirable side effects.
[0539] The effective amount for a particular subject will depend on the condition being treated, the subject's overall health, the method, route and administration, and The dose and severity of side effects may vary depending on factors such as the dose and severity of side effects (e.g., Maynard, et al. (1996) A Handbook of SOPs for Good Clinical Practice,Interpharm Press,Boca Raton,Fla.;Dent(2001)Good Laboratory and Good Clinical Practice, Urch Publ., London n,UK).
[0540] The route of administration may be, for example, topical or cutaneous application, intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, By intra-arterial, intracerebrospinal, or intralesional injection or infusion, or by sustained release system or implant. This can be done by runt (e.g., Sidman et al., 1983, Biopo lymers 22:547-556;Langer et al.,1981,JB iomed.Mater.Res.15:167-277;Langer,1982,C hem.Tech.12:98-105;Epstein et al.,1985,P roc.Natl.Acad.Sci.USA 82:3688-3692;Hwang et al.,1980,Proc.Natl.Acad.Sci.USA 77:4 030-4034; U.S. Patent Nos. 6,350,466 and 6,316,024 Optionally, the composition may contain a solubilizing agent and a steroid at the site of injection. It may also contain a local anesthetic such as lidocaine to relieve pain. For example, it can be administered by use of an inhaler or nebulizer and a formulation containing an aerosolizing agent. See, for example, U.S. Pat. No. 6,019,968, each of which is incorporated herein by reference in its entirety. Specification, Specification No. 5,985,320, Specification No. 5,985,309, No. 5, Specification No. 934,272, Specification No. 5,874,064, No. 5,855,913 Nos. 5,290,540 and 4,880,078; and PCT Publication Number: International Publication No. 92 / 19244, International Publication No. 97 / 3257 Pamphlet No. 2, International Publication No. 97 / 44013, Pamphlet No. 98 / 31 See, for example, WO 99 / 66903 and WO 99 / 66903.
[0541] The compositions of the present disclosure can be prepared by one or more of a variety of methods known in the art. It may also be administered by the above-mentioned routes of administration. As will be understood by those skilled in the art, the route of administration The selected route of administration of TBM and / or the method will vary depending on the desired outcome. The administration may be, for example, by injection or infusion, intravenously, intramuscularly, intradermally, intraperitoneally, subcutaneously, spinally or otherwise. Common routes of administration include enteral and topical administration, usually by injection. may refer to methods of administration, including but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, and orbital. Intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal Alternatively, the compositions of the present disclosure may be administered topically, topically, intravenously, intradermally, intravenously ... non-traditional routes of administration, such as dermal or mucosal, e.g., intranasal, oral, vaginal, rectal, sublingual, or topical In one embodiment, the TBM is administered by injection. In another embodiment, the multispecific epitope binding proteins of the disclosure are administered subcutaneously. can be.
[0542] If the TBM is administered in a controlled or sustained release system, the pump may be used to administer the controlled or sustained release. (Langer, supra; Sefton, 1987, CRC Press, rit.Ref Biomed.Eng.14:20;Buchwald et al. ,1980,Surgery 88:507;Saudek et al.,1989, (See N. Engl. J. Med. 321:574). They can be used to provide controlled or sustained release of therapeutics (see, e.g., Medical Appl ications of Controlled Release,Langer an d Wise(eds.),CRC Pres.,Boca Raton,Fla.(1 974);Controlled Drug Bioavailability,Dru g Product Design and Performance,Smolen and Ball (eds.), Wiley, New York (1984); Rang er and Peppas,1983,J.,Macromol.Sci.Rev.M See Acromol. Chem. 23:61; Levy et al., 19 85,Science 228:190;During et al.,1989,An n.Neurol.25:351;Howard et al.,1989,J.Neu Rosurg. 71:105; U.S. Pat. No. 5,679,377 ;U.S. Patent No. 5,916,597;U.S. Patent No. 5,912,015;U.S. US Patent No. 5,989,463; US Patent No. 5,128,326; PCT Publication number WO 99 / 15154; and PCT publication number WO 9 See also brochure No. 9 / 20253. Examples of polymers used in sustained release formulations Examples include, but are not limited to, poly(2-hydroxyethyl methacrylate), poly(methacrylate), methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly (methacrylic acid), polyglycolide (PLG), polyanhydride, poly(N-vinylpyrrolide) Poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), Polylactide (PLA), poly(lactide-co-glycolide) (PLGA) and polyol In one embodiment, the polymer used in the sustained release formulation is Inert, free of leachable impurities, stable during storage, sterile, and biodegradable Controlled or sustained release systems can be placed near the prophylactic or therapeutic target, thus allowing systemic Only a small fraction of the dose is required (e.g., Goodson, in Medical App plications of Controlled Release, supra, vol. 2, pp. 115-138 (1984).
[0543] Controlled release systems are described in the review by Langer (1990, Science e 249:1527-1533). Any technique known to those skilled in the art may be used to incorporate one or more of the methods disclosed herein. These can be used to prepare sustained release formulations containing TBM. U.S. Pat. No. 4,526,938, PCT Publication WO 2004 / 023994, incorporated herein by reference. Pamphlet No. 91 / 05548, PCT Publication International Publication No. 96 / 20698 Ning et al., 1996, Radiotherapy&Oncolog y 39:179-189, Song et al., 1995, PDA Journa. l of Pharmaceutical Science&Technology 5 0:372-397, Cleek et al., 1997, Pro. Int'l. Sy. mp.Control.Rel.Bioact.Mater.24:853-854 and Lam et al.,1997,Proc.Int'l.Symp.Control See Rel. Bioact. Mater. 24:759-760.
[0544] When TBMs are administered topically, they may be administered as ointments, creams, transdermal patches, or lotions. , gel, shampoo, spray, aerosol, liquid, emulsion or other forms known to those skilled in the art. For example, Remington's Pharmaceuticals al Sciences and Introduction to Pharmace utical Dosage Forms,19th ed.,Mack Pub.Co , Easton, Pa. (1995). For non-sprayable topical dosage forms, , a carrier or one or more liquids compatible with topical application and optionally having a dynamic viscosity higher than water Viscous to semi-solid or solid forms containing excipients are typically used. Examples include, but are not limited to, solutions, suspensions, emulsions, creams, ointments, powders, topical medications, and salves. These may be optionally sterilized or modified to various properties, e.g., osmolality. To affect the effect, auxiliary substances (e.g., preservatives, stabilizers, wetting agents, buffers or salts thereof) and Other suitable topical dosage forms include sprayable aerosol formulations, Wherein the active ingredient, optionally combined with a solid or liquid inert carrier, is pressurized In a mixture with a volatile substance (e.g., gaseous propellant such as chlorofluorocarbon) or squeezed The pharmaceutical compositions and dosage forms are packaged in a bottle. Wetting agents or humectants may also be added to the pharmaceutical compositions and dosage forms as needed. Examples of such additional ingredients are well known in the art.
[0545] When a composition containing TBM is administered intranasally, the TBM may be administered in an aerosol form, a spray, It may be formulated in the form of a mist or drops. In particular, for prophylactic or therapeutic use according to the present disclosure The agent may be mixed with a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas) together with pressurization They may conveniently be delivered in the form of an aerosol spray formulation from a pack or nebulizer. In the case of a dispensed aerosol, the dosage unit may include a valve to deliver a metered amount. The amount of the compound can be determined by adding a powder mixture of the compound and a suitable powder such as lactose or starch. Capsules and cartridges (e.g., fluoropolymers) for use in inhalers or insufflators containing a carrier For example, a formulation composed of gelatin can be prepared.
[0546] The TBMs of the present disclosure may be administered in combination treatment regimens, as described in Section 6.13 below. can be given.
[0547] In certain embodiments, the TBM is formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the present disclosure cross the BBB (if necessary), They can be formulated, for example, in liposomes. See, e.g., U.S. Pat. Nos. 4,522,811; 5,374,548; and 5,399,331. Liposomes are designed to bind to specific cells or organelles. One or more moieties that are selectively transported into the organs, thereby facilitating targeted drug delivery (e.g., Ranade, 1989, J. Clin. Pharmacol. 2 9:685). Exemplary targeting moieties include folate or biotin ( See, e.g., U.S. Patent No. 5,416,016 to Low et al. mannoside (Umezawa et al., 1988, Biochem. Bioph ys.Res.Commun.153:1038); Antibodies (Bloeman et al .,1995,FEBS Lett.357:140;Owais et al.,19 95,Antimicrob.Agents Chemother.39:180);kai Surfactant protein A receptor (Briscoe et al., 1995, Am. JP hysiol.1233:134);p 120(Schreier et al.,1 994, J. Biol. Chem. 269:9090); and Laukkanen,1994,FEBS Lett.346:123;Kil lion and Fidler,1994,Immunomethods 4:273 See also:
[0548] For example, as described in Section 6.13 below, when used in combination therapy, the present disclosure The TBM and one or more additional agents may be administered to a subject in the same pharmaceutical composition. Alternatively, the TBM and the additional agent of the combination treatment are administered simultaneously to the subject in separate pharmaceutical compositions. It is possible.
[0549] The therapeutic methods described herein further include performing a "companion diagnostic" test. whereby a sample from a subject who is a candidate for treatment with the TBM of the present disclosure is obtained by Tested for expression of TAAs targeted by ABM3. Companion diagnostic test may be administered prior to initiating treatment with the TBM of the present disclosure and / or following a subject's continued treatment with TBM. This may be performed during treatment planning with the TBM of the present disclosure to monitor appropriate compatibility. The agent used for the diagnosis of TBM may be TBM itself or another diagnostic agent, e.g., a drug that detects TAA RNA. A single labeled target molecule is used to detect the TAA recognized by ABM3 or the nucleic aci...
Claims
1. (a) an antigen binding module 1 (ABM1) that specifically binds to human CD2; (b) an antigen-binding molecule that specifically binds to a component of the human T cell receptor (TCR) complex; Model 2 (ABM2); (c) an antigen-binding module 3 (ABM) that specifically binds to a human tumor-associated antigen (TAA); 3) and A trispecific binding molecule (TBM) comprising:
2. Each antigen-binding module binds to each of the other antigen-binding modules.
13. The method of claim 1, wherein the nucleotide sequence of ... TBM.
3. ABM1 is, (a) optionally, an anti-CD2 antibody, antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab'), single domain antibody (SDAB), VH or V An immunoglobulin scaffold-based ABM that is an L domain or a Camelidae VHH domain; or (b) optionally, a Kunitz domain, an adnexin, an affibody, a DARPin , Avimar, Anticalin, Lipocalin, Sentin, Versabody, Knottin, Adne Cutin, pronectin, affitin / nanophytin, affilin, atrimer / tetranet Cutin, bicyclic peptide, cys-knot, Fn3 scaffold, obody, Tn3, Affima -, BD, Adhiron, Duocalin, Alpha Body, Armadillo Repeat Protein Non-immunoglobulin scaffold-based ABMs that are repebodies or finomers 2. The TBM of claim 1 ,
4. The TBM of claim 3, wherein ABM1 is an scFv or Fab.
5. 4. The TBM of claim 3, wherein ABM1 comprises any of the binding sequences listed in Table 9.
6. The TBM of claim 1 , wherein ABM1 comprises a receptor binding domain of a CD2 ligand.
7. The TBM of claim 1, wherein ABM1 is a CD58 portion.
8. The TBM of claim 7, wherein ABM1 comprises amino acids 1 to 94 of CD58-2.
9. The TBM of claim 1, wherein ABM1 is a CD48 portion.
10. The TBM of claim 1 , wherein said component of the human TCR complex is CD3.
11. ABM2 is, (a) optionally, an anti-CD3 antibody, an antibody fragment, an scFv, a dsFv, an Fv, Fab, scFab, (Fab'), single domain antibody (SDAB), VH or V An immunoglobulin scaffold-based ABM that is an L domain or a Camelidae VHH domain; or (b) optionally, a Kunitz domain, an adnexin, an affibody, a DARPin , Avimar, Anticalin, Lipocalin, Sentin, Versabody, Knottin, Adne Cutin, pronectin, affitin / nanophytin, affilin, atrimer / tetranet Cutin, bicyclic peptide, cys-knot, Fn3 scaffold, obody, Tn3, Affima -, BD, Adhiron, Duocalin, Alpha Body, Armadillo Repeat Protein Non-immunoglobulin scaffold-based ABMs that are repebodies or finomers 11. The TBM of claim 10,
12. The TBM of claim 11, wherein ABM2 is an scFv or Fab.
13. ABM2 comprises any of the binding sequences set forth in any one of Tables 7A to 7D. The TBM of claim 11.
14. ABM2 comprises the VH and VL sequences of CD3-21 as set forth in Table 7A. The TBM described in
15. 2. The method of claim 1, wherein the component of the human TCR complex is the α subunit of the TCR. TBM.
16. ABM2 is an anti-CD3 antibody, antibody fragment, scFv, Fv, dsFv, Fab, scFab, (Fab')2, single domain antibody (SDAB), VH or VL domain , Camelidae VHH domain, DARPin, Avimer, Anticalin / Lipocalin, Se TB according to claim 15, which is an anti-TB agent selected from the group consisting of ntilin, versabody, duocalin and finomer. M.
17. When the TAA is a receptor, ABM3 is a receptor binding domain of a ligand of said receptor. and when the TAA is a ligand, the ABM3 is a ligand for the receptor of said ligand.
2. The TBM of claim 1, comprising a ribosome-binding domain.
18. ABM3 is, (a) optionally an anti-TAA antibody, antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab'), single domain antibody (SDAB), VH or V An immunoglobulin scaffold-based ABM that is an L domain or a Camelidae VHH domain; or (b) optionally, a Kunitz domain, an adnexin, an affibody, a DARPin , Avimar, Anticalin, Lipocalin, Sentin, Versabody, Knottin, Adne Cutin, pronectin, affitin / nanophytin, affilin, atrimer / tetranet Cutin, bicyclic peptide, cys-knot, Fn3 scaffold, obody, Tn3, Affima -, BD, Adhiron, Duocalin, Alpha Body, Armadillo Repeat Protein Non-immunoglobulin scaffold-based ABMs that are repebodies or finomers 2. The TBM of claim 1 ,
19. The TAA is TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11 Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-β, SSEA-4, MUC1, EGFR, EGFRvIII, NCAM, CAIX, LMP2 , EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-Acetyl Leu-GD2, GD2, folate receptor α, folate receptor β, TEM1 / CD248, TEM7R , CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, poly Sialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, AD RB3, PANX3, GPR20, LY6K, OR51E2, TAARP, WT1, ET V6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MA D-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoint, M L-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Ann drogen receptor, cyclin B1, MYCN, RhoC, CYP1B1, BORIS, S ART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLE C12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD1 9, CD20, CD30, ERBB2, ROR1, FLT3, TAAG72, CD22, CD33, GD2, BCMA, gp100Tn, FAP, tyrosinase, EPCAM, C EA, Igf-I receptor, cadherin 17, CD32b, GPNMB, GPR64, HE R3, LRP6, LYPD8, NKG2D, SLC34A2, SLC39A6, SLIT 19. The TBM of claim 18, which is RK6, TACSTD2 or EphB2.
20. 20. The TBM of claim 18, wherein the TAA is BCMA.
21. ABM3 is in any one of Tables 12A, 12B, 12C, 12D, 12E or 12F.
21. The TBM of claim 20 comprising any of the binding sequences described.
22. The TBM of claim 18, wherein the TAA is CD19.
23. 23. The TB of claim 22, wherein ABM3 comprises any of the binding sequences listed in Table 13. M.
24. 19. The TBM of claim 18, wherein the TAA is Her2.
25. 19. The TBM of claim 18, wherein the TAA is mesothelin.
26. The TBM of claim 18, wherein ABM3 is an scFv or Fab.
27. 2. The TBM of claim 1 which is a trivalent TBM.
28. The trivalent TBM has any one of the forms shown in Figures 1B-1U and 1V-1Z. The TBM of claim 27.
29. 29. The TBM of claim 28 having the configuration shown in FIG. 1I.
30. 30. The TBM of claim 29, wherein the ABM has a morphology designated as T6.
31. 2. The TBM of claim 1 which is a tetravalent TBM.
32. 2. The TBM of claim 1 which is a pentavalent TBM.
33. 2. The TBM of claim 1 which is a hexavalent TBM.
34. A TBM according to any one of claims 1 to 33 and a cytotoxic or cytostatic drug. A conjugate comprising a drug.
35. A pharmaceutical composition comprising the TBM of any one of claims 1 to 33 and an excipient.
36. A method of treating a subject suffering from cancer, comprising administering to a subject suffering from cancer an effective amount of A method comprising administering the TBM of any one of paragraphs 1 to 33.
37. The cancers include HER2+ cancers, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), ), adrenal cortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer, bone Sarcoma, breast cancer, bronchial tumor, Burkitt's lymphoma, cancer of unknown primary site, cardiac tumor, cervical cancer, notochord leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasm , colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, ductal carcinoma, embryonal tumor, endometrium Cancer, ependymoma, esophageal cancer, nasal neuroblastoma, fibrous histiocytoma, Ewing's sarcoma, eye cancer, germ cell gallbladder tumor, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease , glioma, head and neck cancer, hairy cell leukemia, hepatocellular carcinoma, histiocytosis, Hodgkin's lymphoma, Hypopharyngeal carcinoma, intraocular melanoma, pancreatic islet cell tumor, Kaposi's sarcoma, renal carcinoma, Langerhans cell histiocytosis Hyperplasia, laryngeal cancer, leukemia, lip and oral cancer, liver cancer, lobular carcinoma in situ, lung cancer, lymphoma , macroglobulinemia, malignant fibrous histiocytoma, melanoma, Merkel cell carcinoma, mesothelioma, primary Unknown metastatic cervical squamous cell carcinoma, midline duct carcinoma associated with the NUT gene, oral cancer, multiple endometrial cancer Myelodysplastic syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative Tumors, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung Cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, parathyroid cancer, penile cancer , pharyngeal cancer, pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate Cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureter cancer, retinoblastoma, rhabdoid tumor, salivary gland cancer, Sézary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumor, gastric cancer, T-cell lymphoma Lymphoma, teratoma, testicular cancer, pharyngeal cancer, thymoma and thymic cancer, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer 37. The method of claim 36, wherein the cancer is selected from the group consisting of vulvar cancer and Wilms' tumor.
38. 34. One or more nucleic acids encoding the TBM of any one of claims 1 to 33.
39. A cell engineered to express the TBM of any one of claims 1 to 33.
40. A T gene according to any one of claims 1 to 33 under the control of one or more promoters. BM is transfected with one or more expression vectors containing one or more nucleic acid sequences encoding BM. The cells were
41. 1. A method for producing a TBM comprising: (a) culturing the cell of claim 40 under conditions in which the TBM is expressed. and; (b) recovering the TBM from the cell culture; The method includes:
Citation Information
Patent Citations
Method for ex vivo immunization using heterologous intact bispecific and / or trispecific antibodies
JP2008189678A
Trispecific binding molecules that specifically bind to multiple cancer antigens and methods of using the same
JP2017519743A
ROR1-binding molecules, and methods of use thereof
WO2017142928A1
